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Chapter 1
Introduction




Heavy menstrual bleeding, or menorrhagia, is a significant health problem in women 
of reproductive age. Its incidence varies between 9% and 22%.1-3 Menorrhagia is 
defined as a menstruation at regular cycle intervals, but with excessive flow and 
duration. Clinically, menorrhagia is defined as menstrual blood loss exceeding 80 
mL per cycle.4 In recent years, changes in terminology appeared, because there 
was a great variation in the way the terms abnormal uterine bleeding, menorrhagia 
and dysfunctional uterine bleeding were used. It was proposed to use abnormal 
uterine bleeding as the overarching term to describe all symptomatic blood loss 
from normal menstruation or the menstrual cycle. Heavy menstrual bleeding 
(HMB) is a suitable replacement for the term menorrhagia.5 
HMB has a significant impact on the medical, social economic and 
psychological well-being of women.1,6 When medical treatment fails, surgical 
interventions, like destruction of the endometrium or a hysterectomy can be 
considered. Hysterectomies are performed in 30-40% of the patients for treatment 
of severe HMB.4 Hysterectomy is an effective treatment with good health related 
quality of life scores.7 The level of satisfaction with hysterectomy is usually high, but 
it is a major surgical procedure with a complication rate up to 43%, but only about 
4% of these complications are major complications.8 Patient preference studies 
show that women place a high value on retaining their uterus and that they have a 
strong preference for avoiding hysterectomy as a treatment to resolve the problem 
of HMB, but when they do undergo a hysterectomy they are generally satisfied.9 
Endometrial ablation is an alternative to hysterectomy in women with heavy 
menstrual bleeding. It is a relatively minor surgical procedure which preserves the 
uterus yet reduces heavy menstrual bleeding. 
Endometrial ablation 
Endometrial ablation was introduced in the 1980’s. It includes the removal or 
destruction of the basal layer of the endometrium. This results in an inability of the 
endometrium to react on hormonal stimuli, and therefore decreases menstrual 
blood loss. 
The first endometrial ablations were performed with direct hysteroscopic 
vision. They are referred to as first-generation devices. The first-generation devices 




were: endometrial laser ablation, transcervical resection of the endometrium 
and rollerball ablation.10-13 The introduction of endometrial ablation caused 
a rapid decrease in the amount of hysterectomies performed.14 However, the 
first-generation endometrial ablation techniques involved a long learning curve 
and had other disadvantages.7,15,16 Glycine and Sorbitol are both used when 
performing a hysteroscopic guided endometrial ablation. The risk of absorption 
of the distension fluid is present and is characterized by hyponatraemia, water 
intoxication, cerebral edema and cardiac overload, which can result in a fatal 
hyponatremic encephalopathy.17,18 Over the past decade, second-generation 
non-hysteroscopic techniques overcame these disadvantages. Destruction of the 
endometrium by the ‘blind’ endometrial ablation is achieved by different methods, 
the most important being microwave (Microsulis®), high temperature fluids within a 
balloon (Thermachoice®, Cavaterm®, Thermablate®), bipolar radiofrequency energy 
(NovaSure®) and free fluid with a high temperature (Hydrothermablator®).19 The 
second-generation techniques are safer, technically easier and quicker to perform, 
and involve shorter hospital stays.20 Bipolar radiofrequency endometrial ablation 
(NovaSure®) is reported to be superior over balloon ablation (Thermachoice®).21 
Another second-generation device, the Hydrothermablator®, is applied in the 
uterus under hysteroscopic view, thus potentially reducing the risk of uterine 
perforation compared to other second generation techniques. In a randomized 
multicenter study hydrothermablation was found to be equally effective as 
rollerball ablation.19
The advantages of the endometrial ablation seem to diminish within time. 
Two years after ablation, 12% of the women had had a hysterectomy and four 
years after ablation even 30%.20,22 Nevertheless, most women prefer endometrial 
ablation over hysterectomy as therapy for menorrhagia.23
The indication for ablation could be improved by predicting the probability 
of success in each particular case. Factors as a young age, a retroverted uterus, an 
endometrial thickness of at least 4mm and a prolonged duration of menstruation 
seem to be associated with an increased risk of endometrial ablation treatment 
failure.24 However, publications that investigated a relation between a previous 
Cesarean section and the success of an endometrial ablation are lacking.
When endometrial ablation was introduced, the procedures were performed 
in theatre with general anesthesia or regional (spinal) anesthesia. Years after, 
endometrial ablation was also performed at the outpatient clinic with a 
paracervical block combined with intra-venous sedation. One study compared 
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intraoperative and postoperative pain between ThermaChoice® and NovaSure® 
endometrial ablation.25 The NovaSure® system was associated with significantly 
lower intraoperative and postoperative pain. These data supported the idea 
that the NovaSure® procedure could become an office-based procedure with 
local anesthesia, meaning only a paracervical block. The NovaSure® only takes 
a maximum of two minutes to perform the ablation. Lately, more endometrial 
ablation techniques, like Thermablate® and ThermaChoice® III balloon ablation, 
are developed with a shorter treatment time, which seems better applicable for 
treatment in the office with local anesthesia.
This thesis deals with the prognostic factors for the success of endometrial 
ablation and the use of different second-generation endometrial ablation 
techniques in theatre and in the outpatient clinic with a paracervical block. 
Outline of the thesis
This thesis aims to answer the following questions:
1. Which are the prognostic factors for success of endometrial ablation in the 
treatment of heavy menstrual bleeding?
2. What is the effectiveness of bipolar radiofrequency endometrial 
ablation in the treatment of heavy menstrual bleeding as compared to 
hydrothermablation after 12 months and at long-term follow-up in terms 
of amenorrhea, satisfaction, reinterventions and quality of life?
3. Is it safe and acceptable to perform bipolar radiofrequency endometrial 
ablation with a paracervical block in the outpatient clinic?
4. What is the effectiveness of bipolar radiofrequency endometrial ablation 
in the treatment of heavy menstrual bleeding as compared to balloon 
endometrial ablation in the outpatient clinic in terms of amenorrhea, pain, 
satisfaction and quality of life?
5. Which endometrial ablation technique(s) is/are preferred in the treatment 
of heavy menstrual bleeding? 
To answer these questions we conducted the following studies, of which the 
results are presented in this thesis:
Chapter 2 studies a history of Cesarean section and other factors that are 
potentially associated with endometrial ablation failure in the treatment of heavy 




menstrual bleeding. A case-control study was performed, comparing patients 
who had failed ablation versus successful ablation. Failed ablation was defined 
as the need for hysterectomy due to persistent heavy menstrual bleeding after 
ablation. Successful ablation was defined as a satisfied patient who did not need a 
hysterectomy after ablation for menorrhagia. Both groups, cases and controls, were 
identified from the surgery registration in the Máxima Medical Center between 
January 1999 and January 2009.
Chapter 3 presents the results of a double blind randomized controlled trial 
comparing the effectiveness of two second-generation ablation techniques in 
the treatment of heavy menstrual bleeding: bipolar radiofrequency impedance-
controlled endometrial ablation (NovaSure®) and hydrothermablation (HTA®). 
Patients were included between March 2005 and August 2007. The primary 
outcome was amenorrhea at 12 months after treatment. Secondary outcome 
measures were patient satisfaction and reinterventions.
Chapter 4 evaluates the 5-year follow-up results of the study described in chapter 3, 
comparing bipolar radiofrequency endometrial ablation with hydrothermablation 
for the treatment of heavy menstrual bleeding.
Chapter 5 reports the health related quality of life of patients who participated in 
the randomized controlled trial described in chapter 3 and 4. Health related quality 
of life was assessed and compared between both groups before randomization 
and at each follow-up visit at 4 weeks, 6 months, 12 months and 5 years after 
treatment. The questionnaires that were used were the medical outcomes study 
Short-Form (SF-36), Euroqol and the menorrhagia multi-attribute scale (Shaw). The 
menorrhagia outcomes questionnaire (MOQ) was completed at 4 weeks, 6 and 12 
months after treatment.
Chapter 6 describes a prospective cohort study to evaluate the safety, feasibility 
and efficacy of bipolar radiofrequency endometrial ablation with local anesthesia. 
Women with heavy menstrual bleeding were included to undergo bipolar 
radiofrequency endometrial ablation with a paracervical block. We measured the 
acceptability, pain score (visual analog scale), patients’ satisfaction during and after 
the procedure and amenorrhea.
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Chapter 7 presents the results of a multi-center double blind randomized 
controlled trial comparing the effectiveness of two second-generation ablation 
techniques, bipolar radiofrequency endometrial ablation (NovaSure®) and balloon 
endometrial ablation (Thermablate®), in the office with a paracervical block in 
patients with heavy menstrual bleeding. Patients were included between March 
2009 and December 2011. The main outcome was amenorrhea at 12 months 
follow-up. We also measured pain, satisfaction, quality of life and reinterventions. 
Chapter 8 reports a systematic review comparing the efficacy, safety and 
acceptability of methods used to destroy the endometrium in premenopausal 
women with heavy menstrual bleeding. Randomized controlled trials comparing 
different endometrial ablation techniques in women with a complaint of heavy 
menstrual bleeding without uterine pathology were eligible. The outcomes 
included reduction of heavy menstrual bleeding, improvement in quality of life, 
operative outcomes, satisfaction with the outcome, complications and need for 
further surgery or hysterectomy. 
Chapter 9 provides a general discussion and implementations for future research.
Chapter 10 summarizes the data presented in this thesis. A Dutch version is 
included.
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Chapter 2
Prognostic factors for the success of 
endometrial ablation in the treatment 
of menorrhagia with special reference 
to previous Cesarean section
Peeters JA, Penninx JP, Mol BW, Bongers MY 
Eur J Obstet Gynecol Reprod Biol 2013;167:100-3.




Objective: To assess whether, among other prognostic factors, a history 
of Cesarean section is associated with endometrial ablation failure in the 
treatment of menorrhagia.
Study design: We compared women who had failed ablation to women 
who had successful ablation for menorrhagia in a case-control study. Failed 
ablation was defined as the need for hysterectomy due to persistent heavy 
menstrual bleeding after ablation. Successful ablation was defined as an 
ablation for menorrhagia not needing hysterectomy and the woman being 
satisfied with the result. Both cases and controls were identified from the 
surgery registration in the Máxima Medical Center between January 1999 
and January 2009. Cases were women that had an endometrial ablation and 
a hysterectomy, whereas controls only had an endometrial ablation. From 
the medical files we collected for each patient clinical history, including 
the presence of a previous Cesarean section, baseline characteristics at the 
moment of initial ablation, data of the ablation technique and follow-up 
status. We used univariable and multivariable logistic regression to estimate 
the risk of failure of endometrial ablation.
Results: We compared 76 cases to 76 controls. Among the cases, 12 women 
had had a previous Cesarean section versus 15 in the control group (15.8% 
versus 19.7%; odds ratio (OR) 0.76; 95% confidence interval (CI) 0.3-1.8). 
Factors predictive for failure of ablation were dysmenorrhea (OR 3.0; 95% CI 
1.5-6.1), having a submucous myoma (OR 3.2; 95% CI 1.5–6.8) and uterine 
depth (per cm OR 1.3; 95% CI 1.0–1.6). Presence of intermenstrual bleeding, 
sterilization and age were not associated with failure of ablation.
Conclusion: A previous Cesarean delivery is not associated with an increased 
risk of failure of endometrial ablation, but dysmenorrhea, a submucous 
myoma and longer uterine depth are. This should be incorporated in the 
counseling of women considering endometrial ablation.
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Dysfunctional uterine bleeding is a frequent problem in premenopausal women, 
as one in 20 women suffer from menorrhagia.1,2 Menorrhagia has consequences 
for the general well-being of women. Although a hysterectomy guarantees 
amenorrhea in all women, it is expensive and has a significant impact on health-
related quality of life immediately after surgery.3,4 The treatment of dysfunctional 
uterine bleeding by destroying the endometrium without removal of the uterus 
has become common practice. Compared with hysterectomy, transcervical 
endometrial ablation techniques initially show similar efficacy with lower costs and 
less complications.4,5 These beneficial outcomes, however, seem to diminish with 
time, as 12% of the women require hysterectomy within 2 years and 30% within 
4 years after ablation.4,5 Nevertheless, most women choose endometrial ablation 
rather than hysterectomy as therapy for menorrhagia.6 Despite the willingness to 
accept potential risk of treatment failure, counseling of women with menorrhagia, 
who needed surgical treatment, could be improved by predicting the probability 
of success in each particular case. 
Due to the rise in Cesarean sections in the last decade more and more women 
who will get an endometrial ablation have a Cesarean section. Data are lacking 
however, on the association between a previous Cesarean section and the success 
of an endometrial ablation. 
The objective of this study was to assess if, among other potential prognostic 
factors, a Cesarean section could determine the outcome of endometrial ablation 
in women with menorrhagia. 
Materials and Methods
We performed a retrospective case-control study in the Maxima Medical Center 
(MMC). The MMC is a teaching hospital with 500 beds in the south of The 
Netherlands. We studied women who had undergone an endometrial ablation 
between January 1999 and March 2009 for menorrhagia. In our center, endometrial 
ablation for menorrhagia has been carried out since 1994. In the study period we 
performed several randomized clinical trials evaluating balloon ablation, NovaSure® 
and Hydrothermal ablation (HTA). At present, NovaSure® is the treatment of choice 
due to the results of the RCT’s.7-9   
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In this study, we defined cases, i.e. women in whom ablation has failed, as 
women who underwent a hysterectomy for persistent menorrhagia after an 
ablation in the period January 1999 until March 2009. Controls were women 
who had had an ablation without any reintervention. We identified our cases and 
controls from the electronic operation room planning system. For each included 
case patient, the next woman with a successful comparable ablation procedure 
scheduled directly after the index procedure was selected as a control patient. 
Subsequently we checked the medical records of the selected control patients 
whether the endometrial ablation had indeed been successful or not. An 
endometrial ablation was considered to be successful if the patient was satisfied 
without a reintervention. Information on satisfaction was obtained from the 
medical chart and by contacting the patient by telephone. 
We only included patients with dysfunctional uterine bleeding who had 
cavity investigation by a saline infusion sonography and/or a hysteroscopy. 
Submucous myomas, as observed in ultrasound or pre-endometrial ablation 
hysteroscopy, were defined as partial protrusion of myoma into the cavity. Only 
women with submucous myomas smaller than 2 cm, or not disturbing the 
endometrial cavity could undergo endometrial ablation. Exclusion criteria were 
malignancy of the uterus or cervix, presence of intrauterine adhesions, after 
assessing by hysteroscopy, and uterine depth more than 12 cm. The use of oral 
contraceptives, antiprostaglandins and anticoagulants in the previous 3 months 
before the ablation was not an exclusion criterion. 
The three global endometrial ablation methods which were used in MMC 
during the study period were radiofrequency ablation (NovaSure®), hydrothermal 
ablation (HTA®) and balloon ablation (Thermachoice®). All three procedures were 
performed in the operating room under regional or general anesthesia. After 2005 
the NovaSure® also was performed in an outpatient setting under local anesthesia. 
Women who choose the procedure at the outpatient clinic were advised to use an 
oral nonsteroidal anti-inflammatory drug as a painkiller 12 hours and 1 hour before 
the procedure. At the beginning a paracervical block with Ultracaine or Prilocaine 
1% with or without adrenaline was placed.
The aim of the analysis was to relate potential prognostic factors available 
before the start of treatment to the occurrence of an adverse outcome. Apart from 
previous Cesarean section, the case subjects were compared with the control 
subjects with regard to the occurrence of clinical signs and symptoms, abnormal 
laboratory tests, medical history and preoperative characteristics. The position 
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of the uterus was assessed by bimanual examination and confirmed during 
hysteroscopy. Dysmenorrhea, intermenstrual bleeding and an irregular menstrual 
cycle were recorded either present or absent and the duration of menstruation 
was recorded in days. 
All data were obtained from patients’ medical records. In the cases and 
controls in which we were not sure about whether a Cesarean delivery had been 
performed, we contacted the patient. Beside Cesarean delivery we also collected 
data of preoperative characteristics, medical history and main factors about 
dysfunctional uterine bleeding. Age was categorized by using two threshold 
values; one of 40 years and one of 45 years. A 4 mm threshold for endometrial 
thickness was selected.7
Each potential prognostic variable was first evaluated in a univariable logistic 
regression model. Subsequently variables with a P-value ≤ 0.05 were evaluated in 
a multivariable logistic regression model. Odds ratios (ORs) and 95% Confidence 
Interval (CI) were presented. All data were analyzed using SPSS 17.0 for Windows.
Results
We identified 890 women who have had an endometrial ablation in the MMC 
between January 1999 and March 2009. Of these 890 women, 76 had had a 
hysterectomy after their endometrial ablation as treatment for menorrhagia, and 
therefore were considered as having experienced the ablation as unsuccessful. 
These patients were compared to 76 women who had an ablation with a satisfying 
result. Of the 152 women 110 had a NovaSure®, 36 the HTA and the other 6 the 
Thermachoice®. 
Table 1 shows the clinical characteristics of both the cases and controls. 
There were a few differences between case and control subjects. Duration of 
menstruation, intermenstrual bleeding and an age above the 45 years differed 
significantly (respectively: P=.03, P=.03 and P=.03). In the case subjects, the mean 
number of months between the endometrial ablation and the hysterectomy was 
12.6 months. The mean follow-up of the controls was 54.7 months. 
Twelve of the 76 case subjects had had a Cesarean section, as compared with 
15 of the 76 control subjects (OR 0.76; 95% CI, 0.3 to 1.8) (Table 2). Table 2 also 
shows the results of the other potential prognostic factors. Age above 45 years 
reduced the risk of an adverse outcome (OR 0.47; 95% CI 0.2 to 0.9). On the other 
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hand, the risk of an adverse outcome increased when women had dysmenorrhea 
(OR 3.0; 95% CI, 1.5 to 6.1), intermenstrual bleeding (OR 2.1: 95% CI, 1.1 to 4.1), a 
submucous myoma (OR 3.2; 95% CI, 1.5 to 6.8) or a sterilization in medical history 
(OR 2.2; 95% CI, 1.1 to 4.2). An uterus in retroversion flexion increased the risk of 
failure of treatment (OR 2.1; 95 % CI 0.9 to 4.8), whereas endometrial thickness was 
not associated with the risk of an adverse outcome (1.02; 95% CI 0.9 to 1.1). 






Age before treatment (mean ± sd) 42.8 44.1 0.47
(41.8-43.8) (43.0-45.2)
Age 41-45 years (%) 39.5 35.5 0.62
Age ≤ 45 years (%) 56.6 71.1 0.06
Age > 45 years (%) 26.3 43.4 0.03
Previous Cesarean delivery (%) 15.8 19.7 0.52
Parity (mean ± sd) 1.95 2.32 0.42
(1.71-2.18) (2.15-2.48)
Anticoagulance (%) 9.5 2.7 0.09
Dysmenorrhea (%) 60.0 33.3 0.00
Intermenstrual bleeding (%) 45.9 28.9 0.03
Irregular menstrual cycle (%) 25.0 23.9 0.90
Duration (days) bleeding 8 7 0.03
(median + range)  (3-56)  (3-21)
PBAC-score (median + range)*                 17                740 0.12
(27-3000) (340-2000)
Uterus in retroversion flexion (%) 26.8 14.7 0.08
Uterine depth (cm; mean ± sd) 8.77 8.02 0.29
(8.31-9.23) (7.61-8.43)
Endometrial thickness 9.68 9.30 0.12
(cm; mean ± sd) (8.12-11.23) (8.14-10.46)
Endometrial thickness ≥ 4 mm** (%) 87.8 92.6 0.41
Sterilisation (%) 48.7 30.7 0.02
Hemoglobin ((Mmol/I) *** 7.58 7.85 0.03
(7.27-7.89) (7.61-8.08)
Uterus abnormalities
         Uterine polyp (%) 8.5 2.6 0.12
         Submucous myoma (%) 39.4 17.1 0.003
         Nonsubmucous myoma (%) 5.6 2.6 0.36
*    Available for N is 24 (Cases) and 28 (Controls)
 **  Available for N is 49 (Cases) and 54 (Controls)
 *** Available for N is 52 (Cases) and 55 (Controls) 
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OR (95% CI) P-value   
Multivariable analysis
OR (95% CI) P-value  
Age before treatment 0.94 (0.88-1.01) 0.08
Age 41-45 years 1.18 (0.61-2.28) 0.62
Age ≤ 45 years 1.88 (0.96-3.69) 0.07
Age > 45 years 0.47 (0.24-0.92) 0.03 0.40 (0.15-1.05) 0.06
Previous Cesarean delivery 0.76 (0.33-1.76) 0.53
Parity 0.61 (0.42-0.90) 0.01 0.79 (0.47-1.34) 0.38
Anticoagulance  3.76 (0.76-18.75) 0.11
Dysmenorrhea 3.00 (1.47-6.12) 0.03 4.03 (1.58-10.3)  0.004
Intermenstrual bleeding 2.09 (1.06-4.10) 0.03 1.87 (0.72-4.83) 0.20
Irregular menstrual cycle 0.94 (0.44-2.03) 0.88
Duration (days) bleeding 1.02 (0.88-1.19) 0.81
PBAC-score 1.00 (1.00-1.00) 0.45
Uterus in retroversion flexion 2.12 (0.90-4.77) 0.08
Uterine depth 1.28 (1.04-1.57) 0.02 1.36 (1.05-1.75)  0.02
Endometrial thickness 1.02 (0.94-1.10) 0.69
Endometrial thickness ≥ 4 mm 0.57 (0.15-2.12) 0.41
Sterilisation 2.15 (1.10-4.17) 0.03 1.70 (0.68-4.26) 0.26
Hemoglobin (mmol/I) 0.76 (0.51-1.12) 0.17
Uterus abnormalities
         Uterine polyp 3.42 (0.67-17.51) 0.14
         Submucous myoma  3.16 (1.47-6.77) 0.0003 6.45 (2.11-19.7) 0.001
         Nonsubmucous myoma 2.21 (0.39-12.45) 0.37
OR; odds ratio, CI; Confidence interval.
Beside the univariable results, table 2 also shows the results of the multivariable 
logistic regression analysis. Dysmenorrhea, uterine depth and a submucous myoma 
decreased the chance of a successful outcome. All these three associations were 
statistically significant. However, sterilization, intermenstrual bleeding and age 
above the 45 years associated with an increased risk in the univariable analysis, had 
limited impact on the multivariable analysis (respectively: P=.26, P=.20 and P=.06).




In this case-control study, we assessed prognostic failures for endometrial ablation 
in women suffering from menorrhagia. We found that a previous Cesarean section 
did not affect the success rate of endometrial ablation, but dysmenorrhea (before 
treatment), uterine depth and a submucous myoma increased the risk of treatment 
failure. On the other hand we showed that sterilization, intermenstrual bleeding 
and age equal or above the 45 years had also an effect on the treatment outcome, 
although this effect was limited in the multivariable analysis. These results are 
generally in agreement with results of other studies evaluating the outcome of 
various sorts of endometrial ablation techniques.4,10-13
The main limitation of our study was its retrospective character. This resulted in 
partly precluding some objective pre-operatively factors and objective treatment 
outcomes, for example the validated pictorial blood loss assessment chart 
(PBAC) score. Besides that, date of a few potential prognostic factors were partly 
incomplete. Three pre-operative variables, hemoglobin, endometrial thickness 
and the PBAC-score were missing data from more than 20% of patients.
Naturally we realized that retrospective data collection is not as reliable 
as prospective data collection, but we only used properly recorded data of the 
medical records of our own patients. In this way we tried to avoid any kind of bias 
related to the retrospective nature of this study. The strength of our study is the 
long-term outcome, representing the experience of a relatively large geographic 
region in a specialized medical center, and on the other hand the size and diversity 
of the population of clinicians and patients.  
Predictors of treatment failure included dysmenorrhea, uterine depth and 
a submucous myoma. The association between the increased risk of treatment 
failure and dysmenorrhea was described by El Nashar et al. and Bongers et al., 
although in the study of Bongers et al. the association could not be confirmed in the 
multivariable analysis.4,12 An explanation could be that undiagnosed adenomyosis 
may persist after ablation, which could cause pelvic pain and unsatisfied patients. 
Unfortunately we could not find enough reliable (histological) information about 
adenomyosis in the medical records or the operation theatre registration to come 
to a conclusion or give an explanation for possible failure of any endometrial 
ablation. At the end, this could require a hysterectomy. Consistent to the result of 
Gemer et al., Comino and Torrejón and El Nashar et al. a submucous myoma is also 
a risk factor for hysterectomy.11-13 
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Our result that age above 45 years affected the treatment outcome is 
consistent with findings from previous studies showing that older women have 
a better outcome from endometrium ablation than younger women.4,10,12,14 The 
reason for the higher observed rate of hysterectomy in women who underwent a 
sterilization is not clear. There are studies in which a post-ablation tubal sterilization 
syndrome has been described, characterized by pain from the distention of the 
proximal end of the fallopian tube. This supposed to be cause by regeneration of 
the cornual endometrium, intra-uterine adhesions that obstruct the outflow tract 
and tubal ligation that prevents emptying into the peritoneal cavity.15
In this study a retroverted uterus, prolonged duration of menstruation, 
pretreatment endometrial thickness, parity, PBAC-score, and hemoglobin showed 
no statistically significant increased risk of treatment failure (OR’s respectively, 2.1, 
1.0, 0.6, 1.0, 0.8). In contrast, Bongers et al. previously found an association between a 
retroverted uterus, prolonged duration of menstruation and endometrial thickness 
with an increased risk of treatment failure using the thermal balloon ablation.4 The 
association regarding the retroverted uterus may occur because the posterior wall 
of a uterus in retroversion will not have as much thermal injury as the posterior wall 
of an anteverted uterus. However, in our study we used three different endometrial 
ablation methods, including the NovaSure®, a technique based on radiofrequency 
ablation which do not use any balloon. Thick endometrium was suggested to 
prevent a deep intramural thermal effect, so the damage of the basal layer was 
limited.4,12 The duration of menstruation before treatment was, in agreement with 
El Nashar et al., not a significant risk factor for treatment failure.12 The finding that 
those last three factors did not affect the outcome of endometrial ablation in our 
study is consistent with results that were reported in previous studies.12,16
Theoretically, a NovaSure® procedure carries the risk of uterine perforation in 
women with a previous Cesarean section. In our study, we did not observe cases 
of perforation. Obviously, our sample size was not large enough to rule out a small 
risk.
In conclusion, the findings of this study show that Cesarean delivery is not 
associated with an increased risk of endometrial ablation failure in women with 
menorrhagia, but dysmenorrhea, uterine depth and a submucous myoma can 
predict treatment failure. Therefore we believe that the data of this study can be 
used to optimize preoperative patient counseling. 
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Objective: To compare the effectiveness of two second-generation ablation 
techniques, bipolar radiofrequency impedance-controlled endometrial 
ablation and hydrothermablation, in the treatment of menorrhagia. 
Methods: This study was a double-blind, randomized controlled trial, 
which took place in a large teaching hospital in The Netherlands with 
500 beds. Women with menorrhagia were randomly allocated to bipolar 
radiofrequency ablation (bipolar group) and hydrothermablation 
(hydrotherm group). At follow-up, both women and observers remained 
unaware of the type of treatment that had been performed. The primary 
outcome was amenorrhea. Secondary outcome measures were patient 
satisfaction and reintervention.
Results: We included 160 women in the study, of which 82 were allocated 
to the bipolar group and 78 to the hydrotherm group. No complications 
occurred in either of the treatment groups. After 12 months the amenorrhea 
rates were 47% (35 of 75) in the bipolar group and 24% (17 of 71) in the 
hydrotherm group (relative risk (RR) 2.0, 95% confidence interval (CI) 1.2-
3.1). In the bipolar group 87% (65 of 75) of the patients were completely 
satisfied with the result of the treatment compared with 68% (48 of 71) 
in the hydrotherm group (RR 1.3, 95% CI 1.03-1.6). The relative risks for a 
reintervention in the bipolar group compared with the hydrotherm group 
was 0.29 (95% CI 0.12-0.67), whereas for hysterectomy, this was 0.49 (95% 
CI 0.15-1.5).
Conclusion: In the treatment of menorrhagia, bipolar radiofrequency 
endometrial ablation system is superior to hydrothermablation.
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Excessive menstrual bleeding, or menorrhagia, is a frequent problem in 
women of reproductive age. The definition of menorrhagia is menstrual blood 
loss exceeding 80 ml from normal secretory endometrium.1 Its incidence varies 
between 9% and 14%.2 The disorder may cause iron deficiency anemia but also 
shows a significant impact on the medical, social economic and psychological 
well-being of women.3,4 About 30-40% of the hysterectomies are performed for 
treatment of severe dysfunctional bleeding.5   
Endometrial ablation is an alternative to hysterectomy in women with 
dysfunctional bleeding. The first-generation devices for ablation were endometrial 
laser ablation, transcervical resection of the endometrium and rollerball 
ablation. These techniques had disadvantages such as fluid overload or water 
intoxication.6-10 Second-generation techniques overcame these disadvantages of 
the first generation techniques. Moreover, these techniques require less skill of the 
surgeon.11,12,13  
The NovaSure® endometrial ablation device (bipolar radiofrequency 
endometrial ablation) is one of the second-generation devices that use bipolar 
radiofrequency impedance-controlled endometrial ablation to evaporate 
endometrial tissue. Recently, bipolar radiofrequency endometrial ablation was 
reported to be superior over balloon ablation, making it the standard of choice 
in women requesting ablation for dysfunctional uterine bleeding.14 However, 
the method also has disadvantages. It is a blind procedure, which is performed 
without hysteroscopic view. The size and shape of the uterus must be fairly normal 
in order to use the system, and intracavitary fibroids or large polyps interfere with 
the placement of the device.  
The HydroThermAblator® (hydrotherm endometrial ablation) system is a 
second-generation technique that is applied under hysteroscopic view, thus 
potentially reducing the risk of uterine perforation. In a randomized multicenter 
study hydrothermablation was found to be equally effective as rollerbal ablation.15 
Randomized comparisons between bipolar radiofrequency and hydrotherm 
endometrial ablation are lacking. In view of this lack of knowledge, we performed a 
randomized controlled trial comparing these two second-generation endometrial 
devices in women suffering from menorrhagia.




We performed a randomized controlled trial (RCT) in the Máxima Medical Centre, 
Veldhoven, The Netherlands. The Máxima Medical Centre is a teaching hospital 
with 500 beds in the south of The Netherlands. The study was approved by 
the institutional review board (number 457) and registered in the clinical trial 
register (ISRCTN23845359). All participants gave written informed consent before 
enrollment. 
Women with menorrhagia were eligible for the trial. Menorrhagia was defined 
as indicated on the pictorial chart described by Higham et al.16 During their period, 
the patient records the use of tampons and towels, and the loss of clots on a 
scoring system. A lightly stained towel or tampon scored 1 point, a moderately 
stained towel or tampon 5 points, a towel or tampon which was saturated with 
blood scored 20 points. A clot the size of 1p scored 1 point, a 50p sized clot scored 
5 points and flooding also scored 5 points. One period is counted and a minimum 
score of 150 points was described as menorrhagia. We did not select the patients 
with an anemia because women in the Netherlands are seen by their general 
practitioner first. Most of them were already treated with iron therapy and would 
not a low hemoglobin and hematocrit in the hospital.  
Saline infusion sonography or diagnostic hysteroscopy was required 
to confirm a normal uterine cavity, with a cavity length of 6 to 12 cm and a 
histologically benign endometrium. All women underwent a sonography. Patients 
with minimal intracavitary pathology, such as type 2 fibromas and small polyps 
(both ≤2cm), were also included. All women had to have a normal Pap smear, a 
negative Chlamydia test of the cervix, and a premenopausal follicular stimulating 
hormone (FSH)-level of less than 40 IU/l. Exclusion criteria were the presence of 
coagulopathies, use of anticoagulants, a desire to preserve fertility, prior uterine 
surgery (except low segment Caesarean section) and suspected or confirmed 
uterine malignancy. All women who were included in the study preferred to be 
treated by endometrial ablation after careful evaluation of the advantages and 
disadvantages of the other treatment options.  
We planned surgery in day 3 to 8 of the menstrual cycle. Both groups received 
no medical endometrial pre-treatment prior to surgery, because of the side-effects 
of the medication and the bipolar group would have been treated unnecessarily. 
All patients had Naproxen 250 mg 12 hours and one hour before treatment. 
Computer generated randomization was performed by one of the authors (JP or 
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RE) just before the start of treatment in a 1:1 ratio.  
Patients and investigating doctors were masked for the randomization 
allocation, and remained so during the study. The doctors performing the 
endometrial ablation did know at that moment which device was used. The 
patient did not know. The physician who saw the patient at the follow-up visits did 
not know which device was used. At the 12 months follow-up visit the patient was 
told which device was used for the endometrial ablation. The ablation treatments 
in both arms were all performed by two gynaecologists (CK or MB), specialized in 
these ablation techniques. Both surgeons had equal experience with each device. 
The bipolar radiofrequency endometrial ablation system consists of a 
generator and a disposable device. When suction is applied, the endometrial 
lining is brought into contact with the electrode array. It is suitable for a uterus 
with a minimum of 2.5 cm cornu-to-cornu distance, and a depth of 6 to 11 cm as 
measured by uterine sounding.14  
The hydrothermablation provides controlled endometrial ablation by 
circulating heated saline in the uterine cavity under hysteroscopic vision. The 
disposable sheath is inserted into the uterine cavity under direct hysteroscopic 
vision. A tight seal is necessary to prevent leakage of heated saline through the 
cervix. First a diagnostic hysteroscopy with room-temperature saline was performed 
to rule out intracavitary pathology. Continuous-flow circulation is maintained 
by gravity inflow and an aspiration pump. The fluid pressure is determined by 
the height of the fluid measurement reservoir and saline bag. The height of the 
reservoir is 115cm above the patient’s uterus; it gives a net pressure of saline into 
the uterine cavity of 50-55 mmHg, which is well below the 70mmHg at which the 
tubes are opened. Once the diagnostic hysteroscopy was finished, the ablation 
treatment was started. The ablating phase starts with heating the saline in the 
heating canister, the temperature is displayed on the panel. It takes approximately 
three minutes to heat the saline to 90 degrees. The ablation cycle takes 10 minutes, 
the timer is set on the display. During heating and treatment cycle, the procedure 
automatically stops when the fluid loss is 10ml.  
We measured the duration of the procedure which was defined as the 
moment the gynaecologist begun with introduction of a speculum, until the 
end of the ablation. Patients in both groups were treated in a day-care program, 
using either spinal or general anaesthesia. Follow-up visits were carried out at 
the outpatient clinic at four weeks, six months and 12 months after the initial 
treatment. At these consultations, the patients were seen by a doctor who was 
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unaware of the treatment that had been performed. At each visit, duration of 
menstruation, presence of dysmenorrhea and clots were registered. Patients also 
completed a pictorial chart, and expressed their satisfaction about the treatment 
result. Level of satisfaction was categorised as; completely satisfi ed, satisfi ed, 
doubtful or not satisfi ed. Furthermore, we registered whether a reintervention had 
been performed. Reinterventions considered were the use of oral contraceptives 
and performed hysterectomies. Menstrual bleeding was quantifi ed using the 
Pictoral Blood Loss Assessment Chart (PBLAC) of Higham et al. A score of zero (0) 
operationally defi ned “amenorrhea”.  
The primary outcome measure was amenorrhea at 12 months post treatment. 
Secondary outcome measures were the reduction in bleeding, patient satisfaction, 
and complications and hysterectomies in both groups. 
We anticipated an amenorrhea rate of 30% in the hydrotherm group.14 Using 
an equivalence assumption with a 90% success rate for both groups and an 
acceptable diff erence of at maximum 15%, we needed 72 women per arm (80% 
power).17 Assuming that approximately 90% of enrolled patients would complete 
the study protocol, a total of 160 patients (hydrotherm:bipolar 1:1) had to be 
enrolled.  
Analysis  
The analysis was performed according to the ‘intention-to-treat’ principle i.e., 
patients were analysed in the group to which they had been allocated. Patients in 
whom a hysterectomy was performed for bleeding complaints were considered 
as being amenorrhoeic. 
Repeated measures analysis of variance was used to evaluate changes in 
eff ect over time (time eff ect), diff erences in eff ect between both treatment groups 
(treatment eff ect), and interaction between changes in eff ect over time and 
treatment group (time by treatment eff ect).18 Patients with missing measurements 
were included in the repeated measure analysis if data were available for at least 
two diff erent time points.19 P-values less than 0.05 were considered to indicate 
statistically signifi cant diff erences. When a statistically signifi cant diff erence in 
menstrual pattern and patient satisfaction between both treatment groups or an 
interaction between changes in menstrual pattern and patient satisfaction over 
time and treatment group was found, the diff erences between treatment groups at 
specifi c points in time were examined. In case of dichotomous endpoints this was 
done by calculating relative risks and 95% confi dence intervals. For the continuous 
25367 Penninx, Josien.indd   36 11-05-13   17:24
A RCT comparing bipolar and hydrotherm endometrial ablation
37
3
outcome duration of menstruation we calculated a diff erence of the medians with 
a 95% confi dence interval, using a bootstrap procedure.20 The pictorial chart score 
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Amenorrhea: 17/71 (30.4%)  
Figure 1. Trial profi le. HTA= hydrothermablation




Between March 21st 2005 and August 30th 2007 160 women were included in 
the study, of which 82 patients were allocated to the bipolar endometrial ablation 
group and 78 patients to the hydrothermablation group (Figure 1). The baseline 
characteristics of both groups were comparable (Table 1).
All women included in the study underwent sonography. Furthermore, 59 
women in the hydrotherm group and 58 women in the bipolar group had a saline 
infusion sonography, and in each group 17 patients underwent a hysteroscopy. 
Three patients (one in the hydrotherm group and two in the bipolar group) decided 
not to undergo the endometrial ablation after randomization, as they became 
frightened of the procedure. Three patients in the hydrotherm group underwent 
bipolar radiofrequency endometrial ablation, because of technical problems 
with the hydrothermablation device in the operating room at the moment the 
treatment had to be performed.  
The average duration of the bipolar group was 11.8 minutes (range 5 
to 40 minutes) compared to 27.8 minutes (range 14 to 55 minutes) for the 
hydrothermablation group (P<.001). In the bipolar group one patient had a 
perforated uterus. In three patients in the hydrothermablation group leakage of 
saline was reported, but it was possible to complete the procedure in these three 
patients. Two of these three women reported to be satisfied with the treatment 
result at 12 months. 
Overall, seven patients in each group were lost to follow up after 12 months 
(Figure 1). Baseline characteristics of the patients lost to follow-up were 
comparable to those included in the study, but numbers were too low to compare 
this for statistical significance (Table 1). 
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Age (years) 44.7 ± 4.8 44.8 ± 4.9 41.2 43.6
Duration of menstruation (days) 8.8 ± 4.9 10.0 ± 4.9 10.1 10.7
Patients with clots  67 (82) 68 (87) 6 (86) 7 (100)
Duration of clots (days) 3.1 ± 2.7 3.5 ± 2.7 2.8 3.8









       Moderate










       Anteverted
       Midposition
       Retroverted
       Missing data
64 (78)
1   ( 1 )
14 (17)
3   ( 4 )
66 ( 8 )
1   ( 1 )                  
9   (12)
2   ( 2 )
5 (83)




0 ( 0 )
2 (29)
0 ( 0 )
Hemoglobin (mmol/L) 8.1 ± 0.8 8.2 ± 0.8 7.5 8.3
FSH (international units/L) 9.6 ± 15.2 12.4 ± 15.5 5.7 4.6
Uterine length (cm) 9.1 ± 1.2 9.1 ± 1.2 9.2 9.1
Endometrial thickness (mm) 7.5 ± 5.8 7.6 ± 5.7 5.9 10.9
Data are mean ± standard deviation or median (minimum-maximum), or n (%). FSH: follicle-stimulating 
hormone.
Figure 2 shows the patient satisfaction at 4 weeks, and at 6 and 12 months after 
treatment. Both treatment and time effect of patient satisfaction were statistically 
significant (P<.001), whereas time by treatment effect showed no significant 
interaction (P=.06). At 12 months, the patients were more satisfied after bipolar 
endometrial ablation (RR 1,3, 95% CI 1.0-1.6).  














Bipolar ablation Hydrothermablation Bipolar ablation Hydrothermablation Bipolar ablation Hydrothermablation
4 weeks 6 months 12 months
completely satisﬁed satisﬁed doubtful unsatisﬁed
Figure 2. Patient satisfaction at 4 weeks, 6 months, and 12 months after the bipolar or 
hydrotherm ablation. Repeated measure analysis indicates that both, the treatment effect as 
well as the effect in time, on patient satisfaction are statistically significant (P<.001) 
Figure 3 shows the percentage of women with amenorrhea, absence of dysmenorrhea 
and absence of clots after bipolar endometrial ablation and hydrothermablation. 
There were significantly more women reporting amenorrhea at six and 12 months 
after the procedure in the bipolar group (RR at 12 months 2.0, 95% CI 1.2 to 3.1). A 
sensitivity analysis showed that when all women that were lost to follow-up after 
bipolar radiofrequency endometrial ablation would have had amenorrhea, the 
relative risk at 12 months would have been 2.1 (95% CI 1.3 to 3.3). In contrast, when 
all women that were lost to follow-up after hydrothermablation would have had 
amenorrhea, the RR at 12 months would have been 1.7 (95% CI 1.1 to 2.7). 
0 1 2 3 4 5
          Favours                                                 Favours
HydroThermAblator                                        Novasure                                              
At 6 months                                         Novasure  HTA
Amenorrhea                                         28/76     12/74
Absence of dysmenorrhea                 60/76     56/74
Absence of clots                                  72/76     53/74
At 12 months                                      Novasure  HTA
Amenorrhea                                         35/75     17/71
Absence  of dysmenorrhea                59/75     61/71
Absence of clots                                  70/75     59/71
RR       95% CI
2.3      1.3    to 4.1
1.04    0.88  to 1.2
1.3      1.1    to 1.5
2.0       1.2    to 3.1
0.92     0.79  to 1.1
1.1       0.99  to 1.3
Relative risk
Figure 3. Treatment effect of bipolar and hydrotherm ablation at 6 months and 12 months after 
treatment. RR, relative risk; CI, confidence interval
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There was a significant decrease in duration of menstruation after 6 and 12 
months in both groups, as compared to the duration of menstruation at baseline 
(P=.001). The duration of menstruation was significantly shorter in the bipolar 
group in time, treatment and time by treatment effect (P-values <.001). Figure 
4 shows the median pictorial chart score in both groups at baseline, 4 weeks, 6 
months and 12 months after the procedure. 
Six months after the procedure 24 reinterventions had been performed in 
total, five in the bipolar group compared to 19 in the hydrotherm group. One 
patient in the bipolar group had bipolar endometrial ablation again, whereas four 
women had a hysterectomy. In the hydrotherm group, eight patients underwent a 
bipolar endometrial ablation procedure, three patients started oral contraceptives 
and eight women underwent a hysterectomy. At 12 months only two more 
reinterventions were performed. One patient started oral contraceptives in the 
bipolar group and one patient underwent bipolar endometrial ablation in the 
hydrothermablation group. All reinterventions were performed because of 
persisting menorrhagia. Pathologic examination showed normal sized uteri in all 
cases. At 12 months, six reinterventions had been performed in the bipolar group 
versus 20 in the hydrotherm group (RR 0.29 (95% CI 0.1 to 0.7)). Furthermore, a 
total of four patients underwent a hysterectomy in the bipolar group, compared 
to eight in the hydrotherm group (RR 0.49 (95% CI 0.2 to 1.5)). 
Figure 4. Median pictorial (minimum, maximum) chart score at baseline, 4 weeks, 6 and 12 
months after treatment




In this randomized clinical trial, we studied two second-generation endometrial 
ablation techniques during the first year after treatment. The bipolar radiofrequency 
endometrial ablation device performed better than hydrothermablation in terms 
of patient satisfaction, amenorrhea, and menstrual bleeding as scored on the 
mean pictorial chart score.  
We analyzed the study according to intention to treat. Three women in the 
hydrotherm group received the bipolar radiofrequency procedure because of a 
technical defect of the hydrothermablation device. The most reinterventions were 
performed after six months. We expect that these reinterventions can influence 
the results of both groups, but especially the outcome of the hydrotherm group. 
The amenorrhea rate of the hydrotherm group is higher than expected 
probably due to the fact that 35% had a reintervention of which nine hysterectomies 
were performed. These women were scored as amenorrheal and were satisfied 
with the result of the reintervention. We choose to consider women who had a 
hysterectomy as amenorrheal. By doing so, we basically evaluated the effect of 
two strategies, of which hysterectomy was a part. Alternatively, one could consider 
patients who had additional hysterectomy as failures. However, in that case one 
has to make assumptions on the pictorial chart scores, as these women were 
amenorrheal after their hysterectomy.  
As shown in table 1 the average hemoglobin was around 8,1 mmol/L in both 
groups. The women in the Netherlands are seen by their general practitioner first. 
When they visited the hospital they were already treated with iron therapy if there 
was an anemia. These women would not show a low hemoglobin and hematocrit. 
That is why we did not select the patients with anemia but used the pictorial chart 
score to select patients.  
The operation time for the bipolar endometrial ablation was less than half that 
of the hydrotherm procedure. This shortens operating room time and may be an 
important advantage in an outpatient setting. We have not performed an analysis 
of cost-effectiveness. Hydrothermablation is feasible and acceptable in outpatient 
setting, but the ablation cycle takes about 10 minutes compared to 90 seconds of 
the bipolar radiofrequency procedure.22 The very short ablation procedure of the 
bipolar radiofrequency device however, makes it a promising ablation technique 
for outpatient treatment.  
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The amenorrhea rate of the bipolar group was comparable with previously 
reported studies (41%-58%).14,23-24 We expected the hydrotherm group to do 
better, especially in women with small intracavitary pathology, as the circulating 
hot water has the possibility to contact the entire endometrial surface regardless 
of the shape of the uterine cavity. By including women with small intracavitary 
abnormalities, we suspected the bipolar radiofrequency device to be less 
successful. However, we found a lower amenorrhea rate in the hydrotherm group 
compared to the bipolar group, but also lower than reported in previous studies 
using hydrothermablation and comparing the hydrothermablation to rollerball 
endometrial ablation (40-44%).18,25 In most reported studies hydrothermablation 
is performed after GnRH pretreatment. This treatment thins the endometrial layer 
and thus might give better treatment results.18 We wanted to perform an everyday 
practice study and decided to schedule the procedure just after menstruation.  
The patient satisfaction after bipolar radiofrequency endometrial ablation is 
comparable to other studies (90-92%) and slightly lower in the hydrotherm group 
(73%).14,18,26
There is a high reintervention percentage compared to other studies 
(5%).17 The study of Guillot et al. was a retrospective study, it could be that the 
hysterectomies were underreported. It is possible that GnRH-pretreatment is 
necessary for an optimal result in the hydrotherm group. This is a disadvantage 
for the hydrothermablation device in view of the costs and adverse side effects 
of GnRH. In our study only three patients (4%) in the bipolar group underwent a 
hysterectomy in the year after treatment, this percentage is lower than presented 
in previous studies (4,8-8%).14
Both second-generation ablation techniques used in this study are safe and 
easy to perform. However, based on the results of the current randomized trial, 
bipolar endometrial ablation appears to offer higher patient satisfaction and 
amenorrhea rates.
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Objective: To evaluate the results of a previous study comparing bipolar 
radiofrequency endometrial ablation with hydrothermablation for the 
treatment of menorrhagia at 5-year follow-up.
Methods: A double-blind, randomized, controlled trial was performed 
in a large teaching hospital in the Netherlands between March 2005 and 
August 2007. One-hundred sixty women with menorrhagia were randomly 
allocated to bipolar ablation or hydrothermablation. The results of follow-
up at 12 months were previously reported. At 4-5 years of follow-up, a 
questionnaire was sent to all the participants to register amenorrhea rates, 
reinterventions, and patient satisfaction.
Results: At 5-year follow-up, response rates were 90% and 83% in the bipolar 
group and hydrotherm group, respectively. Amenorrhea rates were 55.4% 
and 35.3% in the bipolar group and the hydrotherm group, respectively 
(relative risk (RR) 1.5, 95% confidence interval (CI) 1.05-2.3). The number of 
surgical reinterventions was 11 compared with 23 (RR 0.43, 95% CI 0.23-
0.80). Overall, more women were satisfied in the bipolar group compared 
with the hydrotherm group. 
Conclusion: After treatment, bipolar radiofrequency endometrial ablation 
system is more effective at 5 years than hydrothermablation in the treatment 
of menorrhagia.
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Heavy menstrual bleeding is a common gynecological problem in women 
of reproductive age and is one of the most important reasons for consulting 
a gynecologist.1,2 Hysterectomy is a definitive solution for the treatment of 
menorrhagia. Based on cost-effectiveness hysterectomy should be considered 
as the preferred strategy for the treatment of heavy menstrual bleeding.3 
Nevertheless, it is a major surgical procedure with physical complications and 
social and economic costs.4 Many women opt a less invasive treatment, even 
when they are informed of the fact that success is not always assured.5 So, further 
research should focus on different treatment options and need to contain patients 
preference.
Many endometrial ablation techniques have been evaluated as a treatment 
for menorrhagia and currently have been established as a common practice. The 
first-generation techniques (laser, transcervical resection of the endometrium and 
rollerball) require a hysteroscopy with the use of distension medium and the risk 
of intravasation with fluid overload. These procedures require skilled surgeons to 
minimize adverse events. Second-generation techniques have been developed. 
These techniques are more simple and easy to perform, without the need of a 
hysteroscopy. Second-generation techniques are at least as effective as first 
generation techniques, but often are easier to perform.6 However, 5-year follow-up 
is frequently limited in most of the second-generation studies. The aim of ablative 
therapies is to offer patients a desirable and long term solution. Therefore, adequate 
follow-up of these therapeutic interventions is needed for good evidence-based 
clinical decision making. 
From March 2005 until August 2007, we performed a randomized controlled 
trial in which we compared the bipolar radiofrequency impedance-controlled 
endometrial ablation with hydrothermablation. The primary outcome measure 
was amenorrhea; secondary outcome measures were reintervention and patient 
satisfaction. We concluded that bipolar endometrial ablation is superior to 
hydrothermablation in the treatment of menorrhagia within a follow-up of 12 
months.7 This study evaluates the primary and secondary outcomes at 5-year 
follow-up. 




A randomized controlled trial comparing the bipolar radiofrequency 
impedance-controlled endometrial ablation device (NovaSure®, Hologic) and 
hydrothermablation (HydroThermAblator® system, Boston Scientific) was 
performed in the Máxima Medical Centre, a teaching hospital with 500 beds in 
the south of The Netherlands. The trial has previously been described in detail by 
Penninx et al.7 The randomization techniques were performed by the CONSORT 
guidelines. The individuals gave informed consent at start of the study so we 
could contact them in future for a follow-up study. The ethics committee of the 
Máxima Medical Centre in Veldhoven, the Netherlands, approved the study.7 
Women with menorrhagia as indicated on the pictorial chart described by 
Higham et al, with a minimum score of 150 points, were eligible for the trial.8 They 
were referred by their general practitioner and hormonal treatment was already 
tried but unsuccessful, or patients were not motivated to use hormonal treatment. 
During their menstrual period, the patient recorded the use of tampons and towels, 
and the loss of clots on a scoring system. A lightly stained towel or tampon scored 
1 point, a moderately stained towel or tampon 5 points, a towel or tampon which 
was saturated with blood scored 20 points. A small clot scored 1 point, a moderate 
clot scored 5 points and flooding also scored 5 points. One menstrual period is 
counted and a minimum score of 150 points was described as menorrhagia.
Further inclusion criteria were an uterine depth between 6 and 11 cm and 
a premenopausal state. Patients with minimal intracavitary pathology, such as 
leiomyomata, of which less than 50% of the myoma was present in the uterine 
cavity and small polyps (less than 2 cm), were also included. Women with presence 
of coagulopathies, a desire to preserve fertility and uterine malignancy were 
excluded. 
All participants had to complete a written informed consent form before 
enrollment. Computer-generated randomization was performed by one of the 
authors (JP) just before the beginning of treatment, at which 82 women were 
allocated to the bipolar group and 78 women to the hydrotherm group. Patients 
and doctors who performed the follow-up visits and telephone calls were masked 
for the randomization allocation, and remained so during the study. The doctor 
performing the endometrial ablation did, of course, know at that moment which 
device was used. The patient did not know. The physician who saw the patient at 
the follow-up visits was masked and did not know which device was used. 
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To obtain insight into the 5-year follow-up, postal questionnaires were send 
from November 2010 until January 2011 (4-5 years of follow-up). The mean 
follow-up time was 4.5 years after the original procedure (range 3 to 5-6 years). All 
patients were asked to complete the questionnaires. Outcomes were amenorrhea, 
reinterventions and patient satisfaction with the result of the treatment, which was 
similar to what we previously reported at 12 months follow-up. The preablation 
bleeding was already asked at trial entry.
Patients who did not return the questionnaires received a single reminder 
after one week. If questionnaires were not returned after this reminder in 4 weeks, 
we tried to contact the patients by telephone. A simplified questionnaire was used 
for the telephonic interviews. Women were asked about their menstruation (days, 
clots and dysmenorrhea), treatment satisfaction and reintervention. We contacted 
patients’ general practitioners if we had missing addresses or phone numbers. In 
case of lacking information, we searched patients’ medical records for information 
about reinterventions. 
The analysis was performed according to the intention-to-treat principle, ie. 
patients were analyzed in the group to which they had been allocated. We considered 
women who have undergone a hysterectomy as not having amenorrhea and as 
being dissatisfied with their ablation treatment. Both hysterectomy and reablation 
were scored as a surgical reintervention. Time to surgical reintervention was 
compared with Kaplan Meier analysis. Dichotomous outcomes, such as presence 
of amenorrhea, absence of clots, absence of dysmenorrhea, and reinterventions 
were compared by calculating a relative risk (RR) and its 95% confidence interval 
(CI). Repeated-measures analysis of variance was used to evaluate changes over 
time (time effect) between both groups (treatment effect) and interaction between 
changes in effect over time and treatment group (time by treatment effect).
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n=13  
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Completed 5 -year follow-up  
 




Completed 5 -year follow-up  
 
n=65; 83,3%  
 
 
Figure 1. Trial profile 
Results
Between March 2005 and August 2007, 160 women were included in the trial, 
of which 82 women were allocated to the bipolar group and 78 women to the 
hydrotherm group. In November 2010 we sent questionnaires to all patients, after 
which 125 women returned the questionnaire. Of the non-responding 35 women, 
19 women were contacted by telephone, after which eight women sent the 
questionnaires, eight women were interviewed by telephone, and three women 
did not want to participate. Seven women had unknown addresses or telephone 
numbers (or both), four women died, and five did not answer their telephone 
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multiple times. Non-response was mostly attributable to the fact that patients 
had moved houses or changed telephone numbers. Overall, 21 women (eight in 
the bipolar group and 13 in the hydrotherm group) were lost to follow-up. The 
5-year follow-up rate was 90.2% (n=74) in the bipolar group and 83.3% (n=65) in 
the hydrotherm group (figure 1). The baseline characteristics of both groups were 
comparable (table 1) and resembled those reported in our previous study.5  







Age (years) 49.5 ± 5.0 49.3 ± 4.7
Duration of menstruation (days) 8.6 ± 4.0 9.4 ± 5.2












Data are mean ± standard deviation or median (minimum-maximum), or n (%).
After 5-year follow up, the number of patients with amenorrhea in the bipolar 
endometrial ablation group was 41 of 74 (55.4%), compared to 23 of 65 (35.4%) 
in the hydrotherm group (RR 1.5, 95% CI 1.1-2.3). Table 2 shows the percentage 
of women with amenorrhea, absence of dysmenorroe and absence of clots after 
bipolar endometrial ablation and hydrotherm ablation. A sensitivity analysis 
showed that when we did consider women who have undergone a hysterectomy 
as being amenorrhoeic, as we did in our previous study, the relative risk would 
have been 1.2 (95% CI 0.9-1.5). When we consider all women who were lost to 
follow-up after the endometrial ablation as nonamenorrhoeic, the RR at 5-year 
follow-up would have been 1.6 (95% CI 1.1-2.4). 
We recorded 43 reinterventions, all because of persisting menorrhagia, 14 
in the bipolar group compared to 29 in the hydrotherm group (RR 0.43, 95% CI 
0.25-0.74). Two patients in the bipolar group had undergone bipolar endometrial 
ablation again, whereas nine women had a hysterectomy, two women got a 
levonorgestrel intrauterine device, and one patient underwent a hysteroscopy. 
In the hydrotherm group, 10 patients underwent bipolar endometrial ablation, 
13 patients underwent a hysterectomy, four patients started oral hormonal 
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therapy and two patients had a levonorgestrel intrauterine device placed. When 
reintervention was limited to surgical procedures, 11 women in the bipolar group 
had a surgical reintervention compared to 23 women in the hydrotherm group (RR 
0.43 (95% CI 0.23-0.80)). When we consider the women who were lost to follow-up 
as having had a reintervention, the RR at 5-year follow-up would have been 0.52 
(95% CI 0.34-0.80). The life table analysis is shown in figure 2.












     1 year








     1 year








     1 year














0 20 40 60 80
Bipolar ablation
Hydrotherm ablation





















Figure 2. Percentage of women after bipolar or hydrotherm endometrial ablation without a 
reintervention in months after randomization 
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Pathologic examination of the hysterectomy specimens in the bipolar group 
showed adenomyosis (n=2), leiomyomata (n=4) and no abnormalities (n=3). In 
the hydrotherm group, pathologic examination showed adenomyosis (n=2), 
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Figure 3A. Patient satisfaction at 12 months of follow-up after bipolar and hydrotherm 
endometrial ablation
Patients were more often satisfied in the bipolar group compared with those in the 
hydrotherm group (80.6% versus 48.4%, RR 1.7, 95% CI 1.3-2.2) (Figure 3A en 3B). 
When we consider the nonresponders as not satisfied, the RR would have been 
the same 1.7 (CI 95% 1.3-2.2)). Repeated-measures analysis showed a significant 
treatment effect (P<0.001). Nevertheless, in both groups satisfaction rates were 
decreased as compared to rates at 12 months (time effect P<0.001); time-by-
treatment effect showed no significant interaction (P=0.107).
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Figure 3B. Patient satisfaction at 5 years of follow-up after bipolar and hydrotherm ablation
Discussion
In this follow-up study, we compared the treatment of two second-generation 
endometrial ablation techniques in women with menorrhagia 5 years after 
treatment. Amenorrhea rates were higher in the bipolar group than the hydrotherm 
group, respectively (55.4% and 35.3%, RR 1.50, 95% CI 1.05-2.3), and the number 
of surgical reinterventions was lower (11 compared with 23, RR 0.43, 95% CI 0.23-
0.80). Overall, more women were satisfied in de bipolar group compared to the 
hydrotherm group.
We analyzed the study according to the intention-to-treat principle. Unlike 
our previous study, we evaluated women who had a hysterectomy as being 
non-amenorrhoeic because of the fact that those women chose this treatment 
because of their persisting menorrhagia. We considered patients who had an 
additional hysterectomy as failures of treatment. Scoring hysterectomy as being 
amenorrhoeic, as in our previous study, would not give direct results on the 
ablation effect, especially not with this higher number of surgical reinterventions 
compared with 12-month follow-up. 
Compared to the 1-year follow-up, the 5-year follow up showed an increase 
in amenorrhea rates in both groups. Because the patient characteristics were 
comparable at the beginning of the randomized controlled trial, we would estimate 
that by randomization the amount of women who would be postmenopausal 
would be approximately the same in both groups. The amenorrhea rate of the 
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bipolar group is comparable with that seen in previously reported long-term follow-
up studies (48%-65%).9,10 Long-term studies of hydrothermablation are limited, and 
amenorrhea rates differ from 38% to 53%.11,12 We found lower amenorrhea rates 
in the hydrotherm group compared with those found in the literature, but this is 
in line with our previously reported 12-month result.7 In most studies hydrotherm 
ablation is performed after gonadotropin-releasing hormone pretreatment. 
This might give better treatment result because it thins the endometrial layer.13 
In the Netherlands, we do not administer gonadotropin-releasing hormone 
pretreatment before endometrial ablation; therefore, we scheduled the procedure 
just after menstruation. Differences in numbers comparing absence of clots and 
absence of dysmenorroe between 12 months and 5 years were explained by the 
fact that we considered women with a hysterectomy as being amenorrhoeic at 
the 12-month follow up.
At 5-year follow up, we see a comparable increase in reinterventions in both 
groups. We chose to report the surgical reinterventions rather than hysterectomies 
alone, whereas both hysterectomy and reablation are invasive ways of treatment. 
At 12-month follow-up, the hydrotherm ablation already showed significantly 
more reinterventions, and so does this follow-up study for reintervention in total 
as surgical reintervention. 
We observed a high surgical reintervention rate in both groups compared 
with other studies.9-14 Kopeika et al reported a hysterectomy rate of 11% for the 
hydrotherm ablation at a follow-up of 8 years, but this was a retrospective study.11 
As mentioned, it is possible that gonadotropin-releasing hormone pretreatment 
is necessary for an optimal result in this group.13 The thickness of the endometrial 
layer could be a predictor for failure of hydrotherm ablation treatment. As shown 
in our previous article, there was no difference in baseline endometrial thickness.7 
In the group with reinterventions, the average endometrial thickness was 7,7 in 
the hydrotherm group and 7,9 in the bipolar group. Comparing pathology of 
hysterectomy specimens, differences in both ablation groups were not found. 
Literature reporting on long-term follow-up after bipolar ablation describes 
hysterectomy rates from 3% to 9.8%.9,10,14 However, only Kleijn et al reported a 
patient-blinded and observer-blinded randomized controlled trial, comparable to 
our study. Because of lack of blinding in previous studies, the hysterectomy rate 
might have been overstated in earlier studies. 
This trial described a high satisfaction level for the bipolar ablation 5 years 
after the procedure, whereas satisfaction rates for the hydrotherm group were 
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low. Although we saw an increase in amenorrhea rate in both groups, we also 
saw a significant reduction in satisfaction level in both groups over time. In 
literature, a few trials use satisfaction as an outcome measure and because of 
this, it is difficult to compare these results with other trials. However, Middleton 
et al describes that more women are dissatisfied after endometrial destruction 
than after hysterectomy, but the rates of dissatisfaction are still relatively low.15 
They also noticed that absence of leiomyomata, or polyps shows a trend towards 
reduced dissatisfaction (P=.07).15 In our study, we did not exclude women with 
leiomyomata, because we wanted to evaluate the results of ablation in patients 
with menorrhagia with or without little uterine leiomyomata and in women with 
menorrhagia without hormonal pretreatment. This could have influenced our 
results. Data of success, satisfaction and health related quality of life are essential 
to offer patients a desirable and long-term solution for menorrhagia. Therefore, 
adequate follow-up of these therapeutic interventions is still needed for clinical 
decision making and counselling of patients.  
The results from this follow-up study showed that bipolar ablation has 
many advantages over hydrotherm ablation. Higher amenorrhea rate, less 
reinterventions, and higher levels of satisfaction were shown. So, the bipolar 
radiofrequency endometrial ablation system is more effective than hydrotherm 
ablation in the treatment of menorrhagia.
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Objective: We have previously demonstrated that in women with heavy 
menstrual bleeding bipolar radiofrequency ablation is superior over 
hydrotherm ablation in terms of amenorrhea rates and patient satisfaction. 
In the present study, we report health related quality of life after both 
interventions.
Design: A double blind randomized controlled trial. 
Setting: A teaching hospital in the Netherlands. 
Population: One hundred and sixty women with heavy menstrual bleeding.
Methods: Women were randomly allocated to bipolar radiofrequency 
ablation and hydrothermablation. They were asked to complete quality 
of life questionnaires at baseline, 4 weeks, 6 and 12 months and 5 years 
after randomization. The menorrhagia multi-attribute scale (Shaw), medical 
outcomes study Short-Form (SF-36), and Euroqol before randomization, 
and at each follow-up visit after randomization, were selected to evaluate 
quality of life. The menorrhagia outcomes questionnaire (MOQ) was 
completed at 4 weeks, 6 and 12 months after treatment. 
Main outcome measures: Health related quality of life.
Results: Health related quality of life data were available at at least two 
different time points in 136 patients. Quality of life improved significantly 
over time in all questionnaires. None of the quality of life dimensions 
showed a significant effect between both groups, neither was there a 
significant interaction between time and treatment. 
Conclusions: In all generic and disease specific questionnaires treatment 
of heavy menstrual bleeding improved health related quality of life over 
time. A treatment effect of amenorrhea and satisfaction did not result in 
quality of life benefits.
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Heavy menstrual bleeding (HMB) is a common problem for women in their 
reproductive age. It has psychosocial effects on women and their environment and 
can result in work impairment.1 Heavy menstrual bleeding often is the main reason 
for consultation of a gynaecologist. The perception of women on the severity of 
the bleeding often is very important for the evaluation of treatment success. 
At present, many studies report on amenorrhea and satisfaction rates after 
treatment, as these dimensions are considered to be most important for the 
patient after treatment. Currently, quality of life assessment might potentially also 
be important, as this is a more objective assessment of the patient’s condition. 
However, little data are available on the impact of treatment of HMB on quality 
of life. Besides that, there is an increasing demand on long term follow-up studies 
after treatment.2,3 We recently reported the results of a randomized controlled 
trial comparing bipolar radiofrequency endometrial ablation (bipolar group) and 
HydroThermAblation (hydrotherm group) in women with HMB.4 At 12-month 
follow-up the amenorrhea rates were 47% in the bipolar group compared to 24% 
in the hydrotherm group (relative risk (RR) 2.0, 95% confidence interval (CI) 1.2-3.1). 
At the same time, 94% (45/48) of the patients in the bipolar group were satisfied 
with the result versus 80% (36/45) in the balloon group (RR 1.2, 95% CI 1.0 to 1.4). 
After 5 years, the bipolar group still had higher satisfaction and amenorrhea rates 
compared to the hydrotherm group in the treatment of HMB.5  
We concluded that in the treatment of HMB, bipolar radiofrequency 
endometrial ablation was superior to hydrothermablation. As part of the RCT, we 
measured health related quality of life. In the present paper, we compare quality 
of life after bipolar radiofrequency endometrial ablation and hydrothermablation.
Material and methods
We performed a randomized controlled trial in the Máxima Medical Centre, 
Veldhoven, The Netherlands. Women with HMB, documented by a Highamscore 
of 150 points or more, were eligible for the trial.6 The study was approved by the 
Institutional Review Board (No. 457) and was registered in the international trial 
register (ISRCTN23845359). All participants provided written informed consent 
before enrollment. 
25367 Penninx, Josien.indd   63 11-05-13   17:24
Chapter 5
64
Computer randomization was performed in a 1:1 ratio. Patients and investigating 
doctors were masked for the randomization allocation, and remained so during the 
study. Doctors performing the endometrial ablation obviously did know which 
device was used, but the physician who saw the patient at the follow-up visits did 
not know which device had been used. The patient was not informed during the 
first year of follow-up. Saline infusion sonography or diagnostic hysteroscopy was 
required to exclude patients with intracavitairy pathology. Women with a normal 
uterine cavity or minimal intracavitairy pathology, such as type 2 fibromas and small 
polyps (both ≤ 2cm), were included. All women had to have a histologically benign 
endometrium and a cavity length of 6-12 cm. Women with HMB were randomly 
allocated to bipolar radiofrequency ablation and hydrothermablation in a 1:1 ratio. 
All patients were asked to complete quality of life questionnaires at baseline, 
4 weeks, 6 months, 12 months and 5 years after randomization. The menorrhagia 
multi-attribute scale (Shaw), medical outcomes study Short-Form (SF-36), and 
Euroqol before randomization, and at each follow-up visit after randomization 
were selected to evaluate quality of life.7 The menorrhagia outcomes questionnaire 
(MOQ) was completed at 4 weeks, 6 months and 12 months after treatment.
The SF-36 is a multi-purpose, short-form health survey with only 36 questions. 
It yields an 8-scale profile of functional health and well-being scores as well as 
psychometrically-based physical and mental health summary measures and a 
preference-based health utility index. The SF-36 and MOQ have proven their 
reliability and validity to measure the effects of treatment on quality of life in 
women suffering from HMB.8-11
The menorrhagia outcomes questionnaire (MOQ) was specifically developed 
as a questionnaire that could be administered following treatment, and therefore 
it did not needed a pre-treatment assessment for comparison. The MOQ has four 
score domains: symptoms (2), post-operative complications (3), quality of life (7) 
and satisfaction with outcome (5). Two summary scores are obtained for Quality of 
Life/ Satisfaction (12 items) and Global outcome (17 items).11
The menorrhagia multi-attribute quality-of-life scale (Shaw) has also proven 
its validity and acceptability.12,13 It assesses the effect of HMB on quality of life 
on six domains: practical difficulties, social life, psychological wellbeing, physical 
health, work routine and family life. The statement scores derive from a weighting 
of the domains and a weighting of the statements in level of severity by women in 
the original study. Scores range from 0 (worst possible state in all domains) to 100 
(best possible state in all domains).
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To obtain insight in the long term follow-up, postal questionnaires (SF-36, 
EuroQOL and Shaw) were sent 5 years after the original procedure. All patients 
were asked to complete the questionnaires. Patients who did not return the 
questionnaires received a single reminder after one week. If questionnaires were 
not returned after this reminder in 4 weeks, we tried to contact the patients by 
telephone.
Analysis
Health related quality of life was studied on an intention to treat basis. Repeated 
measure analysis of variance was used to establish changes in health related 
quality of life over time (time effect), differences in health related quality of life 
between both treatment groups (treatment effect), and interaction between 
changes in health related quality of life over time and treatment group (time by 
treatment effect). Patients with missing values were included in the repeated 
measure analysis if data were available for at least two different time points.14 
P-values < 0.05 were considered to indicate statistically significant differences. 
If a statistical difference in health related quality of life between both treatment 
groups, or an interaction between changes in health related quality of life over 
time and treatment group was found, Student’s t-tests were used to examine 
differences between time groups at specific time points. 
Results
Between March 21st 2005 and August 30th 2007, 160 women were included in the 
study, of which 82 patients were allocated to bipolar endometrial ablation (bipolar 
group), and 78 patients to hydrothermablation (hydrotherm group). The number of 
patients allocated to the bipolar group and the hydrotherm group that completed 
the questionnaires at separate time points were: 70 versus 65 at baseline, 73 versus 
67 at 4 weeks, 57 versus 49 at 6 months, 55 versus 50 at 1 year and 74 versus 65 
at 5 years after treatment. The baseline characteristics were comparable in both 
groups (Table 1).
25367 Penninx, Josien.indd   65 11-05-13   17:24
Chapter 5
66





Age (years) 44.5 ± 4.5   44.6 ± 4.3
Duration of menstruation (days) 8.6 ± 3.9 9.8 ± 5.8
Number of patients with clots 47 (85) 43 (86)
Duration of clots (days) 3.4 ± 1.6 3.6 ± 2.9
Pictorial chart 745 (240–2000) 809 (250–2005)
Dysmenorrhea
          Moderate






          Anteverted
          Midposition







Haemoglobin (mmol/L) 8.0 ± 0.8 8.0 ± 0.8
FSH (International units/L) 8.5 ± 12.0 14.1 ± 17.8
Data are mean ± standard deviation or median (minimum-maximum), or n (%).  
FSH: follicle-stimulating hormone.
The results of the comparison between health related quality of life (SF-36) in the 
bipolar and hydrotherm group are shown in table 2. 
It shows no significant effect between both groups nor a significant interaction 
between time and treatment for the SF-36. However, on all measures there was a 
significant effect over time for health related quality of life. Health related quality 
of life improved in all dimensions at 4 weeks, 6 months, 12 months and 5 years 
after treatment, as compared to the baseline measurements in both, the bipolar 
group and the hydrotherm group. Figure 1 shows the changes of the SF-36 over 
time. There were no significant differences between both groups at follow-up, but 
the physical component of the SF-36 score was significantly lower in the bipolar 
group at baseline (P=.010). Health related quality of life improved at 4 weeks, 6 
months and 12 months after treatment, to decrease again at 5-year follow-up. But 
still, it remained however as high or higher compared to the reference value of the 
general population.
Table 2 shows the results of the EuroQOL with the effect measurement at 1 
year and 5 years after treatment. Health related quality of life improved at each 
follow up moment after treatment as compared to the baseline measurements in 
both, the bipolar group and the hydrotherm group. Till 12 months after treatment 
a significant effect over time was found (P=.017). Five years after treatment the 
time effect was not statistically significant anymore (P=.140). Figure 2 shows 
the changes of the EuroQOL over time. The quality of life improved at 4 weeks,
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Bipolar 78±43 86±17 87±18 90±16 90±15 85 <0.001    .069 .22
Hydro-
therm 
65±42 91±14 96±9 95±9 89±20
Role physical Bipolar 50±43 69±41 88±29 90±28 88±29 81 <0.001    .79 .98
Hydro-
therm 
65±42 72±41 94±29 95±19 88±31
Role emo-
tional
Bipolar 67±40 86±25 87±30 92±23 84±46 81 0.005    .11 .12
Hydro-
therm 
69±45 87±21 92±32 96±18 89±27
Social func-
tioning
Bipolar 65±23 82±21 85±24 86±21 82±27 84 <0.001    .63 .72
Hydro-
therm 
75±21 83±20 89±28 90±18 89±16
Mental health Bipolar 68±18 80±15 77±15 78±17 78±17 81 0.001    .17 .89
Hydro-
therm 
73±20 81±16 83±15 85±14 80±18
Energy/vitality Bipolar 47±18 62±19 67±19 70±18 66±20 61 <0.001    .87 .70
Hydro-
therm 
55±21 63±23 71±18 73±18 68±21
Pain Bipolar 60±26 74±22 82±23 82±25 82±20 75 <0.001    1.0 .63
Hydro-
therm 
63±25 74±22 81±20 85±18 81±24
General health Bipolar 64±21 72±22 72±23 77±20 72±21 72 <0.001    .66 .29
Hydro-
therm 
































    28±6




























   .191
   .592
   .121
   
   .19






Results are expressed in mean ±SD. Reference values are general population means.
§ scores could range from 0-100 with higher scores indicating better functioning.
¥scores could range from 0-1 with higher scores indicating better functioning.1=effect till 1 year after 
randomization, 2=effect till 5 years after randomization.
‡scores could range from 10-46 with lower scores indicating better functioning
# scores could range from 11-57 with lower scores indicating better functioning.
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6 months and 12 months after treatment in the hydrotherm group, but decreased 
at 5-year follow-up. In the bipolar group the EuroQOL increased after treatment 
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Figure 1. SF-36 quality of life domains, before and after bipolar radiofrequency endometrial 

















Figure 2. EuroQOL before and after bipolar radiofrequency endometrial ablation and 
hydrotherm endometrial ablation
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Mean scores of the Shaw questionnaire are shown in table 2. There was a 
significant effect over time for health related quality of life (P<.001), but there 
was neither a significant effect between both groups nor a significant interaction 
between time and treatment. 
Figure 3 shows the Shaw scores at baseline and at follow-up. There was a 
significant higher Shaw score at baseline in the hydrotherm group (P=.042). After 
treatment, the bipolar group shows higher Shaw scores, but only at six months 































































Figure 3. Shaw questionnaire score at baseline, 4 weeks, 6 months, 12 months and 5 years after 
bipolar radiofrequency endometrial ablation and hydrothermablation
In each separate Shaw domain the score was significantly higher in the 
bipolar group at six months follow-up, except at domains psychological health 
and physical health/wellbeing (Figure 4). Table 2 shows the means of the MOQ 
score, that significantly improved over time (P<.001). Again, there was neither a 
significant effect between both groups nor a significant interaction between time 
and treatment (Table 2). 
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Figure 4. Shaw domains before and after bipolar radiofrequency endometrial ablation and 
hydrotherm endometrial ablation




This randomized clinical trial comparing bipolar radiofrequency endometrial 
ablation and hydrotherm endometrial ablation in women suffering from 
dysfunctional uterine bleeding showed a significant improvement of health 
related quality of life after treatment for a period of at least 5 years after treatment. 
The generic and disease specific questionnaires gave similar results over time. 
The differences in amenorrhea rate and satisfaction rate between both ablation 
techniques, as reported earlier, did not result in a quality of life difference between 
both treatments.4 
There are two ways to measure health related quality of life.15,16 The generic 
measures can be used for the assessment of a general profile of perceived 
health, with dimensions such as physical, psychological and social health. These 
questionnaires allow comparisons among different types of disease, because 
they are not specific to any particular condition. We used generic quality of life 
instruments (SF-36 and EuroQOL) to ensure appropriate measurement of quality 
of life. We found changes in quality of life after treatment in the SF-36. Others also 
have found the SF-36 to be sensitive for changes in quality of life after treatment 
in women suffering from HMB.17-19 Both, the SF-36 and EuroQOL, do contain many 
items about health problems at a specific moment, which is difficult to answer by 
women with HMB because they mainly have complaints during their menstruation. 
Furthermore, these instruments do not determine the specific impact of a disease 
or condition on quality of life. Disease specific quality of life instruments are 
designed to measure the specific consequences that a particular disease has on 
quality of life. Therefore, we combined generic quality of life instruments with 
disease specific questionnaires (Shaw questionnaire and MOQ).11-13  Shaw et al. 
developed the multi-attribute assessment instrument to assess the effect of HMB 
on quality of life.7 Especially the domain practical difficulties, relating to sanitary 
protection, flooding, etc. in the Shaw questionnaire is specific for HMB compared 
to other quality of life questionnaires.12 The Shaw questionnaire also showed a 
significant improvement over time (time-effect), but no difference between the 
two endometrial ablation techniques (treatment-effect). 
The menorrhagia outcome questionnaire (MOQ) was developed to evaluate 
the outcomes of all surgical interventions for the treatment of HMB.11 It was 
specifically developed as a single questionnaire which could be administered 
once following treatment therefore not needing a pre-treatment assessment 
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for comparison. The questions are framed to elicit an assessment of the patient’s 
current symptoms and quality of life compared to prior to the operation. Then you 
have to rely on post-treatment retrospective items.19 
Sexual health, another important part of woman’s quality of life, may also be 
adversely affected by HMB. Sexual health also should have been assessed before 
and after treatment, but this was not measured by the quality of life questionnaires 
used in this trial. Only one question in the MOQ covered the influence of the 
operation on sexual health. Therefore, sexual health is not extensively measured 
by the quality of life questionnaires used in this trial. 
The improvement in health related quality of life, that was observed in both 
groups over time, could be affected by the fact that patients knew that they had 
been treated. As far as we know, all RCTs evaluating the effect of treatment on 
dysfunctional uterine bleeding have reported an improvement in quality of life 
after treatment. We are unaware of studies that have included a sham procedure or 
a control group without intervention. The role of any medical or surgical treatment 
intervention against no intervention is still an interesting area for research. The 
review of quality of life instruments in studies of HMB showed the absence of a 
standardized instrument for measuring outcomes in trials for abnormal uterine 
bleeding.20 It would be ideal if a validated measure or set of instruments would be 
developed that captured all HMB symptoms. This standardized tool could be used 
in all future trials. 
This RCT, comparing bipolar radiofrequency ablation and hydrothermablation, 
showed a significant improvement over time in health related quality of life in the 
generic and disease specific questionnaires. A treatment effect of amenorrhea and 
satisfaction did not result in quality of life benefits. The better amenorrhea and 
satisfaction rates in the bipolar group compared to the balloon group were not 
accompanied with a difference in quality of life. When looking at the figures 1 till 4, 
the Shaw questionnaire (Figure 4) seems to show a trend to a higher score in the 
bipolar group, which corresponds with the higher amenorrhea and satisfaction 
rate, compared to the other questionnaires, but it only was significant at 6 month 
follow-up. The discrepancy between clinical outcome and quality of life was 
also reported in the trial of Clark et al. in which bipolar endometrial ablation was 
compared with thermal balloon endometrial ablation in the office.21 They used the 
same health related quality of life questionnaires as in our trial, and also found a 
significant time effect, but no significant treatment effect. 
The fact that the better amenorrhea and satisfaction rates in the bipolar 
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group did not result in a difference in quality of life could be explained in two ways. 
First, the quality of life questionnaires that we used may be not sensitive enough 
to measure the effects of treatment on quality of life. Second, an explanation 
for the discrepancy between the similar quality of life scores in spite of different 
amenorrhea and patients satisfaction rates might be that amenorrhea and patient 
satisfaction do not affect quality of life. The impact of HMB on quality of life has 
been reported previously, and therefore it is unlikely that the significant difference 
in amenorrhea rate and satisfaction rate does not affect health related quality of 
life.17,22 But in these studies quality of life was only measured with the generic 
health related quality of life questionnaire (SF-36).
In conclusion, health related quality of life in the treatment of HMB improved 
over time in all generic and disease specific questionnaires in both treatment 
groups. The better amenorrhea and satisfaction rates in the bipolar group 
compared to the balloon group did not result in quality of life benefits.
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Objective: To evaluate the safety, feasibility and efficacy of endometrial 
ablation under local anesthesia.  
Methods: A prospective cohort study was performed at the gynecology 
department of a large teaching hospital. Women with dysfunctional uterine 
bleeding were included to undergo NovaSure® endometrial ablation with 
paracervical block. We measured the acceptability, pain score (visual analog 
score), amenorrhea, and patients’ satisfaction after the procedure.
Results: We treated 33 patients. No complications occurred during the 
procedure or postoperatively. Of the 33 women, 28 found treatment with 
NovaSure® endometrial ablation under local anesthetics acceptable. After 
24 hours, 23 of 33 women reported to be pain free, whereas 10 women 
still had mild pain. Twenty women developed amenorrhea (60.6%) and 
13 women hypomenorrhea (39.4%). All women were satisfied with the 
treatment result and would recommend it to a friend.
Conclusion: NovaSure® endometrial ablation performed under local 
anesthesia is a safe, feasible and efficacious procedure.
25367 Penninx, Josien.indd   80 11-05-13   17:24




Menorrhagia is a frequent problem in premenopausal women. Menorrhagia 
affects 1 in 20 women.1 If the diagnostic work-up has shown no abnormalities, 
the menorrhagia is classified as dysfunctional bleeding. In women with 
dysfunctional bleeding, endometrial ablation is an effective treatment.2 The 
NovaSure Endometrial Ablation Device (Hologic, USA) is a bipolar radiofrequency 
impedance-controlled system to evaporate endometrial tissue.3 In our clinic, the 
NovaSure® was performed from 1998 onward with general anesthesia or regional 
(spinal) anesthesia. The procedure only takes 1 to 2 minutes.4 
We hypothesized that this short duration of treatment would make this 
intervention suitable for local anesthesia. We performed a prospective study to 
assess the feasibility and patient acceptability of NovaSure® endometrial ablation 
in an outpatient setting under local anesthesia.
Materials and Methods
We performed this prospective study in the Maxima Medical Centre (MMC), 
Veldhoven, The Netherlands, approved by the institutional review board. The 
MMC is a teaching hospital with 500 beds. Women suffering from menorrhagia, 
as indicated by a pictorial chart with a Higham score of ≥ 200 points, were eligible 
for the study. Only women with dysfunctional bleeding were included after 
evaluation with saline infusion sonohysterography and hysteroscopy verifying that 
there were no abnormalities. The women had no desire for another child. After 
being informed about the study, women gave written informed consent.
In the MMC, endometrial ablation is performed with a NovaSure® device 
(Hologic, USA). If an ablation treatment of the endometrium was indicated, women 
were asked if they wanted to undergo the procedure under local anesthesia. The 
pain score of their menses was noted. 
The NovaSure® procedure was scheduled at the outpatient clinic. Women 
were advised to use an oral nonsteroidal anti-inflammatory drug (Ibuprofen 
500mg) as a painkiller 12 hours and 1 hour before the procedure. A paracervical 
block with Ultracaine or Prilocaine 1% with or without adrenaline was placed. A 12-
20 mL amount of the solution was injected just under the epithelium of the cervix, 
not deeper than 3 mm, at 2, 5, 7 and 10 o’clock. 
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After placing the paracervical block there was a 3-minute wait time for 
anesthetic effect before starting the NovaSure® procedure. After the NovaSure® 
device had been brought into the uterus, suction was applied, the endometrial 
lining was brought into contact with the electrode array, and the fluid and debris 
generated during the ablation process were removed. During the procedure, 
oxygen saturation was observed by a pulse-oximeter. The procedure was only 
performed by one gynecologist. Four hours after the procedure the patient was 
advised to take Paracetamol 1,000mg, Naproxen 500mg or, Tramal 100mg. 
Visual analog scales (VAS) were used to measure pain when dilating the 
cervix, during the NovaSure® procedure, and at 4 and 24 hours after the procedure. 
The VAS is a straight line with the left end of the line representing no pain and the 
right end of the line representing the worst pain. Patients were asked to mark on 
the line the painfulness of the procedure. 
Follow-up examination was done at 6 weeks after treatment. At this visit the 
menstruation was scored again on a pictorial chart. Women were also asked if they 
would be prepared to undergo the procedure again if needed and if they would 
recommend the procedure to a friend. 
Results
From November 2006 until January 2008, 33 women were included in the study. 
The mean age was 46.7 years, ranging from 33 to 57 years. The average parity 
was 2.0, with three nulliparas. In all women it was feasible to perform the total 
NovaSure® procedure with a paracervical block, and premature termination of the 
procedure was never needed. Four patients developed a vasovagal reaction during 
the procedure. The average procedure time was 110 seconds (range 63-120). The 
average probe length was 8.5 cm (range 7-10), the length of the uterine cavity was 
4.6 cm (range 3.5- 6), and the intercornual length was 4.1 cm (range 2.0-4.8).
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Figure 1. Visual analog scale pain score of the total bipolar ablation procedure
The median pain score during dilatation was 3.0 (range 1.0-7.0). The median pain 
score for the entire procedure was 5.1 (range 0.0-10.0) (Figure 1). After 24 hours, 23 
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Figure 2. Visual analog scale pain score 24 hours after bipolar ablation treatment
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Figure 3. Visual analog scale pain score of dysmenorrhea before treatment
After six weeks 20 women developed amenorrhea (60.6%) and 13 women 
hypomenorrhea (39.4%). They were all satisfied with the result. Thirty-one patients 
found the NovaSure® under local anesthetics to be acceptable (94%); only 2 
patients would not undergo the procedure again. No complications occurred 
during the procedure or postoperatively. 
Discussion
We used the NovaSure® procedure with local anesthesia in 33 patients, and found it 
to be a safe and feasible procedure. In the medical literature almost all endometrial 
ablation procedures are performed at an outpatient clinic or theatre with general 
or local anesthetics, or paracervical block with intra-venous sedation. 
One study compared intraoperative and postoperative pain between 
ThermaChoice® endometrial ablation and NovaSure® procedure.5 The NovaSure® 
system was associated with statistically significant lower intraoperative and 
postoperative pain than the ThermaChoice® system. Data supported the idea that 
the NovaSure® procedure could become an office-based procedure.
In 2006, hysteroscopic endometrial ablation using the HydroThermAblator® 
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was performed under paracervical block without local anesthetics or IV sedation.6 
The patients reported mild pain during the procedure, and most found the 
procedure acceptable. We confirmed this with our study. The percentage of 
women with amenorrhea after the NovaSure® varies from 40-60%.7-10 The finding 
of an amenorrhea rate of 60% after 6 weeks corresponds with previous results in 
the literature. 
In summary, we successfully performed endometrial ablation under local 
anesthesia in our clinic setting, reducing operating room utilization and its 
associated costs and inconveniences. The results of this study support NovaSure® 
endometrial ablation under local anesthesia as a minimally invasive procedure of 
choice for women with dysfunctional uterine bleeding. It is a safe, feasible, and 
efficacious procedure. Whether the procedure is equally effective as treatment 
under general anesthesia should be evaluated in a larger clinical trial.
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Objective: To compare the effectiveness of bipolar radiofrequency 
endometrial ablation (Novasure®) and balloon endometrial ablation 
(Thermablate®) in the office in patients with heavy menstrual bleeding.  
Methods: We performed a multi-center double blind randomized 
controlled trial in three hospitals in The Netherlands. Women with heavy 
menstrual bleeding were randomly allocated to bipolar endometrial 
ablation or balloon endometrial ablation, performed in the office, using 
a paracervical block. The primary outcome was amenorrhea. Secondary 
outcome measures were pain, satisfaction, quality of life and reintervention.
Results: We included 104 women of whom 52 were allocated to bipolar 
ablation and 52 to balloon ablation. Complications did not occur. The mean 
visual analog pain score of the total procedure was 7.1 in the bipolar group 
and 7.4 in the balloon group (P<.577). Amenorrhea rates were 60% (29/48) 
in the bipolar group and 27% (12/45) in the balloon group (relative risk (RR) 
2.3, 95% confidence interval (CI) 1.3 to 3.9). After 12 months, 94% (45/48) 
of the patients in the bipolar group were satisfied with the result of the 
treatment versus 80% (36/45) in the balloon group (RR 1.2, 95% CI 1.0 to 
1.4). The reintervention rates were 5/52 (10%) in the bipolar group and 6/52 
(12%) in the balloon group (RR 1.02, 95% CI 0.9 to 1.2). The Shaw score, 
expressing quality of life, improved over time (P<.001) and was significantly 
higher in the bipolar group at 12 months follow-up (P=.025). 
Conclusion: In the treatment of heavy menstrual bleeding, bipolar 
radiofrequency endometrial ablation is superior to balloon endometrial 
ablation.
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Excessive menstrual bleeding is a significant health problem in women in 
reproductive age. It can cause anemia and reduce quality of life. The incidence 
varies between 9 to 22 %.1-3 About 30-40% of the hysterectomies are performed 
for treatment of severe dysfunctional bleeding.4 Hysterectomy is an effective 
treatment, but it is a major surgical procedure with a complication rate up to 67%.5
Endometrial ablation is a less invasive alternative to hysterectomy, and 
preserves the uterus. The first-generation endometrial ablation techniques were 
laser ablation, transcervical resection of the endometrium and rollerball ablation. 
Disadvantages of these techniques were the chance of fluid overload or water 
intoxication.6-9 Second-generation techniques overcame these disadvantages as 
they were technically simpler, quicker to perform and requiring less skills of the 
surgeon, while satisfaction rates and reduction in heavy menstrual bleeding are 
similar.10
The NovaSure® endometrial ablation device is one of the second-generation 
devices that uses bipolar radiofrequency impedance-controlled endometrial 
ablation to evaporate endometrial tissue. Bipolar radiofrequency endometrial 
ablation was reported to be superior over balloon ablation and hydrothermablation, 
making it the standard of choice in women requesting ablation for dysfunctional 
uterine bleeding.11-13 NovaSure® can be used under local anesthesia in the office.14
The majority of women (70%) prefer an outpatient ablation treatment.15 
Spending less time in the hospital, attending for one visit, feeling well directly 
after treatment and choosing the treatment setting were important factors to 
the majority of women in this choice. Recently we reported that NovaSure® under 
local anesthesia in the outpatient setting was a safe, feasible, and efficacious 
procedure.14
The Thermablate® balloon ablation technique is relatively new on the market. 
It seems perfect for outpatient treatment with local anesthesia because of its small 
diameter and relatively short treatment time of two and a half minutes and a much 
higher temperature compared to the Thermachoice® balloon.16,17 There are no 
randomized trials comparing Thermablate® with other ablation techniques. In view 
of this lack of knowledge, we performed a randomized controlled trial comparing 
these two second-generation endometrial devices with local anesthesia in the 
office.




We performed a multi-centre randomized controlled trial (RCT) in the Máxima 
Medical Centre Veldhoven, Twee Steden Hospital Tilburg and Zuidoost Clinic 
Amsterdam, The Netherlands. The study was approved by the local institutional 
review board (number 813) and registered in the international trial register 
(ISRCTN17974690). All participants gave written informed consent before 
enrollment. 
Women with heavy menstrual bleeding (HMB) were eligible for the trial. HMB was 
defined as indicated on the pictorial chart described by Higham et al.18  One period 
is counted, and a minimum score of 150 points was described as HMB.
All women underwent a sonography. Women with intracavitairy pathology 
were excluded, except women with intracavitary polyps less than 1 cm. Saline 
infusion sonography or diagnostic hysteroscopy was required to confirm a normal 
uterine cavity, with a cavity length of 6 to 12 cm and a histologically benign 
endometrium within 6 months of screening. All women had to have a normal 
Pap smear and a premenopausal follicular stimulating hormone (FSH)-level of 
less than 40 IU/l. Exclusion criteria were the presence of coagulopathies, use of 
anti-coagulants, a desire to preserve fertility, prior uterine surgery other than low 
segment Cesarean section and suspected or confirmed uterine malignancy. All 
women who were included in the study preferred to be treated by endometrial 
ablation in the outpatient setting after careful evaluation of the advantages and 
disadvantages of the other treatment options. The procedure was planned in the 
postmenstrual phase at day 3-8 of the menstrual cycle. Both groups received no 
medical endometrial pretreatment prior to surgery. 
Eligible and consenting women were randomly allocated to bipolar 
endometrial ablation or balloon endometrial ablation in the office. Randomization 
was performed by taking a sealed opaque envelope just before start of treatment 
in every center in a 1:1 ratio. Patients and investigating doctors were masked for 
the randomization allocation, and remained so during the study, while obviously 
the doctors performing the ablation did know at that moment which device was 
used. The physician who saw the patient at the follow-up visits did not know 
which device was used. 
The bipolar radiofrequency endometrial ablation system (NovaSure®) consists 
of a generator and a disposable device. After the device is introduced in the 
uterine cavity, a cavity assessment check has to be completed. When suction is 
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applied, the endometrial lining is brought into contact with the electrode array. It 
is suitable for a uterus with a minimum of 2.5 cm cornu-to-cornu distance, and a 
depth of 6-11 cm as measured by uterine sounding.19
The balloon endometrial ablation (Thermablate® EAS system) consists of a 
hand-held automated Treatment Control Unit (TCU) and a single-use disposable 
catheter balloon cartridge. The cartridge contains 28 ml of a biocompatible 
treatment fluid. It is connected to the TCU which heats the fluid to a temperature 
of 173°C in 8 minutes. This heating process takes place before or during patient 
preparation. The 6 mm, heat shielded, soft-tipped catheter is brought into the 
uterine cavity to the predetermined depth. The TCU’s pneumatic system transfers 
the fluid through the catheter, inflating the silicone balloon within the cavity 
to a set pressure level of 220 mmHg. During treatment, the system performs a 
depressurization and repressurization cycle 3 times to maintain consistent balloon 
surface contact with the uterine cavity. This creates uniform temperature of the 
fluid within the balloon. The treatment time always is 2 minutes and 38 seconds.17 
Before and after the balloon ablation a hysteroscopy was performed, as the balloon 
procedure itself does not verify cavity integrity before treatment. 
All procedures were scheduled at the outpatient clinic. Women used an oral 
nonsteroidal anti-inflammatory drug (Naproxen 500mg) as a painkiller one hour 
before treatment. A paracervical block with Ultracain was placed. A 12-20 mL 
amount of the solution was injected just under the epithelium of the cervix at 2, 5, 
7 and 10 o’clock. After placing the paracervical block there was a 3 minute waiting 
time for the anesthetic effect before starting the dilatation of the cervix. After 
the procedure the patient was advised to take Paracetamol 1,000mg, Naproxen 
500mg or if necessary Tramal 100mg.
Visual analog scales were used to measure pain when dilating the cervix, 
during the endometrial ablation, and at 1, 4, 12 and 24 hours after the procedure. 
The visual analog scale is a straight line with the left end of the line representing no 
pain and the right end of the line representing the worst pain. Patients were asked 
to mark on the line the painfulness of the procedure which corresponds with a 
pain score from 0 to 10. 
Follow-up visits were carried out at the outpatient clinic or by telephone at 6 
weeks, 6 months and 12 months after the initial treatment. At these consultations, 
the patient had contact with a doctor who was unaware of the treatment that had 
been performed. At each visit, duration of menstruation, presence of dysmenorrhea 
and clots were registered. Patients also completed a pictorial chart, and expressed 
25367 Penninx, Josien.indd   93 11-05-13   17:24
Chapter 7
94
their satisfaction about the treatment result. Level of satisfaction was categorized 
as completely satisfied, satisfied, doubtful or not satisfied. 
Menstrual bleeding was quantified using the Pictoral Blood loss Assessment 
Chart (PBAC) of Higham et al. A score of zero (0) operationally defined “amenorrhea”. 
All patients were asked to complete the menorrhagia multi-attribute scale (Shaw 
questionnaire) at baseline and at each follow-up visit to assess the effects of 
HMB on quality of life. The scores of the domains were rated with a score of zero 
points (worst) to 100 points (best).20,21 Furthermore, we registered whether a 
reintervention had been performed. Reinterventions considered were the use of 
oral contraceptives, re-ablation, and performed hysterectomies. 
The primary outcome measure was amenorrhea at 12 months post 
treatment. Secondary outcome measures were pain, reduction in bleeding, patient 
satisfaction, quality of life and reinterventions. 
Based on available information of the Thermablate® and other balloon ablation 
devices, an amenorrhea rate of 30% is anticipated in the balloon group and 50% 
in the bipolar group.11,12,22-25 Using a 1-tailed test of proportions with P=0.05, 
the proposed sample size of 94 patients has 80% power to detect a treatment 
difference of 20% or greater. Assuming that approximately 90% of enrolled patients 
would complete the study protocol, a total of 104 patients (bipolar:balloon 1:1) 
had to be enrolled.
Analysis
The analysis was performed according to the ‘intention-to-treat’ principle i.e., 
patients were analyzed in the group to which they had been allocated. Repeated 
measures analysis of variance was used to evaluate changes in effect over time 
(time effect), differences in effect between both treatment groups (treatment 
effect), and interaction between changes in effect over time and treatment group 
(time-by-treatment effect). Patients with missing measurements were included in 
the repeated measure analysis if data were available for at least two different time 
points.26  
P-values less than 0.05 were considered to indicate statistical significance. 
When a statistically significant difference in menstrual pattern, patient satisfaction 
or multi utility scale score between both treatment groups or an interaction 
between changes in menstrual pattern and patient satisfaction over time and 
treatment group was found, the differences between treatment groups at specific 
points in time were examined. In case of dichotomous endpoints this was done 
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by calculating relative risks and 95% confidence intervals. The pictorial chart 
score and VAS score were compared using the Wilcoxon test.27,28 We calculated 
treatment satisfaction after treatment with a T test. All data were analyzed using 
IBM SPSS statistics 20 for Windows.
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Figure 1. Trial profile. HTA=hydrothermablation




Between March 2009 and December 2011 104 women were included in the study, 
of whom 52 were allocated to the bipolar group, and 52 were allocated to the 
balloon group (Figure 1). Ninety-six patients were included in the Máxima Medical 
Centre in Veldhoven, six patients in the Twee Steden Hospital and two in the 
Zuidoost Clinic. Table 1 shows the baseline patient characteristics of both groups, 
these were comparable. 





Age (years) 45.4 ± 4.7 44.1 ± 4.4
Duration of menstruation (days) 9.3 ± 4.9 8.4 ± 4.9
Patients with clots 47 (90) 51 (98)
Duration of clots (days) 3.2 ± 1.6 3.2 ± 1.1
Pictorial chart 979 (300-2400) 931 (452-2500)
Dysmenorrhea
          Moderate















3 (6)                            
6 (11)
3 (6)
Hemoglobin (mmol/L) 7.5 ± 1.1 8.1 ± 0.7
FSH (international units/L) 10.9 ± 13.0 7.9 ± 9.6
Uterine length (cm) 9.0 ± 1.0 9.2 ± 0.9
Endometrial thickness (mm) 7.4 ± 6.5 10.1 ± 7.6
Data are mean ± standard deviation or median (minimum-maximum), or n (%).
FSH: follicle-stimulating hormone.
In the bipolar group 49 patients had the allocated intervention, while 3 did not. 
One patient decided not to undergo the endometrial ablation, as she became 
frightened of the ambulant procedure after randomization. One patient underwent 
balloon endometrial ablation because of technical problems with the bipolar 
system and one patient had a hydrothermablation because of an uterus subseptus. 
In two patients in the bipolar group it was not possible to perform the procedure 
in the office because, in one patient, dilatation of the cervix was too painful, and in 
one patient stenosis of the cervix made it impossible to introduce the NovaSure®. In 
both patients the procedure was performed in theatre with spinal analgesia.
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In the balloon group, 47 patients had the allocated intervention, while 5 did 
not. One patient decided not to undergo the endometrial ablation, as she became 
frightened of the ambulant procedure after randomization. In another patient 
it was not possible to perform the procedure because of a deformed uterine 
cavity by myomas, as became apparent during the procedure. Three patients 
in the balloon group underwent bipolar radiofrequency endometrial ablation, 
one because of technical problems with the balloon device, while two women 
persisted on having the bipolar treatment after randomization. 
The average treatment duration of the bipolar group was 10.4 minutes (range 
6 to 30) compared to 12.1 minutes (range 5 to 45) for the balloon group (P=.340). 
The mean VAS score of the total ablation procedure was 7.1 in the bipolar group 
compared to 7.4 in the balloon group (P<.577). The VAS score showed no significant 
difference between both groups at all time moments after the procedure at which 
the VAS was measured (Table 2). No complications occurred in both groups. 
Overall, four patients in the bipolar group and seven patients in the balloon group 
were lost to follow-up (Figure 1). 






Menstruation 4.8 ± 2.8 5.1 ± 2.4 .742
Total procedure 7.1 ± 2.1 7.4 ± 2.1 .577
1 hour after treatment 4.6 ± 3.1 4.5 ± 2.6 .799
4 hours after treatment 5.7 ± 2.9 5.5 ± 2.4 .826
12 hours after treatment 2.8 ± 2.0 2.5 ± 2.3 .857
24 hours after treatment 1.5 ± 1.8 1.2 ±1.8 .870
Data are presented as mean ± SD.
Figure 2 shows the percentage of women with amenorrhea, dysmenorrhea and 
patients with clots during their menstruation after bipolar endometrial ablation 
and balloon ablation.  




Figure 2: Treatment effects at 6 months and 12 months after treatment.   
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                     Relative risk 
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At 6 months  Bipolar  Balloon 
 
Amenorrhea  29/49  11/46 
Dysmenorrhea  6/49  9/46 
Absence of clots  47/49  42/46 
 
 
At 12 months  Bipolar  Balloon 
 
Amenorrhea  29/48  12/45 
Dysmenorrhea  7/48  12/45 
Absence of clots  45/48  41/45 
 
Figure 2. Treatment effects at 6 months and 12 months after treatment. 
RR, relative risk; CI, confidence interval.
The number of women reporting amenorrhea at 6 and 12 months after the 
procedure was 29/49 (59%) and 29/48 (60%) in the bipolar group and 11/46 (24%) 
and 12/45 (27%) in the balloon group (RR 2.0, 95% CI 1.3-3.0 and RR 2.3, 95% CI 
1.3 to 3.9, at 6 and 12 months, respectively). There was a significant decrease in 
duration of menstruation after 6 and 12 months in both groups, as compared to 
the duration of menstruation at baseline (P=.001). The duration of menstruation 
was significantly shorter in the bipolar group after 6 months (1.8 vs. 3.4 days, 
P=.039) and 12 months (1.6 vs. 3.4 days, P=.003).
Figure 3 shows the median pictorial chart score in both groups at baseline, 
6 weeks, 6 months and 12 months after the procedure. There was no significant 
difference between both groups in median pictorial chart score at baseline (P=.48). 
The pictorial chart score was significantly lower in the bipolar group at 6 months 
(P=.006) and 12 months (P<.001). 
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Figure 3. Pictorial chart score (PCAS) (median, minimum and maximum) at baseline, 6 weeks, 6 
months, and 12 months after bipolar and balloon endometrial ablation
Figure 4 shows the patient satisfaction at 6 weeks, 6 months and 12 months 
after treatment. Patient satisfaction did not diff er over time (P=.470), as did the 
time-by-treatment eff ect (P=.940). Treatment eff ect of patient satisfaction showed 
a signifi cant diff erence (P=.028). After 12 months, 94% (45/48) of the patients in the 
bipolar group were satisfi ed with the result of the treatment versus 80% (36/45) 
in the balloon group (RR 1.2, 95% CI 1.0 to 1.4). At 12 months, more patients were 
completely satisfi ed after bipolar endometrial ablation (40/48 (83%) versus 29/45 
(64%), RR 1.3, 95% CI 1.0-1.7). 
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Figure 4. Patient satisfaction 6 weeks, 6 months and 12 months after treatment in the bipolar 
and balloon group
After 1 year follow-up, there were 5 reinterventions in the bipolar group and 
6 in the balloon group (RR 1.02, 95% CI 0.9 to 1.2). All, but one, reinterventions 
were performed because of persisting HMB. In the remaining patient in the bipolar 
group a hysterectomy was performed for dysmenorrhea.     
In the bipolar group, we performed five reinterventions. Three patients had a 
hysterectomy, while one patient started oral contraceptives and in one patient a 
bipolar endometrial ablation was performed. This last patient had a Thermablate® 
performed before in the bipolar group because of a technical problem with the 
NovaSure®. In the balloon group, there were six reinterventions performed: four 
patients had a hysterectomy, while two patients started oral contraceptives. 






baseline 48.9 43.2 .245 -3.7 to 13.9
6 weeks 90.5 84.1 .218 -3.3 to 14.4
6 months 95.7 90.5 .273 -2.7 to 10.9
12 months 95.8 88.3 .025 0.9 to 13.7
Score 0 (worst) to 100 (best). CI, Confidence Interval.
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Mean scores of the Shaw questionnaire at baseline, and at 6 weeks, 6 months 
and 12 months after randomization are shown in table 3. There was a signifi cant 
eff ect over time (P<.001), with the Shaw score being signifi cantly higher in the 
bipolar group at 12 month follow-up (P=.025). There was neither a signifi cant eff ect 
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 Figure 5. Shaw score, expressing quality of life, at baseline, 6 weeks, 6 months and 12 months 
after bipolar radiofrequency endometrial ablation and balloon endometrial ablation 
Discussion
In this randomized clinical trial, we studied two second-generation endometrial 
ablation techniques in the outpatient clinic during the fi rst year after treatment. 
The bipolar radiofrequency endometrial ablation device (NovaSure®) performed 
better than the balloon endometrial ablation device (Thermablate®) in terms of 
amenorrhea, duration of menstruation, pictorial chart score, patient satisfaction 
and the Shaw questionnaire score.
The amenorrhea rate of 60% in the bipolar group and 27% in the balloon 
group were comparable with previously reported studies (40-56% for the bipolar 
ablation, and 7-38% for the balloon ablation).24,25,29 The higher amenorrhea 
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rate in the bipolar group is according to the network meta-analysis of second-
generation endometrial ablation techniques of Daniels et al. in which the bipolar 
radiofrequency and microwave ablation techniques appeared to be superior over 
thermal balloon ablation in terms of increased amenorrhea rate in women with 
heavy menstrual bleeding.25
Both office procedures seem acceptable. Our observed pain scores are 
comparable with a previous reported study of Clark et al. comparing bipolar 
ablation with thermal balloon ablation (ThermaChoice® III) in the office.30 Other 
studies mostly use rescue analgesia by inhaling nitrous oxide or conscious sedation 
when performing endometrial ablation in the outpatient setting. A disadvantage 
of the study is that we did not consequently asked women if they experienced 
the treatment as an acceptable procedure, in the office with local anesthesia, and 
if they would recommend it to a friend. As reported in our previous prospective 
cohort study 94% of women found the bipolar endometrial ablation an acceptable 
procedure.14 In the study of Clark et al. one-third of women would have preferred 
a general anesthesia with hindsight. We believe both treatments seem acceptable 
in the office, but we need to improve pain control.
Similarly, patient satisfaction after bipolar radiofrequency endometrial 
ablation was comparable to other studies (90-92%), as was the case for balloon 
endometrial ablation systems (76-77%).11-13,31,32 A prospective cohort pilot study 
of the Thermablate® by Karamandis et al. showed a satisfaction rate of 93% at 
12 months.33 We must be aware that satisfaction is a subjective measure that is 
resulting from subjective expectations and from effectiveness, as women could 
potentially have been more satisfied in the knowledge that a new endometrial 
ablation device was used. In a blinded RCT, the effectiveness of Thermablate® will 
probably decrease.11,29 Immediately before ablation, thinning of the endometrium 
was achieved by sharp curettage. It is plausible that this would have resulted in 
better scores compared to women without pretreatment. 
Finally, the hysterectomy rate also was comparable to other studies (2,4-
7.3%).12,30-33 
Both second-generation ablation techniques used in the office with a 
paracervical block in this study are safe and easy to perform. However, based on 
the results of the current randomized trial, bipolar endometrial ablation appears to 
offer higher amenorrhea rates, patient satisfaction and quality of life.
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Background: Heavy menstrual bleeding (HMB) is a significant health 
problem in premenopausal women; it can reduce their quality of life and 
cause anemia. First-line therapy has traditionally been medical therapy but 
this is frequently ineffective. On the other hand, hysterectomy is obviously 
100% effective in stopping bleeding but is more costly and can cause 
severe complications. Endometrial ablation is less invasive and preserves 
the uterus, although long-term studies have found that the costs of ablative 
surgery approach the cost of hysterectomy due to the requirement for 
repeat procedures. A large number of techniques have been developed 
to ‘ablate’ (remove) the lining of the endometrium. The gold standard 
techniques (laser, transcervical resection of the endometrium and rollerball) 
require visualization of the uterus with a hysteroscope and, although safe, 
require skilled surgeons. A number of newer techniques have recently been 
developed, most of which are less time consuming. However, hysteroscopy 
may still be required as part of the ablative techniques and some of them 
must be considered to be still under development, requiring refinement 
and investigation. 
Objectives: To compare the efficacy, safety and acceptability of methods 
used to destroy the endometrium to reduce HMB in premenopausal 
women. 
Search methods: We searched MEDLINE, EMBASE, CINAHL, PsycInfo, the 
Cochrane Central Register of Controlled Trials and the Cochrane Menstrual 
Disorders and Subfertility Group Specialized Register of controlled trials 
(from inception to July 2012). We also searched trial registers and other 
sources of unpublished or grey literature, reference lists of retrieved studies, 
experts in the field and made contact with pharmaceutical companies that 
manufactured ablation devices. 
Selection criteria: Randomized controlled trials comparing different 
endometrial ablation techniques in women with a complaint of heavy 
menstrual bleeding without uterine pathology were eligible. The outcomes 
included reduction of heavy menstrual bleeding, improvement in quality of 
life, operative outcomes, satisfaction with the outcome, complications and 
need for further surgery or hysterectomy. 
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Data collection and analysis: Two review authors independently selected 
trials for inclusion, assessed trials for risk of bias and extracted data. Attempts 
were made to contact authors for clarification of data in some trials. Adverse 
events were only assessed if they were separately measured in the included 
trials. Comparisons were made with individual techniques and an overall 
comparison between first and second generation ablation methods was 
also undertaken. 
Main results: Twenty five trials (4040 women with sample sizes ranging 
from 20 to 372) were included in the review. A majority of the trials had a 
specified method of randomization, adequate description of dropouts and 
no evidence of selective reporting. Less than half had adequate allocation 
concealment and most were unblinded. 
There was insufficient evidence to suggest superiority of a particular 
technique in the pairwise comparisons between individual ablation 
and resection methods. In the overall comparison of the newer ‘blind’ 
techniques (second generation) with the gold standard hysteroscopic 
ablative techniques (first generation), there was no evidence of overall 
differences in the improvement in HMB (12 RCTs) or patient satisfaction (11 
RCTs). 
Surgery was an average of 15 minutes shorter (mean difference (MD) 
14.9, 95% CI 10.1 to 19.7; 9 RCTs; low quality evidence), local anesthesia was 
more likely to be employed (relative risk (RR) 2.8, 95% CI 1.8 to 4.4; 6 RCTs; 
low quality evidence) and equipment failure was more likely (RR 4.3, 95% 
CI 1.5 to 12.4; 3 RCTs; moderate quality evidence) with second-generation 
ablation. Women undergoing newer (second) ablative procedures were 
less likely to have fluid overload, uterine perforation, cervical lacerations 
and hematometra than women undergoing the more traditional type of 
ablation and resection techniques (RR 0.18, 95% CI 0.04 to 0.79, 4 RCTs; RR 
0.32, 95% CI 0.1 to 1.0, 8 RCTs; RR 0.22, 95% CI 0.08 to 0.61, 8 RCTs and RR 
0.32, 95% CI 0.12 to 0.85, 5 RCTs, all moderate quality evidence, respectively). 
However, women were more likely to have nausea and vomiting and uterine 
cramping (RR 2.0, 95% CI 1.3 to 3.0, 4 RCTs and RR 1.2, 95% CI 1.0 to 1.4, 2 
RCTs, both moderate quality evidence, respectively). The risk of requiring 
either further surgery of any kind or hysterectomy specifically was reduced 
with second generation ablative methods compared to first generation 
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ablation up to 10 years after surgery (RR 0.69, 95% CI 0.48 to 0.99, 1 RCT 
and RR 0.60, 95% CI 0.38 to 0.96, 1 RCT, both moderate quality evidence, 
respectively), but not at earlier follow up. Additional research is required to 
confirm this finding.
Authors’ conclusions: Endometrial ablation techniques offer a less 
invasive surgical alternative to hysterectomy. The rapid development of a 
number of new methods of endometrial destruction has made systematic 
comparisons between individual methods and with the ‘gold standard’ 
first generation techniques difficult. Most of the newer techniques 
are technically easier than traditional hysteroscopy-based methods to 
perform but technical difficulties with new equipment need to be ironed 
out. Overall, the existing evidence suggests that success and satisfaction 
rates and complication profiles of newer techniques of ablation compare 
favorably with hysteroscopic techniques.
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Endometrial destruction techniques for heavy menstrual bleeding 
using the newer global ablation techniques and more established 
hysteroscopic techniques.
Drugs or hysterectomy (removing the uterus) used to be the main option for 
women having problems with heavy menstrual bleeding. In the last few decades, 
surgical techniques have been developed that remove only the lining of the uterus 
(endometrium). These techniques involve either cutting out the endometrium 
(resection) or destroying it with thermal energy from a laser, electric instruments 
or other devices. 
This review identified 25 randomized controlled trials undertaken in 4040 
women. Most of the women knew which treatment they were receiving, which 
may have influenced their judgment about menstrual blood loss and satisfaction. 
Other aspects of study quality varied among the trials. The review has not found 
that any of these procedures is better than any other in reducing heavy menstrual 
bleeding and satisfaction was high with all procedures. The more modern devices 
(second generation ablation) took less time to perform than the older first 
generation devices and were more likely to be performed under local anesthesia 
when the woman is awake. Side effects were generally similar and mostly mild.
Background
Description of the condition
Heavy menstrual bleeding (HMB), or menorrhagia, is a significant cause of ill 
health in premenopausal women and can significantly affect their quality of life.1 
It is clinically defined as blood loss greater than or equal to 80 ml per menstrual 
cycle.2,3 With a monthly blood loss of greater than 50 to 60 ml per cycle, most 
women consuming an average Western diet will develop a negative iron balance 
(Rybo 1966). However, it is the woman’s perception of her own menstrual loss 
that is the key determinant in her referral and, indeed, subsequent treatment. 
One in 20 women in the UK aged between 30 and 49 years of age consult their 
general practitioner (GP) each year with HMB and the condition affects about 
22% of otherwise healthy premenopausal women aged more than 35 years.4,5 A 
comparable prevalence rate is likely in other Western countries. In New Zealand, 
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for example, it is estimated that 2.3% of GP consultations for women less than 50 
years are for heavy menstrual bleeding.6 In the majority of cases no pathology 
(abnormality) is found to explain HMB.1 The causes of HMB, where there is no 
endometrial pathology, remain poorly understood and this has been a barrier to 
the development of new non-surgical therapies. 
First-line therapy is usually with drugs prescribed by general practitioners; 
in 1993 in the UK, 345,225 women were given 821,700 medical prescriptions, 
which cost the UK National Health Service over £7 million, to control their heavy 
menstrual bleeding.1,7 However, efficacy is variable and at best medication reduces 
menstrual blood loss by only 50%. The levonorgestrel-releasing intrauterine 
system, on the other hand, is more effective and reduces HMB by as much as 94% 
at three months.8 Nevertheless, HMB accounts for 12% of all gynaecology referrals 
in the UK.9 A similar rate of referral (11%) is found in New Zealand and is likely to be 
similar in other Western countries.10 
Surgical treatment of HMB often follows failed or ineffective medical therapy, 
although it is also used as a first-line therapy. Hysterectomy has traditionally been 
regarded as the definitive surgical treatment for heavy menstrual bleeding but, in 
spite of a 100% success rate (complete cessation of menstruation) and high levels of 
satisfaction, it is a major surgical procedure with significant physical complications 
and social and economic costs.11 These include a high rate of major and minor 
post-operative complications (up to 67%) and a long recovery time.12 Almost half 
of the hysterectomies performed worldwide were carried out for HMB.13 However, 
many women prefer less invasive surgical treatment even when they are made 
aware that the success of the treatment is not always assured.14
Description of the intervention
Endometrial destruction techniques, which aim to destroy or remove endometrial 
tissue, have become increasingly popular less invasive alternatives in the last two 
decades and, as a result, the number of hysterectomies in the United Kingdom 
declined by 64% between 1995 and 2002.15 The first effective ablation of the 
endometrium under hysteroscopic vision for the treatment of heavy menstrual 
bleeding was performed using laser photovapourisation.16 Rollerball ablation 
(RB) with simple and cheap electrosurgical equipment rather than expensive 
lasers was performed a few years later.17,18 A method to excise rather than ablate 
the endometrium using an unmodified resectoscope (an instrument used for 
resection (excision)) was also developed and good results were reported.19,20 
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The technique transcervical resection of the endometrium (TCRE) is often used 
in conjunction with rollerball ablation. These methods of ablation, also termed 
first generation methods, were the most commonly used and were widely 
regarded as the gold standard for endometrial ablation.21 They all require direct 
visualization by hysteroscope (an instrument for examining the uterine cavity), 
which may confer the additional advantage of diagnosis of polyps. Endometrial 
destruction techniques in use in the UK by 1995 included electrocautery (either 
loop or rollerball) (80%), laser (18%) and radiofrequency (a procedure using 
electromagnetic energy) (2%).22 
The expectation was that these first generation ablation methods would 
become an alternative to hysterectomy but, at least initially, the total number of 
operations for HMB increased.23 More recent figures in the UK suggest that the rate 
of surgery for menorrhagia (based on data from 2004 to 2006) is 143 procedures 
per 100,000 premenopausal women, of which approximately 60% are endometrial 
ablations.24 However, analyses of recent hospital statistics in the UK suggest that 
first generation endometrial ablation has failed to have an impact on hysterectomy 
numbers.25 
The drawbacks of these first generation ablation techniques are the expertise 
needed and patient morbidity. A prospective national audit of hysteroscopic 
endometrial ablation and resection (10,686 cases) in England and Wales between 
1993 and 1994 assessed the incidence of complications and reported a total 
complication rate of 4.4%.26 Endometrial ablation by laser and rollerball were 
significantly safer than endometrial resection; the risk of immediate haemorrhage 
was three times greater and the risk of uterine perforation was four times greater 
with resection than with ablation. These complications are thought to be avoidable 
with good surgical technique and adequate training. However, hysteroscopic 
endometrial ablation requires an operating room environment, a skilled surgeon 
and general or regional anaesthesia. 
Subsequently, second generation non-hysteroscopic techniques have been 
developed, which are considered easier to perform, equally effective and safe.27 All 
of these techniques, with the exception of hydrothermal ablation and endometrial 
laser intrauterine thermal therapy, involve performing surgery without direct 
visualization through a hysteroscope. They can potentially be used in outpatient 
settings and include cryoablation28, hot saline solution irrigation29, diode laser 
hyperthermy (heating)30, microwave ablation31, a heated balloon system32 and 
photodynamic therapy (intrauterine light delivery)33. Economic modelling also 
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suggests that second generation techniques may be more cost effective than first 
generation methods.34
How the intervention might work
Endometrial destruction involves the removal of endometrial tissue. The 
endometrium has great powers of regeneration and to suppress menstruation 
successfully it is essential to remove the full thickness of this lining together with 
the superficial myometrium (wall of the uterus), including the deep basal glands. 
The latter are believed to be the primary foci for endometrial regrowth. This tissue 
may be removed under direct hysteroscopic view either by excision with an 
electrosurgical loop or by ablating the endometrium with some form of thermal 
energy of sufficient power to produce necrosis (cell death) of the full thickness of 
the endometrium when applied to its surface.
Why it is important to do this review
There is a wide range of available techniques for ablating and destroying the 
endometrium to reduce HMB and it is not clear which techniques offer the best 
option in terms of effectiveness and safety. The aim of this review is to assess the 
efficacy, safety and acceptability of all methods both by comparing individual 
techniques pairwise and making overall comparisons with first and second 
generation techniques. Other Cochrane reviews have compared endometrial 
ablation with hysterectomy for HMB and endometrial ablation with medical 
therapies.35,36
Objectives
To compare the effectiveness, safety and acceptability of endometrial destruction 
techniques for heavy menstrual bleeding.
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Criteria for considering studies for this review
Types of studies
All randomized controlled comparisons of techniques for the destruction of the 
endometrium and comparisons of endometrial destruction techniques for the 
reduction of HMB.
Types of participants
Source of recruitment: 
•	 primary care, family planning or specialist clinics. 
Inclusion criteria: 
•	 women of reproductive years with regular heavy periods measured either 
objectively or subjectively. 
Exclusion criteria: 
•	 postmenopausal bleeding (more than one year from the last period);
•	 irregular menstruation and intermenstrual bleeding;
•	 pathological causes of HMB (for example uterine cancer);
•	 iatrogenic causes of HMB (for example intrauterine coil devices). 
Types of interventions 
Endometrial resection and ablation techniques (TCRE, laser ablation, rollerball 
ablation, saline irrigation, microwave ablation, radiofrequency ablation, heated 
balloon, photodynamic therapy, cryoablation and any other endometrial 
destruction techniques) compared to each other or grouped in the broad 
categories of first or second generation techniques and used to reduce heavy 
menstrual bleeding. 
Types of outcome measures 
The assessment of most of the following outcomes was related to the duration of 
follow up after the initial surgical procedure. As the aim of endometrial resection 
and ablation therapies is to offer women a permanent solution to their bleeding 
problems, long term follow up of these treatments is needed to enable informed 
decision making between surgical options. Thus, for the following outcomes, 
evaluation at different time points is considered important to assess effects over 
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time: six months, 12 months, two years, two to five years and more than five 
years. Where trials measured outcomes at two different follow up times within 
the categories (e.g. at three and five years), the longer follow up time only was 
recorded in the category, two to five years.
Primary outcomes
1. Menstrual bleeding:
•	 an objective assessment of improvement in menstrual blood loss 
(measured by the modified alkaline hematin method: modified by 
Newton 1977 from the original technique of Hallberg 1964);37,38 
•	 a semi-objective or subjective assessment of improvement in menstrual 
blood loss (measured by the pictorial chart method (PBAC) or women’s 
perception of improvement).39 
2.  Rate of satisfaction with the outcome of the procedure (this outcome was 




a. Duration of surgery (min’s)
b.  Operative difficulties (such as difficulty of surgery, technical complications, 
abandoning procedure)
c. Proportion having local rather than general anaesthesia. 
2. Recovery:
a. Length of hospital stay. 
b. Time or ability to return to normal activities or work. 
3. Quality of life:
Women’s perceived change in quality of life where this has been recorded 
in a reproducible and validated format. 
4.  Improvement in menstrual symptoms, such as premenstrual syndrome (PMS) 
and dysmenorrhea. 
5.  Complication rate, the frequency of specific adverse events both before and 
after discharge from hospital. 
6.  Requirement for further surgery for menstrual symptoms (by duration of follow-up) 
7. Mortality as a direct result of surgery.
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Search methods for identification of studies 
Electronic searches 
The Menstrual Disorders and Subfertility Group Trials Search Coordinator searched 
the following electronic databases from inception to 7 July 2012: MEDLINE, 
EMBASE, CINAHL, PsycInfo, the Cochrane Central Register of Controlled Trials and 
the MDSG Specialised Register of Controlled Trials. 
The MEDLINE search was combined with Cochrane highly sensitive search 
strategy for identifying randomized trials, which appears in the searching chapter 
of The Cochrane Handbook of Systematic Reviews of Interventions.40 
The EMBASE search was combined with trial filters developed by the Scottish 
Intercollegiate Guidelines Network (SIGN) ( SIGN 2008). 
For the other database searches, filters were modified from those used for the 
MEDLINE and EMBASE searches. 
The principal author of the review (AL) searched other electronic sources (trial 
registers and web sites) to identify additional studies. These sources were: 
•	 Trial registers for ongoing and registered trials - ‘Current Controlled Trials’ 
(http://www.controlled-trials.com/), ‘ClinicalTrials.gov’ 
•	 a service of the US National Institutes of Health (http://clinicaltrials.gov/
ct2/home) and ‘The World Health Organisation International Trials Registry 
Platform search portal’  (http://www.who.int/trialsearch/Default.aspx)
•	 Citation indexes – (http://scientific.thomson.com/products/sci/)  
•	 Conference abstracts in the ISI Web of Knowledge (http://
isiwebofknowledge.com/)
•	 LILACS database, as a source of trials from the Portuguese and Spanish 
speaking world (http://bases.bireme.br/cgi-  bin/wxislind.exe/iah/
online/?IsisScript=iah/iah.xis&base=LILACS&lang=i&form=F)
•	 ClinicalStudyResults for clinical trial results of marketed pharmaceuticals 
(http://www.clinicalstudyresults.org/)
•	 PubMed (http://www.ncbi.nlm.nih.gov/pubmed/) - the random control 
filter for PubMed will be taken from the searching chapter of The Cochrane 
Handbook of Systematic Reviews of Interventions 
•	 OpenSIGLE database(http://opensigle.inist.fr/) and Google for grey 
literature




The reference lists of articles retrieved by the search were hand searched. Some of the 
newer second generation techniques are undergoing development and rigorous 
testing. Expert researchers in the field and companies that manufacture the newer 
devices were contacted to try and locate ongoing trials and unpublished data. Two 
experts in the field were contacted about ongoing research on endometrial ablation 
techniques: Dr David Parkin (Aberdeen Royal Infirmary, UK) and Dr Jed Hawe (South 
Cleveland Hospital, UK). A number of ongoing trials were described but insufficient 
details were provided to enable the review authors to initiate contact. Novasure, a 
company that manufactures the bipolar device Novacept, was also contacted but 
no reply was received. No new trials were identified from these methods.
Data collection and analysis
Data collection and analysis was conducted in accordance with the Cochrane 
Handbook for Systematic Reviews of Interventions.40
Selection of studies
One review author (AL) screened the abstracts of all publications which were 
obtained by the search strategy for eligible RCTs; for the 2009 and 2012 updates, 
this process was undertaken by two reviewers (either AL and JB or AL and JP). 
Where the screened abstract was a potential RCT, the full article was obtained and 
inspected to assess its relevance to this review based on the criteria for inclusion. 
Uncertainty over eligibility was clarified by discussion between AL and either MH, 
JB or JP. Disagreements as to study eligibility were resolved by consensus and it 
was not necessary to involve a third author to arbitrate over selection
Data extraction and management
Data extraction 
Data extraction was performed independently by the two review authors (AL and 
either MH or JP), using forms designed according to Cochrane guidelines. 
The following details were collected: 
Trial characteristics: 
1. method of randomization; 
2. presence or absence of blinding to treatment allocation; 
3. quality of allocation concealment;
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4. number of women randomized, excluded or lost to follow up; 
5. whether an intention-to-treat analysis was done; 
6. whether a power calculation was done; 
7. duration, timing and location of the study; 
8. source of funding. 
Characteristics of the study participants:
1. age and any other recorded characteristics of women in the study; 
2. other inclusion criteria; 
3. exclusion criteria. 
Interventions used: 
1. type of endometrial destruction technique. 
Outcomes: 
1. methods used to measure menstrual blood loss; 
2.  methods used to evaluate participant satisfaction, change in quality of life and 
menstrual symptoms. 
Data management 
Additional information on trial methodology and trial results was sought from 
the corresponding authors of some trials which appeared to meet the eligibility 
criteria. This was when aspects of methodology were unclear or where the 
data were in a form unsuitable for meta-analysis. Authors of the following trials 
provided extra information: Abbott 2003; Soysal 2001; Gynecare (pharmaceutical 
company providing funding for Boujida 2002; Meyer 1998; Perino 2004; van Zon-
Rabelink2003).41-46 One of the authors (JP) provided additional information for 
Penninx 2010.47
Assessment of risk of bias in included studies
Two independent reviewers (AL and JP) assessed risk of bias of each study, using 
the risk of bias tool developed by the Cochrane Collaboration.40 The following 
domains were assessed: 
1)  sequence generation (whether the allocation sequence was adequately 
generated, for example, random number table, computer random number 
generator, coin tossing, throwing dice) 
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2)  allocation concealment (whether the allocation was adequately concealed, for 
example, sequentially numbered containers of identical appearance, central 
allocation, sequentially numbered, opaque sealed envelopes) 
3)  blinding of participants, personnel and outcome assessors (whether knowledge 
of the allocated intervention was adequately prevented during the study, for 
example, by ensuring blinding or participants and key personnel or, where 
there is no blinding, knowledge of the intervention is not likely to influence the 
outcomes) 
4)  incomplete outcome data (whether incomplete outcome data were adequately 
addressed, for example, missing data balanced in numbers across intervention 
groups, proportion of missing outcomes insufficient to affect estimates, reasons 
for missing data unlikely to be related to the outcomes) 
5)  selective outcome reporting (whether the reports of the study were free of 
suggestion of selective outcome reporting, for example, previous publication of 
a study protocol, other evidence that the study contains all of the prespecified 
outcomes) 
6)  other sources of bias (whether the study was apparently free of other problems 
that could put it at a high risk of bias, e.g. baseline imbalance, bias related to 
study design, early termination of study). 
These domains were scored as either: 
•	 Criterion met, i.e. low risk of bias 
•	 Unclear, i.e. uncertain risk of bias 
•	 Criterion not met, i.e. high risk of bias
Measures of treatment effect 
Almost all of the outcomes were measured by either dichotomous or continuous 
data. Two authors extracted data to enable calculation of relative risks (RRs) for 
dichotomous data and mean differences (MDs) for continuous data, together 
with 95% confidence intervals (CIs). Some outcomes, such as satisfaction with 
treatment, were measured by ordinal data. These data were dichotomised to 
represent satisfaction (highly satisfied and satisfied combined) vs no satisfaction 
(doubtful or dissatisfied) with surgery by collapsing categories. Continuous data 
were inspected for evidence of skew, where possible, according to guidance in 
the Cochrane Handbook, by calculating the observed mean minus the lowest (or 
highest) possible value divided by the standard deviation.
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Assessment of heterogeneity 
Differences between studies in terms of methodological factors and variations 
between participants, interventions and outcomes were analysed to determine 
whether it was appropriate to combine the studies in meta-analysis. If they were 
sufficiently homogeneous to consider pooling, statistical heterogeneity between 
the results of different studies were examined by inspecting the scatter in the data 
points on the graphs, the overlap in their confidence intervals and, more formally, 
by checking the results of the chi squared tests (with P value <0.1 considered 
evidence of significant heterogeneity) and the I squared quantity. The I squared 
quantity is a measure of the consistency between trials in a meta-analysis.40 As 
a general rule, I squared values of up to 25% are evidence of low heterogeneity, 
values from 25% to 50% are considered moderate heterogeneity and 75% or 
above is considered substantial heterogeneity.
Assessment of reporting biases 
A comprehensive search was undertaken, along with careful inspection of the 
search results to identify duplicates, in order to reduce the risk of reporting bias. 
If sufficient trials were identified, it was planned to investigate publication bias by 
undertaking funnel plots of study results.
Data synthesis 
Where there was no evidence of clinical heterogeneity between the studies and 
no evidence of major skew in the data, the outcomes were pooled statistically in 
a meta-analysis using RevMan software. Relative risks and 95% CIs were combined 
for meta-analysis using the Peto-modified Mantel-Haenszel method. For some 
dichotomous outcomes (for example, the proportion of participants requiring 
further surgery), a higher proportion represented a negative consequence of that 
treatment and for other outcomes (for example proportion with improvement in 
menstrual blood loss), a higher proportion was considered a benefit of treatment. 
This discrepancy between the categorizing of outcomes should be noted when 
the summary graphs for the meta-analysis are viewed for the assessment of the 
benefits as opposed to the harms of treatment. Thus, for some of the dichotomous 
outcomes a treatment benefit is displayed as RR and CIs to the left of the centre 
line while for others a treatment benefit is displayed to the right of the centre line. 
The forest plot for each outcome is labeled clearly for clarification. 
Mean differences and 95% CIs were combined for meta-analysis using the 
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inverse variance method. For all continuous outcomes in this review, a high 
value represents a negative consequence of treatment, for example duration of 
surgery, amount of fluid deficit (difference between input and output fluid during 
surgery), pictorial menstrual blood loss assessment chart (PBAC) score. Thus, in the 
evaluation of the summary graphs means and confidence intervals to the left are 
considered a benefit of the experimental or comparative treatment. 
A fixed effect approach was used to calculate summary effect measures. 
Where there was substantial statistical heterogeneity, results from the fixed 
effects model were compared with those from a random effects model to 
determine whether results were altered substantially by choice of model. A priori, 
it was expected that two of the outcomes, regardless of comparison, duration of 
surgery and proportion having local instead of general anaesthesia, would have 
heterogeneous results. For these comparisons a random effects model was initially 
used. For all overall comparisons where first generation methods were compared 
with second generation methods, a random effects model was used because of 
the expected clinical heterogeneity between trials. 
Where there was evidence of skewed data in the measurement of outcomes (for 
example, summary trial results were expressed as a median and range), the data for 
these outcomes were not pooled in the meta-analysis but included in table format.
Subgroup analysis and investigation of heterogeneity 
Subgroup analyses were planned for different times of follow up after surgery, 
in particular for amenorrhea rates, satisfaction and requirement for additional 
surgery. These outcomes were collected at six months, one, two, two to five years 
and greater than five years after surgery. 
Sensitivity analysis 
A priori, it was intended that sensitivity analysis would be performed to test the 
robustness of pooled results in the meta- analysis based on:
(1)  trials with good methodology (evidence of adequate allocation concealment 
and intention-to-treat analysis) versus all included trials; 
(2)  trials with and without power calculations for sample size; 
(3)  trials with participants who had confirmed objective heavy menstrual blood 
loss (more than 80 ml per cycle) versus all included trials; 
(4)  trials with participants who had initially failed medical treatment for HMB versus 
all included trials. 
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For most comparisons there was an insufficient number of included studies to be 
able to perform any of these sensitivity analyses. 
Overall quality of the body of evidence 
A summary of findings table for the overall outcome of first generation versus second 
generation ablation techniques was generated using GRADEPRO software (Summary 
of findings, Table 1). This table evaluates the overall quality of the body of evidence 
for each of the main review outcomes, using GRADE criteria (study limitations (ie. 
risk of bias), consistency of effect, imprecision, indirectness and publication bias). 
Judgements about the evidence quality (high, moderate, low or very low) have been 
documented and incorporated into the reporting of results for each outcome.
Results
Description of studies
Results of the search
2005 update: Twenty three studies were considered potentially eligible to be 
included in the review in the 2005 update and full copies of the papers retrieved 
for closer inspection. One study was excluded because it compared two types 
of balloon ablation, Menotreat and Cavaterm.48 Three other studies were later 
publications of trials that were already included in the review.44,49,50 Thus, 19 studies, 
some of which had a number of different publications describing longer follow up 
or different outcomes, met the inclusion criteria of the review for the 2005 update. 
2009 update: A further six potential studies were considered potentially 
eligible for the 2009 update and full copies of the papers retrieved for closer 
inspection. One conference abstract and one Chinese trial are waiting assessment 
because it is unclear whether the two comparative groups were randomised. Of 
the remaining four studies, two were later publications of trials already included 
in the review. One of these studies was a five year follow up of a trial comparing 
bipolar radiofrequency ablation to balloon ablation and the other was 10 year 
follow up of a trial comparing TCRE with rollerball ablation.43,51 Two new RCTs (21 
studies overall) were eligible for the 2009 update.52,53 
2012 update: An additional seven studies were considered potentially 
eligible for the 2012 update and full copies of the papers were retrieved for closer 
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inspection. Two were excluded; one because it compared different wave forms 
for rollerball ablation (Chang 2009) and the other because it was not randomized 
(El-Nashar 2009). One other trial was a 10 year follow up, comparing long term 
outcomes, of a study already included in the review.49 Four new trials, one of which 
had two publications were included in the 2012 update.47,54-56 
Thus, 25 studies (4040 women, with sample sizes ranging from 20 to 372) were 
eligible for the review. Full details of the studies can be found in the corresponding 
article at the Cochrane library.  
Study design 
All of the trials had a parallel group design. Six large trials were multicentre, each 
with 200 to 300 participants and one smaller multicentre trial had 62 participants. 
Eighteen of the trials were single-centre studies (one each from Germany, Australia, 
Egypt and Denmark; two from Turkey; three from the Netherlands and Italy; and six 
from the UK). Six of the seven multicentre trials were based in the USA, with three 
having additional centers in Canada, UK or Australia and one multicentre trial had 
6 centres all based in France. 
Few of the studies had strict intention to treat analyses or specified methods to 
deal with missing data. Twelve trials did not report an intention-to-treat (ITT) analysis. 
Seven trials claimed that ITT analysis was performed but over time a percentage 
of participants was lost to follow up so the claim of ITT was misleading. However, 
ITT analysis was usually performed when assessing outcomes such as complication 
rates in these studies. Four trials had true ITT analysis and one trial had no reported 
dropouts. One other trial did not report ITT analysis and replaced dropouts with 
new cases. Seventeen trials reported either pharmaceutical or medical equipment 
company partial or complete funding or had authors with a conflict of interest. 
Participants 
The 25 included studies contained 4056 premenopausal participants, mostly 
within the age range 30 to 50 years. In all of the studies women, with a complaint 
of heavy menstrual bleeding were recruited from secondary or tertiary referral 
centres or clinics. 
Presence of fibroids was an exclusion criterion in twelve studies and all trials 
required that the uterine cavity be normal in size with no uterine pathology. One 
trial required women to have myoma-induced menorrhagia but excluded women 
with submucous fibroids greater than 3 cm or less than 50% intramural extension.42 
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One other trial excluded only submucous fibroids and one trial excluded both 
submucous fibroids and extra cavity fibroids >3 cm.52,54 In one trial, 637 women 
with self-assessed HMB were screened but, after the application of exclusion 
criteria, less than half (n = 276) were enrolled and randomized.57 Almost half of the 
excluded women had uterine pathology in the form of fibroids or polyps. 
Nineteen trials required women to have completed their families and fourteen 
trials included women who previously had not tolerated or had had ineffective 
medical therapy for their heavy bleeding. Twelve trials objectively confirmed the 
women’s complaint of excessive bleeding by requiring them to record their blood 
loss. This was prior to surgery and before entry into the trial. Nine trials required 
women to have pictorial blood loss chart measurements of 150 or greater prior to 
entry, two trials required women to have PBAC measurements of 100 or greater 
prior to entry, one trial required a blood loss score of more than 185 and one trial 
included women only if their blood loss exceeded 70 ml per cycle (as measured by 
the alkaline haematin method.38,39 All but one trial had comparable demographic 
characteristics between comparison groups at baseline; in the Brun trial women 
undergoing balloon ablation had significantly more heavy blood loss than those 
undergoing TCRE.52 
Interventions 
Most of the studies (particularly, first generation techniques) had some kind of 
pretreatment prior to surgery. In thirteen of the trials, participants had preoperative 
GnRH (gonadotropin-releasing hormone) analogues to prepare and thin the 
endometrium prior to surgery, although in one of these studies pretreatment was 
given only to the TCRE group and not to the balloon group. Three months, 14 
or 7 days of preoperative treatment with progestogens was also used in three 
trials. One trial required two months of oral contraceptive therapy prior to surgery 
to ensure that women were scheduled at a similar time in their cycle. One trial 
required a dilation and curettage procedure prior to ablation surgery. Four other 
trials used NSAIDs (non-steroidal anti-inflammatory drugs) to prevent uterine 
cramping. The remaining three trials had no preoperative therapy. 
Five trials compared first generation ablation methods: two compared laser 
ablation with TCRE (one argon laser, the other Nd:YAG (neodymium yttrium 
aluminium garnet)), one compared a vaporising electrode procedure with TCRE, 
and two compared rollerball with TCRE. All of the TCRE comparison groups also 
had rollerball ablation to treat the uterine cornua (a horn-like area in the uterus) 
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and fundus (body of the uterus). It was claimed that the vaporising electrode 
(unlike rollerball) could be used to treat submucous fibroids. Another fourteen 
trials compared second generation methods with first generation methods: 
four compared balloon ablation (three with Thermachoice, one with Cavaterm) 
with rollerball, one compared the Vesta system with rollerball, two compared 
microwave ablation with TCRE and rollerball, one compared heated saline 
(Hydro Thermablator) with rollerball, one compared cryoablation with rollerball, 
one compared thermal laser with TCRE, two compared electrode ablation with 
TCRE plus rollerball, one compared balloon (Cavaterm) with laser (Nd:YAG), and 
two compared balloon (Cavaterm) with TCRE plus rollerball. Five trials compared 
second generation techniques: bipolar electrode ablation (Novasure) with either 
balloon or hydrotherm ablation or microwave compared with balloon ablation. 
All of the first generation techniques (laser, rollerball, vaporising electrode and 
transcervical resection), which use the hysteroscope, were then combined and 
compared with all the second generation techniques (balloon, microwave, Vesta 
system, cryoablation, thermal laser, bipolar electrode ablation and hydrothermal 
ablation), which are blind techniques. An additional trial compared overcurettage 
with ablative curettage.56 
Outcomes 
Most of the trials assessed amenorrhea (some included ‘light’ or ‘normal’ bleeding), 
satisfaction rates and frequency of complications. Eighteen trials compared the 
duration of surgery; nineteen trials compared menstrual blood scores on the PBAC 
chart or success of treatment; twelve assessed the frequency of any additional 
surgery after treatment; fifteen trials compared hysterectomy rates after treatment; 
thirteen trials assessed quality of life measures such as SF36, improvement in 
dysmenorrhea or PMS symptoms; and a few trials measured ability to work, 
difficulty of surgery, rate of acceptability, degree of fluid deficit and duration of 
hospital stay. The types of anaesthesia used (‘local’ versus ‘general’) were compared 
between first and second generation techniques. 
One trial assessed outcomes only after six months follow up. Eight trials 
assessed outcomes one year after surgery. Six trials assessed outcomes at both six-
months and one-year follow up. Three trials assessed outcomes at both one and 
two years follow up and the remaining trials had longer term follow up: at either 3, 
5 or 10 years follow up. Two trials did not specify the time at which postoperative 
outcomes were assessed.
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Risk of bias in included studies
The risk of bias in the included studies is summarized in Figure 1 and Table 1.
Allocation (selection bias) 
Sixteen studies had adequate randomization methods, either computer generated 
or lists of random numbers. In four studies, no details were provided on the 
randomization method. One study gave details of an inadequate randomization 
method; participants were allocated to treatment in the order in which they came 
into clinic.53 Ten studies provided evidence of adequate allocation concealment, 
either sequentially numbered opaque envelopes or central method for allocation 
to groups. Ten studies did not provide any details as to whether allocation was 
concealed and the remaining study was scored as having no concealment.
Blinding (performance bias and detection bias) 
In most of the trials, blinding was either specifically denied or not reported; for 
all these trials, blinding was unlikely due to the nature of the interventions. Two 
trials that compared second generation techniques (bipolar radiofrequency vs 
balloon)41,51 and one other comparing balloon with laser58 had triple blinding 
(patients, investigators and assessors), and three other second generation trials 
had double blinding (patients and assessors) (although in the Clark trial, women 
were likely to have guessed allocation).47,54,55
Incomplete outcome data (attrition bias) 
Eight trials did not report any dropouts after treatment (five of these had dropouts 
ranging from 1% to 4% after randomization and before treatment). The remaining 
trials had dropout rates ranging from 3% to 18% after one-year follow up, from 9% 
to 17% after two-years follow up, from 2% to 16% after 5 years follow up and from 
6% to 28% after 10 years follow up. In one of these trials, with a 9% dropout rate, 
one arm of the trial (the hydro thermoblator (HTA) group) had a higher dropout 
rate than the other arm, due to equipment failure.50 In another trial, 18% of the 
study population were excluded from the study after randomization and before 
treatment in unequal numbers per group, making randomization unbalanced.52 
In assessments regarding incomplete outcome data, sixteen trials were scored 
as having adequately addressed their missing data (if any), either because there 
were no reported dropouts, missing data was balanced between groups or there 
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was minimal loss to follow up that was unlikely to affect the calculation of estimates. 
For five studies, it was unclear whether their missing data could cause bias and for 
three studies, missing data was highly likely to bias the estimates, two because of 
substantial loss to follow up and the other because there were imbalances in the 
loss of missing data between groups. One other trial had dropouts which were 
replaced by other cases, which is likely to also cause major bias.56
Selective reporting (reporting bias) 
There were insufficient trials identified to undertake funnel plot analysis for 
publication bias or small study bias. Most trials were scored as at low risk of 
reporting bias as a result of selective reporting of outcomes. In these trials, all 
prespecified outcomes were reported in the results sections. 
Other potential sources of bias 
Most studies had no evidence of any other potential source of bias. Three studies 
had potential sources of bias; one recruited participants over two different time 
periods and comparison of the two groups indicated substantial differences, 
one study used denominators for the outcomes that did not correspond to the 
denominators originally specified and in another study, the numbers in the 2 
randomized groups differed substantially with no explanation given.
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Abbott 2003 + + + + + + ?
Clark 2011 + + - - - + ?
Bongers 2004 + + + + + ? ?
Boujida 2002 + + - - + + +
Brun 2006 + + - - - + -
Clark 2011 + + ? ? - + +
Cooper 1999 + + - - + + ?
Cooper 2002 + ? - - ? + ?
Cooper 2004 + ? - - + + ?
Corson 2000 + + - - ? + ?
Corson 2001 + ? - - ? + ?
Duleba 2003 ? ? - - ? + ?
Hawe 2003 + + + + + + ?
McClure 1992 ? ? - - + + +
Meyer 1998 + ? - - + + ?
Onuglu 2007 - - - - + - +
Pellicano 2002 + ? - - ? + ?
Penninx 2010 + + ? + + ? +
Perino 2004 + ? - - + + +
Romer 1998 ? ? - - + ? +
Sambrook 2009b + + ? + + + +
Soysal 2001 + + - - + + ?
Thabet 2010 ? ? - - - + ?
Figure 1. Methodological quality summary: review authors’ judgments about each 
methodological quality for each included study 
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Table 1. Summary of findings 
Second generation compared to first generation endometrial ablation for heavy menstrual bleeding
Patient or population:patients with heavy menstrual bleeding
Settings:    Intervention: second generation endometrial ablation
Comparison: first generation endometrial ablation

















At 1 year follow up
usually by questionnaire









At 1 year follow up
patient questionnaire








Success of treatment 
(PBAC < 75 or accept-
able improvement)-At 
12 months follow up








Duration of operation 
(mins) Measured in vari-
ous ways by clinicians
Mean duration in 
intervention groups 







local aneaesthesia (%) 



















Requirement for any 
additional surgery->
5 years follow up








*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. 
The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison 
group and the relative effect of the intervention ( and its 95% CI). 
CI:Confidence interval, RR:Risk ratio. PBAC:Pictorial Blood Assessment Chart
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the esti-
mate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the esti-
mate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
Footnotes
1 Substantial heterogeneity (I square=74%) that could not be explained.
2 Most studies had relatively small sample sizes and effects had wide confidence intervals
3 As most trials were unblended, participant knowledge of the treatment they received could bias their 
assessments of satisfaction
4 Substantial heterogeneity (I square=97%) that is likely to be due to different methods of measuring the 
time taken in surgery, differing expertise of surgeons, and numerous other factors
5 Subtantial heterogeneity (I square=85%) which is likely to be explained by different methods being pooled 
under the general headings of first and second generation ablation
6 Few events and wide confidence intervals
7 Based on only one trial using specific types of first and second generation ablative devices
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Effects of interventions 
First generation technique comparisons 
1. Laser versus transcervical resection of the endometrium (TCRE) (Comparison 1): 
PRIMARY OUTCOMES: There was no evidence of significant differences between 
groups in the primary outcomes measured: amenorrhea rate, combined 
amenorrhea/hypomenorrhoea rate, menstrual blood loss at six months or 
satisfaction at 12 months. 
SECONDARY OUTCOMES: Duration of laser surgery was an average of nine 
minutes longer than for TCRE (mean difference (MD) 9.15, 95% CI 7.2 to 11.1). 
The risk of equipment failure and fluid overload were also greater among 
women who had laser ablation when compared with TCRE (risk ratio (RR) 
5.5, 95% CI 1.7 to 18.6; RR 4.9, 95% CI 1.4 to 16.6, respectively). There was no 
evidence of significant differences between laser ablation and TCRE for the 
other secondary outcomes: other types of operative difficulties, improvement 
in symptoms, improvement in dysmenorrhea, requirement for further surgical 
treatment, other complications and general health after treatment. 
2. Vaporising electrode ablation versus TCRE (Comparison 2):
PRIMARY OUTCOMES: There was no evidence of significant differences 
between TCRE and vaporising electrode ablation for measurement of bleeding 
or satisfaction: amenorrhea or hypomenorrhoea (scanty menstruation) rate, 
pictorial chart method (PBAC) score at 12 months and satisfaction with 
treatment. 
SECONDARY OUTCOMES: The odds of ‘difficult’ surgery (assessed subjectively 
into three categories by surgeons) were less likely with vaporising electrode 
ablation when compared with TCRE (RR 0.29, 95% CI 0.10 to 0.82). The amount 
of fluid deficit was greater (MD 258 ml, 95% CI 173.9 to 342.1) and the duration 
of surgery longer (MD =1.5 min, 95% CI 0.35 to 2.65) in the TCRE group when 
compared with vaporising electrode ablation. 
3. Rollerball versus TCRE (Comparison 3):
PRIMARY OUTCOMES: There were no primary outcomes measured in the 
included studies. SECONDARY OUTCOMES: There was no evidence of significant 
differences between these two first generation ablation methods, rollerball 
and TCRE, in the proportion requiring either hysterectomy or any surgical 
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intervention after two, five and ten years follow up or in the complication rates 
measured (fluid deficit ad perforation). Non-parametric analysis confirmed that 
the duration of surgery was significantly shorter with rollerball than with TCRE 
in one trial (median 13 minutes with rollerball versus 20 minutes with TCRE, P 
value < 0.05) but this was not confirmed by another small trial that assessed 
mean difference between groups.
Second generation first generation technique comparisons
4. Thermal laser versus TCRE (Comparison 4): 
PRIMARY OUTCOMES: The odds of amenorrhea at one and three years after 
surgery was significantly greater for women in the thermal laser group when 
compared with women in the TCRE group (RR 2.5, 95% CI 1.5 to 4.0; OR 2.5, 
95% CI 1.5 to 4.2, respectively) in one study with 111 participants. There was 
no evidence of statistical differences in the satisfaction rates between groups. 
SECONDARY OUTCOMES: Mean length of surgery was an average of nine 
minutes shorter for women in the thermal laser group when compared with 
women in the TCRE group (MD 9.3, 95% CI 11.4 to 7.2). However, women 
appeared to experience more pain with thermal laser treatment (MD 0.7 units 
on pain scale, 95% CI 0.02 to 1.4), which just reached significance (P value 0.05). 
There was no evidence of differences in the requirement for more surgical 
intervention or complication rates (urinary tract infection) between the groups. 
5. Hydro thermoblator (HTA) versus rollerball (Comparison 5): 
PRIMARY OUTCOMES: There was no evidence of significant differences 
between groups in amenorrhea rate, other menstrual loss outcomes or success 
of treatment. 
SECONDARY OUTCOMES: The chance of having local rather than general 
anaesthesia was increased twofold for women having HTA ablation (RR 2.0, 
95% CI 1.3 to 3.1). Women in the HTA group were also less likely to experience 
the adverse event of hematometra (haemorrhage in the uterus) from surgery 
(RR 0.18, 95% CI 0.04 to 0.93) but more likely to experience abdominal pain (RR 
1.4, 95% CI 1.0 to 1.9) and nausea and vomiting after surgery (OR 3.1, 95% CI 
1.4 to 7.0). There was no evidence of significant differences between groups 
for the other outcomes: need for further surgery and other operative adverse 
events. 
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6. Cryoablation versus rollerball (Comparison 6): 
PRIMARY OUTCOMES: Women having cryoablation were less likely to have 
amenorrhea one year after surgery than women having rollerball treatment 
(OR 0.5, 95% CI 0.36 to 0.69). There was no evidence of significant differences 
between groups for satisfaction with treatment at one or two years follow up. 
SECONDARY OUTCOMES: Women having cryoablation were more likely to 
have local rather than general anaesthesia when compared with women 
having rollerball ablation (RR 6.6, 95% CI 3.2 to 13.6). There was no evidence 
of significant differences between groups for the other secondary outcomes 
measured: requirement for further surgery or hysterectomy alone two years 
after ablation treatment and rates of intraoperative complications. 
7. Electrode ablation (balloon or mesh) versus TCRE (Comparison 7):
PRIMARY OUTCOMES: There was no evidence of significant differences 
between groups for any of the primary outcomes measured: amenorrhea rate, 
PBAC score <75, PBAC score or satisfaction rate. 
SECONDARY OUTCOMES: The duration of the procedure was significantly longer 
for women having TCRE compared with VESTA or Novasure (MD 18.7 mins, 95% 
CI 16.8 to 20.7). Women undergoing electrode ablation were also more likely 
to have local rather than general anaesthesia than women having TCRE (RR 3.9, 
95% CI 2.9 to 5.0). Perforation and cervical tears or lacerations were less likely 
with electrode ablation than with TCRE (RR 0.13, 95% CI 0.02 to 1.0; RR 0.11, 
95% CI 0.01 to 0.9). There was no evidence of significant differences between 
groups for the other secondary outcomes compared: other complication rates 
or requirement to have hysterectomy after two years follow up.
8. Microwave versus TCRE plus rollerball (Comparison 8): 
PRIMARY OUTCOMES: There was no evidence of significant difference between 
groups in the primary outcomes measuring menstrual blood loss: amenorrhea 
rate or success of treatment, measured by PBAC < 75, or the rates of satisfaction 
one or up to 10 years after surgery. However, with the follow up at two years, 
there was a significant benefit for microwave ablation in terms of satisfaction 
with treatment when compared with TCRE (RR 1.2, 95% CI 1.0 to 1.4) and this 
benefit was maintained at five years (RR 1.2, 95% CI 1.0 to 1.4) but not at longer 
follow up in the same trial. 
SECONDARY OUTCOMES: In one study, the duration of the procedure was 
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significantly shorter with microwave when compared with TCRE (MD -3.6 mins, 
95% CI -5.7 to -1.4). In one study, the risk of equipment failure was higher in 
the microwave group when compared with the TCRE group (RR 3.8, 95% CI 
1.1 to 13.3). Vomiting and uterine cramping were more likely with microwave 
treatment than with TCRE (RR 3.6, 95% CI 1.3 to 10.0: RR 1.2, 95% CI 1.0 to 
1.4, respectively). Patients undergoing microwave ablation were more likely 
to have local anaesthesia than those undergoing TCRE (RR 2.5, 95% CI 1.7 
to 3.7). At 10 year follow up, the risk of further surgery or hysterectomy was 
marginally reduced with microwave ablation (any surgery: RR 0.7, 95% CI 0.5 to 
1.0; hysterectomy: RR 0.6, 95% CI 0.4 to 1.0). For all other secondary outcomes, 
there was no evidence of significant differences between groups: rate of 
other complications, abandoning the procedure, postoperative analgesia, 
improvement in dysmenorrhea, change in change in most SF 36 scores (Short 
Form 36 scale, a generic measure of subjective health), duration of hospital 
stay, requirement for further surgery at other time points, inability to work, or 
improvement in symptoms.
9. Balloon versus rollerball (Comparison 9:) 
PRIMARY OUTCOMES: Amenorrhea was less likely after balloon ablation than 
after rollerball ablation at one year follow up (RR 0.63, 95% CI 0.41 to 0.97; three 
studies) but there were no significant differences between groups two and up 
to five years after treatment, although a strong trend was shown in favor of 
rollerball ablation. There was no evidence of significant differences between 
groups for the other outcomes assessing menstrual blood loss: satisfaction, 
rate of amenorrhea and hypomenorrhoea combined, success of treatment 
and PBAC score at one year, although one trial found a significantly lower PBAC 
score at two years in women having balloon ablation which was not confirmed 
by other trials assessing PBAC score at one year. 
SECONDARY OUTCOMES: The mean difference between duration of surgery 
for women in the balloon group and women in the rollerball group was 21 
minutes (MD -20.9, 95% CI -19.3 to -22.5; three studies). There was no evidence 
of significant differences between groups for the other secondary outcomes 
compared: complication rates, inability to work, improvement in dysmenorrhea 
or premenstrual syndrome (PMS), technical complication rate or requirement 
for further surgery or hysterectomy. 
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10. Balloon versus laser (Comparison 10): 
PRIMARY OUTCOMES: There was no evidence of statistical differences in the 
amenorrhea or satisfaction rates or in the PBAC score after treatment between 
groups. 
SECONDARY OUTCOMES: Most outcomes were not significantly different 
between treatment groups. However, women having balloon treatment had a 
significantly greater pain score than women in the laser group (MD 32.7, 95% 
CI 23.7 to 41.7; one study). At 12 months after treatment, women in the balloon 
group had higher scores on the Euroquol 5D VAS than women in the laser 
group (MD 10.1, 95% CI 2.4 to 17.8; one study), which was not found at earlier 
follow up or for other quality of life scores. 
11. Balloon versus TCRE (Comparison 11): 
PRIMARY OUTCOMES: There was no evidence of a difference in amenorrhea 
rates at 6 and 12 months follow up after surgery between groups. Satisfaction 
with treatment was greater in the balloon group than in the TCRE group two 
years after surgery (RR 1.4, 95% CI 1.1 to 1.7; one study) but this difference was 
not found 6 months or one year after surgery. 
SECONDARY OUTCOMES: Duration of surgery was significantly shorter (35%) 
with balloon than with TCRE treatment in one trial (MD 13 min, 10.8 to 15.2) 
but this finding was not confirmed by another trial which could not be pooled 
in the forest plot.52 Mean intraoperative blood loss (measured in ml) was 
significantly less for balloon treatment compared to laser treatment in one 
small trial (MD -81.8, 95% CI -70.3 to -93.3). Postoperative pain (as measured by 
a continuous VAS scale) was significantly higher for women in the TCRE group 
than for women in the balloon group in one small trial (MD 0.6 points, 95% CI 
0.3 to 0.9) which was confirmed by another trial that could not be included in 
the forest plot.52 Recovery, as measured by stay in hospital and return to normal 
activities, was faster for women in the balloon group than for those in the TCRE 
group in one small trial (MD 0.3 of a day, 95% CI 0.1 to 0.5; MD 2.1 days, 95% CI 
0.8 to 3.4, respectively); another trial which could not be included in the forest 
plot confirmed the finding that balloon surgery was associated with a shorter 
hospital stay but there was no evidence of a difference in return to normal 
activities in this trial.52 There was no evidence of differences between groups 
for the other secondary outcomes: other complication rates, equipment failure 
or requirement for further surgery.
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2nd generation ablation comparisons 
12. Bipolar electrode ablation versus balloon (Comparison 12): 
PRIMARY OUTCOMES: Amenorrhea was more likely for women in the electrode 
ablation group than those in the balloon group both at six months and 12 
months after treatment (RR 4.4, 95% CI 2.0 to 9.7, two studies and RR 3.8, 
95% CI 2.1 to 6.9, two studies); at five years follow up, a small trial did not find 
significant differences between treatment groups in amenorrhea rates but a 
non-significant trend favored bipolar ablation. One trial at 12 months follow 
up did not find a difference in the PBAC score after treatment between groups. 
There was no evidence of significant differences between groups in rates of 
satisfaction after treatment, although a trend at 12 months follow up favored 
bipolar ablation. 
SECONDARY OUTCOMES: Duration of procedure time was from 5 minutes 
to 19 minutes shorter with bipolar ablation when compared with balloon 
ablation in three trials (two of which recorded significant differences). 
For most of the quality of life scores, there was no evidence of significant 
differences between groups. However, women having balloon ablation had 
significantly higher scores on the SF35 emotional role domain than women 
having bipolar ablation five years after their treatment (MD -9.0 points, 95% 
CI -3.6 to -14.5), but not at other follow up times. Results were inconsistent for 
rates of dysmenorrhea and PMS: two trials found no evidence of a difference 
in dysmenorrhea rates between groups and one trial found no evidence of 
a difference in premenstrual syndrome symptoms. However, another trial 
found that bipolar ablation was associated with improved dysmenorrhea 
and PMS symptoms (summary figures not provided). There was no evidence 
of significant differences between groups for the other secondary outcomes: 
technical complication rate or requirement for further surgery. 
13. Microwave ablation versus balloon ablation (Comparison 13): 
PRIMARY OUTCOMES: Amenorrhea rates were significantly higher with 
microwave ablation than balloon ablation at 6 months follow up (RR 1.5, 95% 
CI 1.1 to 2.1) but not at 12 months follow up. PBAC scores and satisfaction rates 
were not significantly different between groups at 12 months follow up. 
SECONDARY OUTCOMES: Operation time was reduced by almost seven 
minutes with microwave ablation when compared to balloon ablation (MD 
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-6.6 minutes, 95% CI -5.8 to -7.4) and the microwave device was less likely to 
fail (RR 0.1, 95% CI 0.01 to 0.7). There was no evidence of significant differences 
between groups for the other secondary outcomes: other device difficulties, 
proportion choosing local anaesthesia, quality of life scores, requirement for 
analgesia, overnight stay, need for further surgery or pain scores. 
14. Bipolar electrode ablation versus hydrothermal ablation (Comparison 14): 
PRIMARY OUTCOMES: Amenorrhea rates were significantly increased with 
bipolar ablation when compared to hydrothermal ablation at all time points (6 
months: RR 2.3, 95% CI 1.3 to 4.1; 12 months: RR 2.0, 95% CI 1.2 to 3.2; 5 years: 
RR 1.6, 95% CI 1.1 to 2.3) and satisfaction rates were significantly increased (RR 
1.3, 95% CI 1.1 to 1.5). 
SECONDARY OUTCOMES: There was a greater chance of eliminating 
dysmenorrhea symptoms with bipolar ablation when compared to 
hydrothermal ablation (RR 1.3, 95% CI 1.0 to 1.7) at 5 years follow up but 
not at 12 months follow up. The duration of the procedure was significantly 
shorter with bipolar ablation (11.8 minutes with bipolar versus 27.8 minutes 
with hydrothermal ablation). There was a significantly reduced risk of requiring 
any surgery with bipolar when compared to hydrothermal ablation both at 
12 months and up to 5 years follow up (12 months: RR 0.3, 95% CI 0.1 to 0.7; 5 
years: RR 0.4, 95% CI 0.2 to 0.8). There was no evidence of significant differences 
between groups for the other secondary outcomes: complications or future 
hysterectomy. 
15. Ablative curettage versus overcurettage (Comparison 15):
PRIMARY OUTCOMES: Ablative curettage resulted in significantly higher 
rates of amenorrhea than overcurettage (RR 4.5, 95% CI 2.3 to 8.7) and rates 
of amenorrhea and normal menses combined (RR 1.9, 95% CI 1.3 to 2.7). The 
authors stated that these outcomes were measured 3 years after surgery.
SECONDARY OUTCOMES: Bleeding complications were significantly less likely 
with ablative curettage than overcurettage (RR 0.21, 95% CI 0.07 to 0.70) and 
failure rates of the procedure were less likely (RR 0.29, 95% CI 0.12 to 0.74). 
Overcurettage was associated with a significantly reduced hospital stay in 
comparison to ablative curettage (MD 1.6 days, 95% CI 1.2 to 2.0). There was 
no evidence of significant differences between groups for the other secondary 
outcomes: other complications and requirement for further surgery.
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16. Second generation ablative techniques versus first generation ablation 
techniques (overall): 
PRIMARY OUTCOMES: There was no evidence of significant differences in the 
rates of amenorrhea or successful treatment at any follow up time, from six 
months to ten years after surgery. There was also no evidence of significant 
differences in satisfaction rates at any time point.
SECONDARY OUTCOMES: On average, first generation ablation techniques 
required an extra 15 minutes treatment time when compared with second 
generation techniques (MD -14.9, 95% CI -10.1 to -19.7). There was also a greater 
risk of equipment failure with second generation devices (RR 4.3, 95% CI 1.5 to 
12.4) and greater chance of using local rather than general anaesthesia with 
second generation devices (RR 2.8, 95% CI 1.8 to 4.4). Regarding complications, 
women undergoing second generation ablation procedures were less likely 
to have fluid overload, perforation, cervical lacerations and hematometra as a 
result of their surgery than women undergoing first generation ablation (RR 0.2, 
95% CI 0.04 to 0.8; RR 0.3, 95% CI 0.1 to 1.0; RR 0.2, 95% CI 0.08 to 0.6; RR 0.3, 95% 
CI 0.1 to 0.9, respectively). They had a significantly greater risk of having nausea 
and vomiting and uterine cramping (RR 2.0, 95% CI 1.3 to 3.0; RR 1.2, 95% CI 1.0 to 
1.4, respectively). There was no evidence of significant differences for the other 
secondary outcomes compared: inability to work, other complication rates and 
requirement for any additional surgery or hysterectomy. The main outcomes 
for this overall comparison can be viewed in the Summary of findings (Table 1). 
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Analysis 16.1. Second generation endometrial ablation compared to first generation 
endometrial ablation for heavy menstrual bleeding. 





Risk Ratio Risk Ratio
Study or Subgroup Events Total Events Total Weight M-H, Random, 95% Cl M-H, Random, 95% Cl
16.1    At 1 year  follow up
Brun 2006 10 28 5 17 4.8% 1.21 [0.50, 2.95]
Cooper 1999 46 116 49 124 10.8% 1.00 [0.73, 1.37]
Cooper 2002 63 154 29 82 10.4% 1.16 [0.82, 1.64] 
Cooper 2004 119 215 49 107 11.7% 1.21 [0.95, 1.53] 
Corson 2000 38 122 39 112 10.1% 0.89 [0.62, 1.29] 
Corson 2001 67 167 42 83 11.2% 0.79 [0.60, 1.05]
Duleba 2003 43 156 40 72 10.6% 0.50 [0.36, 0.69] 
Hawe 2003 10 34 13 33 6.6% 0.75 [0.38, 1.46]
Meyer 1998 19 125 31 114 8.3% 0.56 [0.34, 0.93]
Perino 2004 35 56 14 55 8.5% 2.46 [1.50, 4.03]
Romer 1998 4 10 3 10 3.1% 1.33 [0.40, 4.49]
Soysal 2001 5 45 8 48 3.9% 0.67 [0.24, 1.89]
Subtotal (95% Cl) 1228 857 100.0% 0.94 (0.74, 1.20]
Total events 459 322
Heterogeneity: TaU2 = 0.1 2; Chi2 = 41_76,  
df= 11 (P < 0.0001 ); 12 = 7 4%
Test for overall effect: Z= 0.50 (P = 0.61)
Analysis 16.2. Second generation endometrial ablation compared to first generation 
endometrial ablation for heavy menstrual bleeding. 





Risk Ratio       Risk Ratio
Study or Subgroup Events Total Events Total Weight M-H, Random, 95% Cl M-H, Random, 95% Cl
16.2  At 1 year follow up
Brun 2006 27 28 17 19 1.6% 10.8 [0.91,128]
Cooper 1999 89 116 93 124 2.3% 1.02 [0.89,1.18]
Cooper 2002 143 154 77 82 8.9% 0.99 [0.92,1.06]
Cooper 2004 193 196 96 97 45.6% 0.99  [0.97,1.02]
Duleba 2003 176 193 74 86 5.0% 1.06 [0.96,1.17]
Hawe 2003 28 30 26 27 3.1% 0.97 [0.86,1.09]
Meyer 1998 120 125 113 114 24.8% 0.97 [0.93,1.01]
Pellicano 2002 35 37 34 38 2.6% 1.06 [0.93,1.21]
Perino 2004 53 56 50 55 4.2% 1.04 [0.94,1.16]
Romer 1998 10 10 10 10 1.4% 100 [0.83,1.20]
Soysal 2001 30 45 29 48 0.5% 1.10 [0.81,1.50]
Subtotal (95% Cl) 990 700 100.0% 1.00 [0.97,1.02]
Totalevents 904 619
Heterogeneity: Tau2=0.00; Chi2=10.55, df=10 (P=0.39); I2=5%
Test foroverall effect: Z=0.36 (P=0.72)
0.1 0.2 0.5 1 2 5 10
Favours 1st gen abl       Favours 2nd gen abl
0.1 0.2 0.5 1    2       5     10
Favours 1st gen abl         Favours 2nd gen abl
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Analysis 16.3. Second generation endometrial ablation compared to first generation 
endometrial ablation for heavy menstrual bleeding 
Outcome 3: Satisfaction of treatment (PBAC < 75 or acceptable improvement) at 1-year 
follow-up
0.1 0.2 0.5 1 2 5 10
Favours 1st gen ablation          Favours 2nd gen ablation
2nd generation abl 1st generation abl Risk Ratio Risk Ratio
Study or Subgroup Events Total Events Total Weight M-H, fixed, 95% Cl M-H, fixed, 95% Cl
16.3.1 At 12 months follow up
Cooper 1999 91 116 94 124 17.4% 1.03 [0.90, 1.19]
Cooper 2002 136 154 67 82 16.8% 1.08 [0.96, 1.22]
Cooper 2004 187 215 89 107 22.8% 1.05 [0.95, 1.16]
Corson 2000 106 122 93 112 18.6% 1.05 [0.94, 1.17]
Corson 2001 128 167 68 83 17.4% 0.94 [0.82, 1.07]
Soysal 2001 34 45 38 48   7.0% 0.95 [0.77, 1.19]
Subtotal (95% Cl) 819 556 100.0% 1.02 [0.97, 1.08]
Total events 682 449
Heterogeneity: Chi2= 3,37, df= 5 (P = 0.64); I2= 0%
Test for overall effect Z= 0.91 (P = 0.36) 
Heterogeneity 
1. Specific types of endometrial resection or ablation: 
Most of the forest plots comparing specific types of endometrial ablation were 
comparisons between groups in individual trials or pooled two or three studies 
at most, and there was little evidence of statistical heterogeneity. However, 
substantial statistical heterogeneity (I2 >50%) was found for the following forest 
plots: 
Comparison 1.5: duration of operation (laser versus TCRE) 
Comparison 7.5: duration of operation (electrode ablation versus TCRE + RB) 
Comparison 9.8: duration of operation (balloon versus RB) 
Comparison 9.14: requirement for further surgery (two year follow up) (balloon 
versus RB) 
Comparison 12.3: satisfaction rate (six months follow up) (bipolar RF ablation 
versus balloon) 
Comparison 12.33: requirement for further surgery (bipolar RF versus balloon) 
Duration of operation is affected by numerous confounding factors, such as 
expertise of individual surgeons, hospital type and procedures and differences 
between groups of women. For the comparison, laser versus TCRE, the Bhattacharya 
study59 did not include the total time spent in theatre and the McClure study60 
recorded the induction and reversal of anaesthesia in the estimate of operation 
time which resulted in much larger estimates. In this latter trial, temporary laser 
malfunction prolonged two laser cases to 240 minutes. For the comparison, 
electrode ablation versus TCRE + rollerball, differences between studies are likely to 
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be explained by the two different systems used; the Corson study61 used the Vesta 
balloon ablation and the Cooper study used Novasure.62 In the comparison, balloon 
vs rollerball, all three pooled studies used the Thermachoice balloon system. The 
operation time recorded for the rollerball ablation was similar in the three trials 
but times differed between studies for balloon ablation. The Meyer study had no 
preoperative treatment to thin the endometrium whereas the other two studies 
had two months of GnRHa pretreatment.44 In the Soysal study42, participants 
had both myomas and heavy menstrual bleeding. Other factors such as cavity 
length were correlated with operation time and it is not clear whether these were 
similarly distributed between the participants in the three trials. Another major 
confounding factor was the ability to use local rather than general anaesthesia 
which was more likely in the trials comparing second generation ablation to first 
generation ablation methods. 
Satisfaction is also likely to vary because of different methods of measurement. 
In the comparison, bipolar RF ablation vs balloon, satisfaction rates at 6 months 
in the small Abbott trial may have been related to a technical failure rate of the 
Novasure procedure, but rates at 12 months follow up were similar and not 
significantly different at 12 months follow up.63 
Significant heterogeneity was also found for the outcome, requirement for 
further surgery, in the comparison of balloon with rollerball and bipolar electrode 
ablation versus balloon. The different results in the two pooled trials for either 
comparison could not be explained by examination of their characteristics. Neither 
trial reported a significant difference in the outcome by ablation technique. 
2. Overall analyses comparing first and second generation techniques: 
Substantial heterogeneity was displayed for many of the outcomes where first 
generation procedures were compared with second generation procedures 
(comparison 16); in particular, amenorrhea rate, duration of operation, and 
proportion having local as opposed to general anaesthesia. The value for the 
outcome, amenorrhea at one year after surgery was 74%, at two years 50% and at 
three years 80%. The rates of amenorrhea ranged widely in the included trials and 
no statistical difference was reported between groups. Estimates calculated with 
the fixed effects model were compared with estimates calculated with a random 
effects model; the estimates did not change markedly but the confidence intervals 
were wider with the latter approach. There was thus no evidence that amenorrhea 
rates varied according to whether first or second generation techniques were 
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used to ablate the endometrium.
The forest plots of the outcomes, duration of surgery and local versus general 
anaesthesia also indicated substantial heterogeneity. Since these two categories 
are very broad and they include a number of different ablative techniques, 
heterogeneity was expected and a random effects model was used to display 
results. As previously explained, apart from differences between techniques, 
duration of surgery is likely to be affected by extraneous factors such as skill 
and expertise of the surgeon, hospital policy and the operating environment. 
However, each of the included trials reported separately that second generation 
techniques took significantly less time to perform than first generation techniques, 
regardless of the procedures compared. A random effects approach indicated 
significantly less time required for second generation procedures; each of the trials 
individually indicated a statistically significant difference. The other comparison, 
proportion of women having local as opposed to general anaesthesia, also 
indicated highly significant heterogeneity. In all trials in the meta-analysis, the 
proportion of women undergoing ablation with first generation techniques using 
local anaesthesia (either: TCRE plus RB or RB alone) ranged from 8% to 23% while 
the proportion undergoing second generation ablation using local anaesthesia 
(Vesta, HTA, Novasure, cryoablation or microwave) ranged from 45% to 86%. All 
trials separately reported large significant differences between first and second 
generation techniques. A random effects model confirmed these differences in 
the pooled result.
To sum up, random effects analyses confirmed the following: 
(1)  There was no evidence of a difference in the amenorrhea when first 
generation techniques are compared with second generation techniques. 
(2)  Duration of surgery with second generation techniques overall was less than 
with first generation techniques. Because of heterogeneity, which is probably 
explainable by other factors such as experience of surgeons, the difference 
of fifteen minutes between procedures represents an average which is not 
informative and this difference is unlikely to be clinically significant. 
(3)  Women undergoing ablation with second generation techniques are more 
likely to have local anaesthesia compared to those having ablation with first 
generation techniques. 
Sensitivity analyses 
Sensitivity analyses were performed only on the comparisons where five or more 
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trials were pooled, specifically for the comparison of satisfaction and amenorrhea 
rates at one-year follow up between first and second generation ablation. There 
were no significant differences reported between randomized groups and the 
planned sensitivity analyses did not substantially change the results of all included 
trials, although heterogeneity was reduced.
Discussion
Summary of main results
A significant number of women with heavy menstrual bleeding (HMB) who seek 
treatment will not benefit from, or will not wish to continue with, medical treatment 
and are keen to preserve their uterus. Thus, there appears to be a distinct role for 
an effective, relatively minor surgical procedure such as endometrial ablation or 
resection which preserves the uterus yet reduces heavy menstrual bleeding. This 
review has assessed a wide range of efficacy, satisfaction and safety outcomes 
relating to different methods of ablating the endometrium for women who 
complain of excessive menstrual bleeding. 
Comparison of different types of first generation techniques 
The first generation ablation techniques have been traditionally acknowledged as 
the “gold standard” by which other, newer procedures are judged. Improvement in 
menstrual bleeding and satisfaction seems to be similar. The complication profile 
for the four techniques is slightly different; for example, fluid overload was more 
likely with laser ablation when compared to TCRE and also more likely with TCRE 
when compared to vaporizing electrode. However, it is likely that operator safety 
is a much more important arbiter of patient safety than the instrument itself. 
Duration of surgery was longer with laser when compared to TCRE and was longer 
with TCRE when compared to vaporizing electrode ablation. Equipment failure 
was more likely with laser ablation when compared to TCRE and more difficult 
with TCRE when compared to vaporizing electrode ablation. 
Comparison of different types of first generation with second generation 
techniques 
With reference to the comparisons of the different types of second generation 
techniques with first generation techniques, thermal laser was more effective than 
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TCRE at reducing blood loss (as measured by amenorrhea rates) but this did not 
result in any difference in the satisfaction that the women felt with their surgery. 
Although rollerball was more likely to result in amenorrhea when compared to 
cryoablation, there was also no evidence that women were more satisfied. Similarly, 
the finding that rollerball was associated with significantly more amenorrhea 
when compared to balloon ablation at some time points, but not at others, is not 
useful as there was no evidence that this benefit was confirmed by other bleeding 
outcomes of importance to women, such as PBAC score or scanty menstruation. 
Patients appeared to be more satisfied with microwave than TCRE at 2 and 5 years 
after surgery, but these findings were not significant at other time points. 
With regards to secondary outcomes, duration of surgery was consistently 
shorter with second generation ablation and local anaesthesia was more likely to be 
given. Pain was also more likely with some types of second generation technique, 
such as thermal laser, balloon and HTA but this outcome was not measured by all 
trials. The intra- and post-operative complication rates are summarized below.
Comparison of different types of second generation techniques 
Bipolar radiofrequency ablation was associated with significantly more amenorrhea 
than balloon ablation but this was not confirmed by a comparison of PBAC scores 
or the extent to which women were satisfied with their surgery. Surgery was shorter 
with bipolar ablation and PMS scores reduced. There was no evidence that bipolar 
radiofrequency ablation resulted in less re-operation as a result of dissatisfaction 
with surgery. Bipolar ablation also increased amenorrhea and satisfaction rates 
when compared with hydrothermal ablation. The procedure time was shorter 
with bipolar ablation and women were less likely to require additional surgery 
at later follow up. Amenorrhea rates appeared to be increased with microwave 
when compared with balloon but no differences were found in PBAC scores or 
satisfaction. Operation time was also reduced with microwave ablation. 
Comparison of curettage techniques 
One small trial found advantages for an ablative curettage (devised by the author 
of the trial) over overcurettage (where the curettage is continued beyond the gritty 
sensation felt at the basal endometrium) in terms of improved amenorrhea and 
normal menstruation rates and reduced failure rate and bleeding complications, 
but longer hospital stay. The objective of the study was to find effective techniques 
for developing countries which may not have the resources and skills to undertake 
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other types of ablation discussed in this review, but the authors acknowledged 
that curettage may only have a temporary role. 
Overall comparison of first generation with second generation techniques 
Regarding the overall comparison of second generation with first generation 
techniques, there is no evidence that either broad category is more effective than 
the other in reducing heavy menstrual bleeding and there was no evidence that 
rates of satisfaction differed significantly. Overall, second generation techniques 
were at least as effective as first generation methods but were often easier 
to perform with shorter surgery times and the ability to use local rather than 
general anaesthesia. Some types of intra and postoperative complications, such 
as fluid overload, perforation, cervical lacerations and hematometra, were more 
common with first generation ablation and other types of complication, nausea 
and vomiting and uterine cramping and pain, were more common with second 
generation techniques. Concerns about these ‘blind’ methods leading to bowel 
injuries from undetected uterine perforations did not seem to be confirmed in the 
published studies. However, there are many anecdotal examples that such events 
can occur and great care must be taken to minimize the risk of such potentially 
serious complications. There was no evidence that rates of re-intervention, 
either repeat ablation and/or hysterectomy, differed between first and second 
generation ablation. A recurrent comment about the newer techniques which rely 
on ‘devices’ inserted into the uterine cavity to destroy the endometrium was the 
incidence of equipment failure. This may represent expected ‘teething problems’ 
associated with new equipment. However, since the older methods are extremely 
simple (a loop, laser or diathermy to destroy the endometrium below it) and the 
newer techniques are potentially quite complex (microwaves, bags of fluid etc) the 
potential remains for mechanical breakdown to occur. In addition, considerable 
experience in intrauterine cavity assessment and manipulation is required to safely 
use any of these devices. There are potential disadvantages to stressing how little 
operator skill is required for a device which has the capacity to cause extensive 
intra-abdominal trauma.
Overall completeness and applicability of evidence 
A perennial and unresolved problem in the assessment of any treatment for HMB 
is the accuracy of the original diagnosis and the quandary that many women who 
complain of excessive bleeding will be shown to have menstrual losses (MBL) 
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within normal population limits when blood loss is objectively measured.64,65 The 
‘gold standard’ technique for the measurement of MBL involves the collection of 
all menstrual pads and tampons as well as clots and other blood lost, which is 
impractical for many women. Also, the assessment of blood loss (via the alkaline 
hematin method) is a time consuming and laborious task, although objective data 
are helpful in the research setting. Consequently, a number of more pragmatic 
alternatives have been suggested to attempt to objectively assess MBL in a 
normal clinical setting, such as the pictorial blood loss assessment chart (PBAC). 
Unfortunately, none of these alternatives have been shown to reliably correlate with 
the gold standard. Some authors have accepted that it is the woman’s subjective 
complaint of HMB which is of primary importance in directing intervention in 
a clinical setting. However, this subjectivity raises problems when used for the 
comparison of one treatment method with another and in assessing outcome 
over time. Participants in the trials included in this review all had complaints of 
heavy menstrual bleeding but there is likely to be a large variation in the extent of 
the problem because of the subjective nature of the condition. 
To make matters more confusing, evidence from a large cross-sectional 
survey suggests that whilst many women are referred with menorrhagia, many 
of these women do not complain of HMB when directly questioned; suggesting 
a tendency for broad menstrual complaints to be reframed as excessive bleeding 
at referral and during management.66 As the authors concluded, this is likely to 
result in women receiving inappropriate care and will also influence the actual and 
perceived efficacy of treatment modalities for HMB. 
The published literature on endometrial destruction techniques for HMB 
covers a wide range of surgical methods and uses a variety of outcome measures 
to assess treatment success, making clear comparisons between studies difficult. 
The participant groups were varied and often potentially important clinical factors, 
such as the presence of uterine fibroids or a perimenopausal state, were not 
mentioned in the inclusion or exclusion criteria. This is particularly important with 
longer follow-up studies. Current clinical approaches to HMB advise that medical 
therapy should be offered in the first instance and it would be unusual in normal 
practice to advise endometrial resection or ablation without trying any medical 
therapies. Indeed, since medical treatment with the levonorgestrel-releasing 
intrauterine system (Mirena, Schering) reduces MBL by 94% at three months, and 
has been shown to be as effective as endometrial ablation,67,68 it could be argued 
that endometrial surgery is only appropriate for those who are unsuitable or do 
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not wish to have treatment with the intrauterine system.8 Fourteen published 
studies focused on women with failed medical management of HMB and there 
were insufficient studies within each comparison to determine whether women 
in these studies differed systematically in their response to treatment than 
other women. Many researchers are aware of the difficulties in recruitment to 
randomized clinical trials and the need to obtain sufficient participants to meet 
the requirements of power calculations. However, the inclusion of unsuitable or 
unrepresentative participants in trials does not add to our understanding of the 
role of new therapies in normal clinical practice. 
The published studies show a wide variation in the outcome criteria used in 
assessing endometrial destruction techniques. Since HMB is the main indication for 
this procedure, we were surprised to find that only one trial objectively measured 
MBL.60 Several studies used the pictorial blood loss assessment chart (PBAC) which 
does not correlate well with objective measurement.39,69 In addition, the entry criteria 
for PBAC score varied widely between studies. However, if comparisons are made 
between studies of changes in PBAC scores following endometrial destruction, 
few differences were seen between treatment modalities. Some variations 
were seen in the number of women with amenorrhea following treatment, but 
since menstrual destruction methods cannot guarantee amenorrhea they are 
generally not suitable for women who feel strongly that they do not want any 
more bleeding. A number of studies attempted to quantify participant satisfaction 
with the procedure but used a variety of different measurements to do so, limiting 
comparisons between studies. Overall, participant satisfaction was high with most 
procedures and differences found were unlikely to be clinically significant. Large 
study numbers would be needed in order to demonstrate a significant difference 
in satisfaction between different methods of endometrial destruction.
Quality of the evidence 
The evidence base on which this review is based was of variable quality. In particular, 
few studies were blinded and in most of the comparisons between individual 
techniques, a limited number of studies provided data. Lack of blinding is likely to 
influence more subjective outcomes, such as satisfaction rates so findings of these 
types of outcomes should be viewed with caution. 
Substantial heterogeneity was identified in some of the outcomes of the 
overall comparison between first and second generation techniques, and the 
quality of the evidence has been downgraded to reflect the uncertainty around 
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the summary effect estimates. See Summary of findings table 1.
Potential biases in the review process 
A comprehensive search for relevant studies together with duplicate and 
independent study selection, data extraction and quality assessment of studies 
has minimized the chance of potential bias in the review process. 
Agreements and disagreements with other studies or reviews 
Surprisingly, although there have been numerous RCTs and observational 
studies of specific types of endometrial ablation techniques, there have been few 
systematic reviews identified that have made overall comparisons of the specific 
endometrial ablation techniques for the reduction of HMB. Numerous narrative 
reviews have been published together with comprehensive audits for first 
generation techniques. Comparing the first generation methods of endometrial 
ablation versus resection, the MISTLETOE study concluded that the methods 
produced similar outcomes in terms of bleeding and participant satisfaction, but 
that resection methods have significantly more complications, suggesting that 
ablation should be used in all women with a non-fibroid uterus.26 
Systematic reviews, one with individual patient data, have not been able to 
determine major differences between first and second generation techniques in 
terms of effectiveness or satisfaction with treatment.11,70 However, Middleton has 
confirmed the results of this review that second generation techniques are faster, 
local anaesthesia is more likely to be used and some complications less frequent. 
The suggestion in this review that additional surgery may be less likely with second 
generation techniques at longer follow up (10 years) is based on only one trial and 
needs confirmation from further research. 
Of the second generation techniques, the most studied have been Novasure, 
balloon and microwave ablation.71 A recent network meta-analysis has reported 
that bipolar radiofrequency and microwave ablation resulted in higher rates of 
amenorrhea than thermal balloon ablation at 12 months after treatment but there 
was no evidence of a convincing difference between the three techniques in 
satisfaction rates or the number of women still experiencing heavy bleeding and 
other outcomes were not assessed.72 However, the lack of a consistent measure of 
effectiveness has made it difficult to adequately compare techniques and reach 
conclusions over the technique of choice. Other authors have suggested that 
there might be commercial resistance to comparing devices, given the likely effect 
25367 Penninx, Josien.indd   148 11-05-13   17:24
A review comparing endometrial ablation/resection techniques
149
8
on the market share for the inferior treatment.73 It has also been suggested that 
a potential limitation of second generation devices are the restrictions relating 
to one or a combination of the size and configuration of the endometrial cavity 
that may prevent general application of any device to the HMB population.74 
Many of the included studies in this review that evaluated these devices had fairly 
strict inclusion criteria, limiting the applicability of results to women with large 
or distorted uteri. Thus, not all women with HMB may be candidates for second 
generation ablation and it has been suggested that gynaecologists should retain 
their skills in hysteroscopic surgery for certain types of intrauterine pathology.75 
An additional issue is the role of patient preferences in decision making on 
treatments for heavy menstrual bleeding. A recent review suggested that reaching 
a decision on a “one size fits all” approach may be elusive and that eliciting patient 




Endometrial destruction by first or second generation techniques should 
be considered for all women with normal uteri who wish to reduce their heavy 
menstrual bleeding and wish to retain their uterus.
The potential for second generation methods to be performed under local 
anaesthesia is a considerable advantage and should be considered in cases where 
general anaesthetic may confer particular risk. 
There is sufficient evidence to confirm that, on average, second generation 
techniques are technically simpler and quicker to perform than first generation 
techniques while satisfaction rates and reduction in heavy menstrual bleeding are 
similar. However, technical difficulties have not yet been completely resolved.
Implications for research 
Future studies should aim to include women in whom medical treatment for 
heavy menstrual bleeding has been ineffective. 
Menstrual blood loss should be objectively or semi-objectively measured in 
all comparative studies (by the alkaline hematin method or the PBAC), although 
the assessment of the woman in the clinical setting is nearly always based on more 
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subjective criteria, such as perception of heavy bleeding. 
Amongst first generation techniques for endometrial destruction, there are 
good data to support the use of endometrial ablation rather than resection.26 
There is a need to systematically compare first generation ablation methods 
with second generation techniques using standardized criteria of participant 
satisfaction and quality of life and objectively measured menstrual blood loss in 
order to establish which of the newer methods has an established role and when 
they should be the instruments of choice. This may require referral to another unit 
where such techniques are available. There was insufficient evidence in this review 
to determine the superiority of one type of second generation technique over 
another. Equipment reliability for the second generation techniques needs to be 
established.
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General discussion




Heavy menstrual bleeding (HMB) is a significant health problem in women in 
reproductive age. The incidence varies between 9 to 22 %.1,2 Before, HMB was 
named menorrhagia. Lately, changes in terminology have been introduced 
because there was a great variation in the way the terms abnormal uterine 
bleeding, menorrhagia and dysfunctional uterine bleeding were used. It was 
proposed to use abnormal uterine bleeding as the overarching term to describe 
all symptomatic flow of normal menstruation or the menstrual cycle. HMB is a 
suitable replacement for menorrhagia.3 HMB is defined as cyclical blood loss of 
>80ml during each menstrual period.4 However, the amount of blood loss is 
difficult to objectify. The amount of menstrual blood loss can also be scored on 
the pictorial blood loss assessment chart (PBAC), described by Higham et al.5 One 
period is counted and a minimum score of 150 points is described as HMB. 
Only about half the women with HMB who turn to healthcare providers 
indeed have blood loss greater than the traditional threshold of 80 mL per 
menstrual cycle.6 Nevertheless, the diagnosis is often based on the subjective 
impression of the patient. Regardless of the exact amount of blood loss assistance 
may be needed when women feel that their everyday activities are affected.6,7 This 
corresponds with the description of health by the WHO, formulated in 1948: “a state 
of complete physical, mental and social well-being and not merely the absence of 
disease or infirmity”.8 Recently, Huber et al. proposed the formulation of health as 
the ability to adapt and to self-manage.9 That is why clinical guidelines propose a 
shift in emphasis from the amount of menstrual blood loss to the more patient 
centered definition of HMB that interferes with woman’s physical, emotional and 
social life.10,11 
Women included in our studies had HMB scored >150 points on a PBAC. 
We have not experienced that a significant part of women with heavy menstrual 
bleeding in fact did have less than 150 points on their pictorial chart score. This 
may be explained by the fact that women in the Netherlands are often first seen 
by their general practitioner before they are referred to a gynecologist. 
Why and when do women perceive menstrual bleeding as a problem?                
The fact that only half of the women who turn to healthcare providers with 
HMB objectively do have blood loss >80 mL or scored > 150 points on a PBAC, 
raises the question why some women perceive a ‘normal’ menstruation as heavy 




while others do not. There is evidence that in such cases a lack of understanding 
between patients with HMB and their doctors is present.7,12 Women with HMB 
were interviewed and they had a precise understanding of their complaint. The 
problem for many women was the change of their cycle, without reference to 
outside criteria. Women attached the most importance to how they felt and to 
their ability to function and they rejected the medical emphasis on blood loss 
evaluation. Many women were dissatisfied with the consultation and experienced 
their doctors as being dismissive of their problem. They were seeking an 
explanation for the fact that their periods had changed and had concerns relating 
to their understanding of menstrual bleeding.11 O’Flynn proposed that the disease 
model should be replaced by illness models.12 This could suggest that women 
should be helped by clinicians listening to women’s accounts of their menstrual 
problems in their broadest sense, clarifying presenting symptoms and their impact 
on everyday life, and offering help and advice for these problems. If women do 
receive inappropriate care, this will also influence the actual and perceived 
efficacy of treatment modalities for HMB. This could be the reason why women 
remain unsatisfied with the result after treatment and will only be satisfied after 
a hysterectomy has been performed. It would be interesting to study possible 
correlations between absolute pictorial chart scores and pictorial chart score 
changes before and after therapy with satisfaction:
•	 Does satisfaction correlate best with a certain decrease in pictorial chart 
score after therapy or with an absolute pictorial chart score?
•	 Is there a difference in satisfaction between women with high versus 
relatively low pictorial chart scores before treatment? 
Is it necessary to screen women with HMB for bleeding disorders? 
In the majority of cases no abnormality is found to explain HMB when women 
are referred for menorrhagia.13 Nevertheless, systemic problems such as platelet 
and coagulation disorders as well as hepatic disease, may cause HMB. In women 
with HMB, inherited coagulopathy is the underlying cause in 10% to 20% of white 
women and 1% to 2% of black women.14,15 Platelet dysfunction and deficiency 
of von Willebrand factor (vWF) are the two most common coagulation disorders 
observed in HMB.16 Approximately 74% to 92% of women with deficiency of vWF 
experience HMB.17 Among women with deficiencies in factor I, XI, or XIII, HMB 
prevalence ranges from 35% to 70%.18 Carriers of haemophilia are more likely 
to have a better outcome in treating their HMB with gynaecological or surgical 
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management compared with medical management.19 Despite these figures, 
only one third of interviewed fellows of the American College of Obstetricians 
and Gynecologists would consider bleeding disorders as a cause for HMB in 
reproductive aged women.20 According to the ACOG, blood collection to screen for 
hematologic disorders should be performed before initiating treatment in women 
who have had heavy menstrual bleeding since menarche and have personal or 
family history suggesting a coagulation disorder.10,21 Most studies comparing 
endometrial ablation, including our own, do not mention if they excluded women 
with a bleeding disorder. 
The optimal treatment of HMB in women with bleeding disorders is not yet 
known, illustrating the need for better information concerning the influence of 
von Willebrand Factor (vWF) levels and levels of factor XI on the treatment effect 
of resp. the LNG-IUS and endometrial ablation. The MIRA study (LNG IUS versus 
endometrial ablation) will measure factor XI and von Willebrand factor and 
investigate their influence on the treatment effect of LNG-IUS and endometrial 
ablation. We have to wait for the results of this study.
What treatment options are available for heavy menstrual bleeding? 
Not that long ago women presenting with HMB for whom oral drug regimens did 
not help, had a hysterectomy performed. In the last decades treatment of HMB 
has changed. The levonorgestrel intrauterine system (LNG IUS) and endometrial 
ablation became alternatives. A recent study of Gupta et al. concluded that in 
women with HMB who turned to primary care providers, the LNG IUS was more 
effective than usual medical treatment in reducing the effect of heavy menstrual 
bleeding on quality of life.22 Nonetheless, at two years, 36% of women in the 
levonorgestrel-IUS group had the system removed, generally because of lack of 
effectiveness or irregular or prolonged bleeding. High satisfaction rates (85-90%) 
with significant decrease in blood loss (80-90%) are shown after endometrial 
ablation. Results of randomized controlled trials, comparing the effectiveness of the 
LNG-IUS and endometrial ablation in the treatment of heavy menstrual bleeding, 
are lacking. We will have to wait for the results of the Dutch MIRA study, which is a 
randomized controlled trial comparing the costs and effects of the levonorgestrel 
IUS and endometrial ablation in women with heavy menstrual bleeding.  
As shown in our randomized controlled trials, comparing three second-
generation endometrial ablation techniques (Chapter 3 and 7), bipolar ablation 
seems superior in the treatment of HMB. This corresponds with the network 




meta-analysis of second-generation ablation techniques of Daniels et al., which 
also includes our trial comparing bipolar ablation and HTA.23 They concluded that 
bipolar radiofrequency and microwave ablative devices are more effective than 
thermal balloon and free fluid ablation in the treatment of HMB with second-
generation endometrial ablation devices. When comparing first-generation and 
second-generation endometrial ablation devices (Chapter 8), the existing evidence 
suggests that success and satisfaction rates and complication profiles of newer 
techniques compare favorably with hysteroscopic first-generation techniques. 
The newer techniques are technically easier to perform. However, technical 
difficulties with new equipment need to be ironed out. As implicated for further 
research in chapter 8, there is a need to systematically compare first-generation 
ablation methods with second-generation techniques using standardized criteria 
of participant satisfaction and quality of life and objectively measured menstrual 
blood loss in order to establish which of the newer methods has an established 
role and when they should be the instruments of choice. However, we do believe 
it is not reasonable to perform a randomized controlled trial comparing a first 
and second-generation ablation device, because severe intra and postoperative 
complications, such as fluid overload, perforation, cervical lacerations and 
hematometra, were more common with first generation ablation (Chapter 8). 
Another disadvantage would be that the first-generation techniques are only used 
by a few gynecologists, which are specialized in performing these techniques, this 
can potentially bias the results of the first-generation technique and it may require 
referral to another unit where such techniques are available.  
Is it acceptable to perform an endometrial ablation in the office?
Second generation non-hysteroscopic techniques are considered easier to perform, 
with shorter treatment time and are equally effective and safe as first-generation 
endometrial ablation techniques.24 Along with an advanced technology, ablations 
are performed more often in the office instead of in the operating room. It 
appears that with proper patient selection, equipment and anesthesia techniques 
endometrial ablation can be performed safely and effectively in an office setting. 
Whereas initially endometrial ablations were performed with local anesthesia 
combined with conscious sedation, recently studies have been performed only 
using a paracervical block.25,26 As shown in chapter 6 and 7, endometrial ablation 
with a paracervical block seems acceptable and feasible, but discomfort during 
office surgery remains the main obstacle to more widespread implementation. 
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Further work is required to improve the identification of women likely to tolerate 
the procedure well, to improve the patient experience and to minimize pain while 
maintaining a simple and safe procedure. 
Which measures should be used to assess the success of endometrial ablation?
Published literature on endometrial destruction techniques for menorrhagia 
covers a wide range of surgical methods and uses a variety of outcome measures 
to assess treatment success. Amenorrhea, satisfaction and re-intervention rates are 
often used as outcome measures, but besides these measures, it seems important 
to measure quality of life by validated questionnaires when comparing treatment 
for HMB. 
HMB can cause significant distress to women by affecting their performance 
at work as well as their social activities, and leads to a measurable reduction in 
quality of life.27 Measurement of quality of life might give a better presentation 
of the effectiveness of the treatment for women compared to the amount of 
patients with amenorrhea. Quality of life improves after any endometrial ablation 
procedure, but a discrepancy between clinical outcome in different endometrial 
ablation techniques and quality of life was found in most randomized studies.28-31 
This was also present in our study, assessing health related quality of life after 
bipolar endometrial ablation and hydrothermablation (chapter 5). We concluded 
that in all generic and disease specific questionnaires treatment of HMB improved 
health related quality of life over time, but the treatment effect of amenorrhea and 
satisfaction did not result in quality of life benefits.
The pictorial chart score and quality of life scores are never analyzed to 
answer the question: What is clinical relevant decrease of blood loss in women 
with heavy menstrual bleeding?’. Besides this, the question arises if women would 
prefer a return to eumenorrhea rather than amenorrhea. In case of eumenorrhea 
quality of life and satisfaction should be the primairy outcome of trials comparing 
endometrial ablation techniques. If they prefer amenorrhea this could explain why 
they are more satisfied after a hysterectomy. A preference study could determine 
this problem. 




What is the benefit of treatment by endometrial ablation in perimenopausal 
women?
Most women who are seeking help for HMB are perimenopausal. These women 
often ask how long their complaints will persist, that is, when they will become 
postmenopausal. A recent study analyzed the spontaneous resolution of heavy 
menstrual bleeding in the premenopausal years. When the heaviness of menstrual 
bleeding interfered with the quality of life of women, the overall rate of resolution 
without recurrence of heavy menstrual bleeding in naturally menstruating women 



























Figure 1. Percentage of women with amenorrhea after first- and second-generation endometrial 
ablation
Figure 1 shows the amenorrhea rate from long-term follow-up studies after 
endometrial ablation. The amenorrhea rate starts to increase two years after 
treatment and even becomes significant after five years, which could be explained 
by the fact that most women became postmenopausal.24 This corresponds with 
the fact that the average age of participants at recruitment of the studies was 40-
45 years, and the average age of the menopause in developing countries is 51 
years.33 If we will inform women that the chance of getting postmenopausal will 
probably be within 2-5 years, they will possibly not have the endometrial ablation 
performed. 






























Figure 2. Percentage of women being satisfied with the result of endometrial ablation after first-
and second-generation endometrial ablation
Remarkable is the decrease in percentage of women being satisfied more than 
5 years after treatment (Figure 2). Whereas the amenorrhea rate increases, the 
satisfaction rate decreases during time. An explanation could be that a few years 
after treatment women forget how the HMB interfered with their life before and 
answer that they are less satisfied. Another explanation could be that satisfaction 
is not the correct outcome measure evaluating the effect of endometrial ablation 
at long term follow up. A third explanation could be that women are less satisfied 
because they are peri- or postmenopausal and do experience physical changes as 
hot flushes, irregular bleeding and vaginal dryness can appear, or mental changes 
as mood swings, depressive feelings or insomnia. Long term studies evaluating 
success, satisfaction and health related quality of life are essential to offer patients 
information with respect to a desirable and long term solution for heavy menstrual 
bleeding.
What are the long term risks of endometrial ablation?
At long term follow up, unknown morbidity may become apparent, especially 
endometrial carcinoma. As endometrial ablation is a relatively new therapy with 
a variety of techniques, data on incidence of long-term follow-up problems, i.e. 
endometrial cancer after endometrial ablation are lacking. It is suggested that 
the incidence of endometrial cancer after endometrial ablation is reduced in 
case of maximal destruction of the endometrium.34 However, some evidence 




suggests that incidence of endometrial cancer is unchanged after endometrial 
ablation with first generation techniques. So far, most cases are reported after 
first generation techniques. The diagnosis of endometrial carcinoma may be 
delayed after ablation, because adhesions or scars could mask the symptoms of 
the disease. If postmenopausal bleeding occurs, interpretation of the thickness 
of the endometrium and hysteroscopy can be difficult to perform because of the 
anatomical distortion of the uterine cavity. The next decade will provide us with 
data, because women treated with the first generation endometrial ablation devices 
are 50-60 years of age, being the age with the highest prevalence of endometrial 
cancer. Therefore, adequate follow-up of these therapeutic interventions is still 
needed for clinical decision making and counselling of patients. 
In conclusion, my suggestions for future research would be:
•	 to evaluate the patient preference in treatment of heavy menstrual 
bleeding.
•	 to study if there is a relationship between the decrease of pictorial chart 
score and satisfaction and if we could tell at which pictorial chart score 
women will be satisfied.
•	 to study how to improve the patient experience with endometrial 
ablation in the office and how to identify those women likely to tolerate 
the procedure well. Trials incorporating different anaesthetic approaches 
on how to minimize pain would help to refine the evidence available to 
women and gynaecologists.
•	 to continue long term follow up studies, especially focusing on 
endometrial cancer. 
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Chapter 10
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Heavy menstrual bleeding is a significant health problem in women of 
reproductive age. Its incidence varies between 9% and 22%. Menorrhagia is 
defined as a menstruation at regular cycle intervals, but with excessive flow and 
duration. Clinically, menorrhagia is defined as menstrual blood loss exceeding 80 
mL per cycle. In recent years changes in terminology appeared, because there was 
a great variation in the way the terms abnormal uterine bleeding, menorrhagia 
and dysfunctional uterine bleeding were used. It was proposed to use abnormal 
uterine bleeding as the overarching term to describe all symptomatic blood loss 
from normal menstruation or the menstrual cycle. Heavy menstrual bleeding 
(HMB) is a suitable replacement for term for menorrhagia. 
HMB has a significant impact on the medical, social economic and psychological 
well-being of women. When medical treatment fails surgical interventions, 
like destruction of the endometrium or a hysterectomy, can be considered. 
Hysterectomies are performed in 30-40% of the patients for treatment of severe HMB. 
The level of satisfaction with hysterectomy is usually high with good health related 
quality of life scores, but it is a major surgical procedure with a complication rate up 
to 43%. Patient preference studies show that women place a high value on retaining 
their uterus and that they have a strong preference for avoiding hysterectomy as a 
treatment to resolve the problem of HMB, but when they do undergo a hysterectomy 
they are generally satisfied. Endometrial ablation is an alternative to hysterectomy in 
women with heavy menstrual bleeding. It is a relatively minor surgical procedure 
which preserves the uterus yet reduces heavy menstrual bleeding. 
Endometrial ablation 
Endometrial ablation was introduced in the 1980’s. Endometrial ablation removes 
or destroys the basal layer of the endometrium. This results in an inability of the 
endometrium to react on hormonal stimuli, and therefore decreases menstrual 
blood loss. The first endometrial ablations were performed under direct 
hysteroscopic vision. They are referred to as first-generation devices. The first-
generation devices were; endometrial laser ablation, transcervical resection of the 
endometrium and rollerball ablation. The introduction of endometrial ablation 
caused a rapid decrease in the amount of hysterectomies performed. However, 
the first-generation endometrial ablation techniques involved a long learning 
curve and had the risk of absorption of the distension fluid (Glycine or Sorbitol). 




This is characterized by hyponatraemia, water intoxication, cerebral edema and 
cardiac overload, which can result in a fatal hyponatremic encephalopathy. Over 
the past decade, second-generation non-hysteroscopic techniques overcame 
these disadvantages. Destruction of the endometrium by the ‘blind’ endometrial 
ablation methods is achieved by different methods, the most important being 
microwave (Microsulis®), high temperature fluids within a balloon (Thermachoice®, 
Cavaterm®, Thermablate®), bipolar radiofrequency energy (NovaSure®) and free 
fluid with a high temperature (Hydrothermablator®). The second-generation 
techniques are safer, technically easier and quicker to perform, and involve shorter 
hospital stays. When endometrial ablation was introduced, the procedures 
were performed in theatre with general anesthesia or regional (spinal) anesthesia. 
Years after, endometrial ablation was also performed at the outpatient clinic with 
a paracervical block combined with intra-venous sedation. One study compared 
intraoperative and postoperative pain between ThermaChoice® and NovaSure® 
endometrial ablation. The NovaSure® system was associated with significantly 
lower intraoperative and postoperative pain. These data supported the idea that 
the NovaSure® procedure could become an office-based procedure with local 
anesthesia, meaning only a paracervical block. 
This thesis deals with the prognostic factors for the success of endometrial 
ablation and the use of different second-generation endometrial ablation 
techniques in theatre and in the outpatient clinic with a paracervical block. 
Chapter 1 outlines the aim of the thesis, and is formulated into five questions. This 
thesis aims to answer the following questions:
1. Which are the prognostic factors for success of endometrial ablation in the 
treatment of heavy menstrual bleeding?
2. What is the effectiveness of bipolar radiofrequency endometrial ablation in the 
treatment of heavy menstrual bleeding as compared to hydrothermablation 
after 12 months and at long term follow-up in terms of amenorrhea, satisfaction, 
reinterventions and quality of life?
3. Is it safe and acceptable to perform bipolar radiofrequency endometrial 
ablation with a paracervical block in the outpatient clinic?
4. What is the effectiveness of bipolar radiofrequency endometrial ablation in the 
treatment of heavy menstrual bleeding as compared to balloon endometrial 
ablation in the outpatient clinic in terms of amenorrhea, pain, satisfaction and 
quality of life?
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5. Which endometrial ablation technique(s) is/are preferred in the treatment of 
heavy menstrual bleeding? 
Chapter 2 studies a history of Cesarean section and other factors that are 
potentially associated with endometrial ablation failure in the treatment of heavy 
menstrual bleeding and answers the first question:
Which are the prognostic factors for success of endometrial ablation in the 
treatment of heavy menstrual bleeding?
We compared women who had failed ablation to women who had successful 
ablation for heavy menstrual bleeding in a case-control study. Failed ablation 
was defined as the need for hysterectomy due to persistent HMB after ablation. 
Successful ablation was defined as a satisfied patient who did not need a 
hysterectomy after ablation for HMB. Both groups, cases and controls were 
identified from the surgery registration in the Máxima Medical Center between 
January 1999 and January 2009. Cases were women that had an endometrial 
ablation and a hysterectomy, whereas controls only had an endometrial ablation. 
From the medical files we collected clinical history, including the presence of 
a previous Cesarean section, baseline characteristics at the moment of initial 
ablation, data of the ablation technique and follow-up status for each patient. 
We compared 76 cases to 76 controls. Among the cases, 12 women had had a 
previous Cesarean section versus 15 in the control group (15.8% versus 19.7%; odds 
ratio (OR) 0.76; 95% confidence interval (CI) 0.3–1.8). Factors predictive for failure of 
ablation were dysmenorrhea (OR 3.0; 95% CI 1.5–6.1), having a submucous myoma 
(OR 3.2; 95% CI 1.5–6.8) and uterine depth (per cm OR 1.3; 95% CI 1.0–1.6). Presence 
of intermenstrual bleeding, sterilization and age were not associated with failure 
of ablation.
In conclusion, a previous Cesarean delivery is not associated with an increased 
risk of failure of endometrial ablation, but dysmenorrhea, a submucous myoma 
and longer uterine depth are. This should be incorporated in the counseling of 
women considering endometrial ablation.




What is the effectiveness of bipolar radiofrequency endometrial ablation in the 
treatment of heavy menstrual bleeding as compared to hydrothermablation 
after 12 months and at long-term follow-up in terms of amenorrhea, 
satisfaction, reinterventions and quality of life?
Chapters 3, 4 and 5 focused on this second question.
Chapter 3 presents the results of a double blind randomized trial comparing the 
effectiveness of two second-generation ablation techniques in the treatment 
of heavy menstrual bleeding: bipolar radiofrequency impedance-controlled 
endometrial ablation (NovaSure®) and hydrothermablation (HTA®). Patients 
were included between March 2005 and August 2007. The primary outcome 
was amenorrhea at four weeks, six months and twelve months after treatment. 
Secondary outcome measures were patient satisfaction and re-intervention.  
We included 160 women in the study, of which 82 were allocated to the bipolar 
group and 78 to the hydrotherm group. No complications occurred in either of 
the treatment groups. After 12 months the amenorrhea rates were 47% (35/75) in 
the bipolar group and 24% (17/71) in the hydrotherm group (relative risk (RR) 2.0, 
95% CI 1.2-3.1). In the bipolar group 87% (65/75) of the patients was completely 
satisfied with the result of the treatment, against 68% (48/71) in the hydrotherm 
group (RR 1.3, 95% CI 1.03-1.6). The relative risk for a re-intervention in the bipolar 
group compared to the hydrotherm group was 0.29 (95% CI 0.12 to 0.67), whereas 
for hysterectomy this was 0.49 (95% CI 0.15-1.5).
In the treatment of heavy menstrual bleeding, the bipolar radiofrequency 
endometrial ablation system is superior to hydrothermablation
Chapter 4 evaluates the 5-year follow-up results of the study described in chapter 3, 
comparing bipolar radiofrequency endometrial ablation with hydrothermablation 
for the treatment of HMB. At 5-year of follow-up, a questionnaire was sent to all the 
participants to register amenorrhea rates, reinterventions, and patient satisfaction. 
At 5-year follow-up, response rates were 90% in the bipolar group and 
83% in the hydrotherm group. Amenorrhea rates were 55.4% and 35.3% in the 
bipolar group and the hydrotherm group, respectively (RR 1.5, 95% CI 1.1-2.3). The 
number of surgical reinterventions was 11 compared with 23 (RR 0.43, 95% CI 0.2-
0.8). Overall, more women were satisfied in the bipolar group compared with the 
hydrotherm group. 
25367 Penninx, Josien.indd   177 11-05-13   17:24
Chapter 10
178
The results from this follow-up study showed that bipolar ablation has 
advantages over hydrothermablation. Higher amenorrhea rate, less re-interventions, 
and high levels of satisfaction were shown. So, the bipolar radiofrequency 
endometrial ablation system is more effective than hydrothermablation in the 
treatment of HMB.
Chapter 5 reports the health related quality of life of patients who participated in 
the randomized controlled trial described in chapter 3 and 4. Health related quality 
of life was assessed and compared between both groups. Patients were asked to 
complete quality of life questionnaires at baseline, 4 weeks, 6 and 12 months and 
5 years after randomization. The medical outcomes study Short-Form (SF-36), 
Euroqol and menorrhagia assessment scale (Shaw), before randomization and 
at each follow-up visit were selected to evaluate quality of life. The menorrhagia 
outcomes questionnaire (MOQ) was completed at 4 weeks, 6 months and 12 
months after treatment. 
Quality of life improved significantly over time in all questionnaires. None of 
the quality of life dimensions showed a significant effect between both groups, 
neither was there a significant interaction between time and treatment. In all 
generic and disease specific questionnaires treatment of HMB improved health 
related quality of life over time. A treatment effect of amenorrhea and satisfaction 
did not result in quality of life benefits.
Chapter 6 describes a prospective cohort study to evaluate the safety, feasibility 
and efficacy of bipolar radiofrequency endometrial ablation under local anesthesia, 
which answers the third question:
Is it safe and acceptable to perform bipolar radiofrequency endometrial 
ablation with a paracervical block in the outpatient clinic?
Women with HMB were included to undergo bipolar radiofrequency endometrial 
ablation with a paracervical block. We measured the acceptability, pain score 
(visual analog scale) and patients’ satisfaction during and after the procedure and 
amenorrhea at 6 weeks follow-up. 
We treated 33 patients. No complications occurred during the procedure 
or postoperatively. Of the 33 women, 28 (85%) did found treatment with bipolar 
radiofrequency endometrial ablation under local anesthetics acceptable. After 
24 hours, 23 of 33 (70%) women reported to be pain free, whereas 10 women 




still had mild pain. Twenty women developed amenorrhea (61%) and 13 women 
hypomenorrhea (39%). All women were satisfied with the treatment result and 
would recommend it to a friend. 
Bipolar radiofrequency endometrial ablation performed under local 
anesthesia seems a safe, feasible and efficacious procedure.
What is the effectiveness of bipolar radiofrequency endometrial ablation in 
the treatment of heavy menstrual bleeding compared to balloon endometrial 
ablation in the outpatient clinic in terms of amenorrhea, pain, satisfaction and 
quality of life?
Chapter 7 presents the results of a multi-center double blind randomized trial 
comparing the effectiveness of two second-generation ablation techniques, 
bipolar radiofrequency endometrial ablation (NovaSure®) and balloon endometrial 
ablation (Thermablate®), in the office with a paracervical block in patients with 
heavy menstrual bleeding. Patients were included between March 2009 and 
December 2011. Women with HMB were randomly allocated to bipolar or balloon 
endometrial ablation, performed in the office, using a paracervical block. The 
primary outcome was amenorrhea. Secondary outcome measures were pain, 
satisfaction, quality of life and re-interventions.
We included 104 women, of whom 52 were allocated to bipolar ablation 
and 52 to balloon ablation. Complications did not occur. The mean visual analog 
scale pain score of the total procedure was 7.1 in the bipolar group and 7.4 in the 
balloon group (P<.577). Amenorrhea rates were 60% (29/48) in the bipolar group 
and 27% (12/45) in the balloon group (RR 2.3, 95% CI 1.3 to 3.9) a 12-month follow-
up. 94% (45/48) of the patients in the bipolar group were satisfied with the result 
of the treatment versus 80% (36/45) in the balloon group (RR 1.2, 95% CI 1.0 to 1.4). 
The reintervention rates were 5/52 (10%) in the bipolar group and 6/52 (12%) in 
the balloon group (RR 1.02, 95% CI 0.9 to 1.2). The Shaw score, expressing quality of 
life, improved over time (P<.001) and was significantly higher in the bipolar group 
at 12 months follow-up (P=.025). 
Both second-generation ablation techniques used in the office with a 
paracervical block in this study are safe and easy to perform. However, based on 
the results of the current randomized trial, bipolar endometrial ablation appears to 
offer higher amenorrhea rates, patient satisfaction and quality of life.
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Which endometrial ablation technique(s) is/are preferred in the treatment of 
heavy menstrual bleeding?
Chapter 8 reports a systematic review to compare the efficacy, safety and 
acceptability of methods used to destroy the endometrium in premenopausal 
women with heavy menstrual bleeding. Randomized controlled trials comparing 
different endometrial ablation techniques in women with a complaint of heavy 
menstrual bleeding without uterine pathology were eligible. The outcomes 
included reduction of heavy menstrual bleeding, improvement in quality of life, 
operative outcomes, satisfaction with the outcome, complications and need for 
further surgery or hysterectomy. Twenty five trials (4040 women with sample sizes 
ranging from 20 to 372) were included in the review. 
In conclusion, the rapid development of a number of new methods of 
endometrial destruction has made systematic comparisons between individual 
methods and with the ‘gold standard’ first generation techniques difficult. Most of 
the newer techniques are technically easier than traditional hysteroscopy-based 
methods to perform but technical difficulties with new equipment need to be 
ironed out. Overall, the existing evidence suggests that success and satisfaction 
rates and complication profiles of newer techniques of ablation compare favorably 
with hysteroscopic techniques.
Chapter 9 provides a general discussion and implementations for future 
research.
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Hoofdstuk 10
Samenvatting




Hevig menstrueel bloedverlies is een belangrijk gezondheidsprobleem voor 
premenopauzale vrouwen. De incidentie varieert van 9% tot 22%. Menorragie 
wordt gedefinieerd als een regelmatige cyclus met hevig bloedverlies tijdens 
de menstruatie in combinatie met een lange duur van de menstruatie. Klinisch 
wordt menorragie gedefinieerd als maandelijks meer dan 80 ml bloedverlies. 
De afgelopen jaren heeft er een verandering plaats gevonden in terminologie, 
omdat er sprake was van een grote variatie waarin de termen abnormaal uterien 
bloedverlies, menorragie en dysfunctioneel uterien bloedverlies werden gebruikt. 
Er werd voorgesteld om abnormaal uterien bloedverlies als overkoepelende 
term te gebruiken, om alle vormen van symptomatisch bloedverlies tijdens de 
menstruatie of tijdens de menstruatiecyclus te beschrijven. Hevig menstrueel 
bloedverlies (HMB) werd voorgesteld al een geschikte vervanger van de term 
menorragie.  
HMB heeft grote invloed op het fysieke, sociaal economisch en psychologisch 
welzijn van de vrouw. Wanneer de medicamenteuze behandeling niet helpt 
of een vrouw dit niet wenst, kunnen chirurgische interventies, zoals een 
endometriumablatie of een uterusextirpatie worden overwogen. Bij 30-40% van 
de patiënten wordt ter behandeling van het HMB een uterusextirpatie verricht. 
De tevredenheid na een uterusextirpatie is meestal hoog met hoge scores op 
kwaliteit van leven, maar het blijft een grote chirurgische behandeling met een 
complicatierisico tot 43%. Patiënt preferentie studies laten zien dat vrouwen het 
belangrijk vinden om hun uterus te behouden. Ze hebben een sterke voorkeur om 
een uterusextirpatie te voorkomen, maar wanneer zij een uterusextirpatie hebben 
gehad zijn ze meestal wel tevreden. Een alternatief voor een uterusextirpatie 
in de behandeling van HMB is een endometriumablatie. Het is een relatief 
kleine chirurgische procedure waarbij de uterus behouden blijft, maar toch het 
menstrueel bloedverlies wordt gereduceerd. 
Endometriumablaties 
De endometriumablatie werd geïntroduceerd in de jaren tachtig. Tijdens een 
endometriumablatie wordt de basale laag van het endometrium verwijderd of 
beschadigd. Het endometrium kan dan niet meer reageren op hormonale stimuli 
en hierdoor reduceert het menstrueel bloedverlies. De eerste endometriumablaties 
werden verricht met behulp van een hysteroscopie. Zij worden eerste generatie 




endometriumablaties genoemd. De eerste generatie endometriumablatie 
technieken waren, laserablatie, transcervicale resectie van het endometrium 
(TCRE) en de rollerball ablatie. Na de introductie van de endometriumablatie was 
er een sterke reductie in het aantal verrichte uterusextirpaties. Maar de eerste 
generatie endometriumablatie technieken vereisen training en hebben een 
lange leercurve. Daarnaast hebben zij nog een ander groot nadeel. Glucose en 
Sorbitol worden beiden gebruikt als distensievloeistof tijdens de hysteroscopische 
endometriumablatie. Daarbij is een risico op absorptie van de distensievloeistof 
aanwezig. Als gevolg hiervan kan hyponatriemie, waterintoxicatie, cerebraal 
oedeem of overvulling ontstaan wat kan leiden tot een fatale hyponatremische 
encefalopathie. Daarom werden het afgelopen decennium tweede generatie 
niet-hysteroscopische technieken ontwikkeld, die deze nadelen niet hadden. 
Destructie van het endometrium bij de belangrijkste ‘blinde’ endometriumablatie 
methoden wordt bereikt door radiogolven (Microsulis®), hete vloeistof in een ballon 
(Thermachoice®, Cavaterm®, Thermablate®), bipolaire radiofrequente weerstand 
gecontroleerde energie (NovaSure®) en vrije vloeistof met een hoge temperatuur 
(Hydrothermablator®). De tweede generatie endometriumablatie technieken 
zijn veiliger, technisch simpeler en sneller te verrichten dan de eerste generatie 
technieken en omvatten een kortere opname in het ziekenhuis.
Na introductie van de endometriumablatie werd deze verricht op de 
operatiekamer met algehele anesthesie of spinaalanesthesie. Jaren later werd 
de endometriumablatie ook op de poliklinische operatiekamer verricht met een 
paracervicaal block, maar wel gecombineerd met intraveneuze sedatie. In één 
studie, waarin de ThermaChoice® en NovaSure® werden vergeleken, werd de intra-
operatieve en postoperatieve pijn gemeten. Tijdens en na de behandeling met de 
NovaSure® gaven patiënten significant lagere pijnscores dan na de ThermaChoice®. 
Deze data ondersteunden het idee dat deze procedure een poliklinische 
behandeling zou kunnen worden met alleen lokaalanesthesie (paracervicaal 
block).
In dit proefschrift zullen de prognostische factoren voor het succes van 
een endometriumablatie worden behandeld, tevens worden de resultaten van 
verschillende tweede generatie endometriumablatie technieken, verricht op de 
operatiekamer en polikliniek, beschreven. 
In hoofdstuk 1 staat het doel van dit proefschrift beschreven. Dit doel is aan de 
hand van vijf vragen geformuleerd:
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1. Wat zijn de prognostische factoren aan de hand waarvan het succes van een 
endometriumablatie kan worden voorspeld in de behandeling van hevig 
menstrueel bloedverlies?
2. Wat is de effectiviteit van bipolaire endometriumablatie in de behandeling van 
hevig menstrueel bloedverlies in vergelijking met hydrothermablatie, voor wat 
betreft amenorroe, tevredenheid, het aantal re-interventies en kwaliteit van 
leven na 12 maanden en 5 jaar follow-up? 
3. Is het veilig en acceptabel om een bipolaire endometriumablatie op de 
polikliniek te verrichten met een paracervicaal block?
4. Wat is effectiviteit van bipolaire endometriumablatie in vergelijking met ballon 
endometriumablatie, in de behandeling van hevig menstrueel bloedverlies, 
voor wat betreft amenorroe, pijn, tevredenheid en kwaliteit van leven?
5. Welke endometriumablatie techniek(en) heeft/hebben de voorkeur in de 
behandeling van hevig menstrueel bloedverlies? 
Hoofdstuk 2 onderzoekt factoren die invloed kunnen hebben op het slagen van 
de endometriumablatie in de behandeling van HMB, met speciale aandacht voor 
de sectio Caesarea in de anamnese. 
Wat zijn de prognostische factoren aan de hand waarvan het succes van een 
endometriumablatie kan worden voorspeld in de behandeling van hevig 
menstrueel bloedverlies?
In een patiënt-controle studie werden patiënten vergeleken waarbij het 
resultaat van de endometriumablatie was geslaagd met patiënten waarbij 
de endometriumablatie niet was geslaagd. Patiënten met een niet geslaagde 
ablatie werden geïncludeerd als er een uterusextirpatie was verricht in verband 
met persisterend HMB na de endometriumablatie. Een succesvolle ablatie werd 
gedefinieerd als een ablatie voor HMB waarna geen uterusextirpatie werd verricht 
en de patiënt tevreden wat met het resultaat. De patiënten en controles werden 
geïdentificeerd uit het chirurgisch registratiesysteem in het Máxima Medisch 
Centrum, tussen januari 1999 en januari 2009. De patiënten waren vrouwen 
die een endometriumablatie en een uterusextirpatie hadden ondergaan. De 
controles hadden alleen een endometriumablatie gehad. Uit de medische status 
werd de klinische voorgeschiedenis achterhaald, de patiënt karakteristieken op 
het moment van de endometriumablatie, gegevens van de endometriumablatie 
en de follow-up van elke patiënt. 




We vergeleken 76 patiënten met 76 controles. Binnen de patiënten hadden 
12 vrouwen een sectio Caesarea in de anamnese versus 15 in the controle 
groep (15.8% versus 19.7%; odds ratio (OR) 0.76; 95% CI 0.3–1.8). Voorspellende 
factoren voor het falen van de endometriumablatie waren de aanwezigheid van 
dysmenorroe (OR 3.0; 95% CI 1.5–6.1), een submuceus myoom (OR 3.2; 95% CI 
1.5–6.8) en de uteruslengte (per cm OR 1.3; 95% CI 1.0–1.6). 
De aanwezigheid van tussentijds vaginaal bloedverlies, een sterilisatie in de 
voorgeschiedenis en de leeftijd waren niet geassocieerd met het falen van de 
endometriumablatie.Concluderend lijkt de sectio Caesarea in de voorgeschiedenis 
niet geassocieerd met een hogere kans op falen van de endometriumablatie, maar 
de aanwezigheid van dysmenorroe voor de behandeling, een submuceus myoom 
en een grote sondelengte zijn wel geassocieerd met een hogere kans op falen van 
de endometriumablatie. Dit is belangrijk om mee te nemen in de counseling van 
de patiënt die een endometriumablatie overweegt. 
Wat is de effectiviteit van bipolaire endometriumablatie, in vergelijking met 
hydrothermablatie, in de behandeling van hevig menstrueel bloedverlies, voor 
wat betreft amenorroe, tevredenheid, het aantal re-interventies en kwaliteit 
van leven, na 12 maanden en 5 jaar follow-up?
De hoofdstukken 3, 4 en 5 bespreken het antwoord op deze tweede vraag.
In Hoofdstuk 3 worden de resultaten van een dubbelblinde gerandomiseerde 
studie gepresenteerd waarin de effectiviteit van twee tweede generatie 
endometriumablatie technieken wordt vergeleken in de behandeling van HMB, 
de bipolair radiofrequente weerstand gecontroleerde endometriumablatie 
(NovaSure®) en de hydrothermablatie (HTA®). Patiënten werden geïncludeerd 
tussen maart 2005 en augustus 2007. De primaire uitkomst was amenorroe. 
Secundaire uitkomsten waren tevredenheid en het aantal re-interventies.
Er werden 160 vrouwen geïncludeerd in de studie, 82 vrouwen werden 
gerandomiseerd voor een bipolaire ablatie en 82 voor een hydrothermablatie. 
Er traden geen complicaties op. Na 12 maanden was het percentage patiënten 
met een amenorroe 47% (35/75) in de bipolaire groep en 24% (17/71) in de 
hydrotherm groep (RR 2.0, 95% CI 1.2-3.1). In de bipolaire groep was 87% (65/75) 
van de patiënten zeer tevreden met het resultaat van de behandeling, vergeleken 
met 68% (48/71) in de hydrotherm groep (relatief risico (RR) 1.3, 95% CI 1.03-1.6). 
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Het relatief risico om een re-interventie te moeten ondergaan in de bipolaire 
groep vergeleken met de hydrotherm groep was 0.29 (95% CI 0.12 to 0.67), voor 
een uterusextirpatie was het relatief risico 0.49 (95% CI 0.15-1.5).
Concluderend geeft het bipolaire endometriumablatie systeem betere 
resultaten dan de hydrothermablatie in de behandeling van hevig menstrueel 
bloedverlies. De bipolaire groep heeft namelijk een hoger percentage amenorroe, 
minder re-interventies en meer patiënten zijn tevreden met het resultaat van de 
behandeling.
Hoofdstuk 4 evalueert de 5-jaars follow-up van de studie beschreven in 
hoofdstuk 3, waarin de bipolaire endometriumablatie en hydrothermablatie 
worden vergeleken in de behandeling van HMB. Vijf jaar na de behandeling werd 
een vragenlijst naar alle deelnemers verstuurd om het percentage amenorroe, re-
interventies en patiënt tevredenheid te registreren.
Vijf jaar na de endometriumablatie had 90% van de vrouwen in de bipolaire 
groep de vragenlijst ingevuld versus 83% in de hydrotherm groep. Het percentage 
amenorroe was 55% in de bipolaire groep en 35% in de hydrotherm groep (RR 
1.5, 95% CI 1.05-2.3). Het aantal re-interventies was 11 versus 23 (RR 0.43, 95% CI 
0.23-0.80). In de bipolaire groep waren significant meer vrouwen tevreden met het 
resultaat van de behandeling dan in de hydrotherm groep. 
De resultaten van deze follow-up studie laten zien dat bipolaire ablatie 
voordelen heeft ten opzichte van hydrotherm ablatie. De bipolaire groep heeft 
namelijk een hoger percentage amenorroe, minder re-interventies en meer 
patiënten zijn tevreden met het resultaat van de behandeling vijf jaar na de 
endometriumablatie. De bipolaire ablatie is dus effectiever in de behandeling van 
HMB dan de hydrothermablatie. 
Hoofdstuk 5 rapporteert de kwaliteit van leven van de patiënten uit de 
gerandomiseerde studie zoals beschreven in hoofdstuk 3 en 4. De kwaliteit 
van leven werd beoordeeld en vergeleken tussen beide groepen. Patiënten 
vulden verschillende kwaliteit van leven vragenlijsten in voor de behandeling, 
en 4 weken, 6 maanden, 12 maanden en 5 jaar na randomisatie. De algemene 
gezondheidstoestand vragenlijst (SF-36), Euroqol en de menorragie vragenlijst 
(Shaw) werden voor randomisatie, en tijdens elk follow-up bezoek ingevuld om de 
kwaliteit van leven te evalueren. De menorragie uitkomst vragenlijst (MOQ) werd 
ingevuld 4 weken, 6 maanden en 12 maanden na de behandeling.




De kwaliteit van leven liet een significant tijdseffect zien in alle vragenlijsten, 
zowel de algemene als ziektespecifieke vragenlijsten. Geen van de kwaliteit van 
leven dimensies liet een significant behandeleffect tussen de groepen zien, of een 
interactie tussen tijd en behandeling. Een behandeleffect, dus een hoger percentage 
amenorroe en tevredenheid, liet geen kwaliteit van leven voordelen zien. 
Hoofdstuk 6 beschrijft een prospectieve cohort studie die de veiligheid en 
geschiktheid van de bipolaire endometriumablatie met lokaalanesthesie 
onderzoekt. Dit beantwoord de derde vraag.
Is het veilig en acceptabel om een bipolaire endometriumablatie op de 
polikliniek te verrichten met een paracervicaal block?
Vrouwen die een bipolaire endometriumablatie (NovaSure®) wilden ondergaan 
op de poliklinische operatiekamer (POK) met een paracervicaal block, werden 
geïncludeerd in de studie. Wij registreerden de pijnscore (visueel analoge schaal), 
patiënt tevredenheid tijdens en na de behandeling, of patiënten de behandeling 
op de POK acceptabel vonden en het percentage amenorroe 6 weken na de 
behandeling.
Er werden 33 patiënten behandeld met de bipolaire endometriumablatie. 
Er traden geen complicaties op tijdens de procedure of postoperatief. Van de 33 
patiënten vonden 28 patiënten (85%) de ablatie met lokaalanesthesie op de POK 
acceptabel. Vierentwintig uur na de behandeling rapporteerden 23 van de 33 
patiënten (70%) dat zij pijn vrij waren en 10 patiënten hadden milde pijn. Twintig 
vrouwen hadden een amenorroe (61%) en 13 een hypomenorroe (39%). Alle 
patiënten waren tevreden met het resultaat van de behandeling en zouden het 
aanraden aan een vriendin. 
Hieruit concluderend lijkt de bipolaire endometriumablatie verricht met 
lokaalanesthesie op de POK een veilige en werkzame procedure. 
Wat is effectiviteit van de bipolaire endometriumablatie in vergelijking 
met ballon endometriumablatie, in de behandeling van hevig menstrueel 
bloedverlies, voor wat betreft amenorroe, pijn, tevredenheid en kwaliteit van 
leven?
Hoofdstuk 7 presenteert de resultaten van een multicenter dubbel blind 
gerandomiseerde studie waarin de effectiviteit van twee tweede generatie 
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endometriumablatie technieken wordt vergeleken, bipolaire radiofrequente 
endometriumablatie (NovaSure®) en ballon endometriumablatie (Thermablate®). 
Patiënten werden geïncludeerd van maart 2009 tot december 2011. 
Vrouwen met HMB werden willekeurig gepland voor een bipolaire of een ballon 
endometriumablatie. De procedure werd verricht op de POK met een paracervicaal 
block. De primaire uitkomst was amenorroe. De secundaire uitkomsten waren pijn 
tijdens en na de behandeling, tevredenheid, kwaliteit van leven en het aantal re-
interventies. 
Er werden 104 vrouwen geïncludeerd, 52 ondergingen de bipolaire ablatie 
en 52 de ballon ablatie. Er traden geen complicaties op. De gemiddelde pijnscore 
(visueel analoge schaal) van de totale procedure was 7.1 in de bipolaire groep en 
7.4 in de ballon groep (P<.577). Na 12 maanden was het percentage amenorroe 
60% (29/48) in de bipolaire groep en 27% (12/45) in de ballon groep (RR 2.3, 95% CI 
1.3 tot 3.9). 94% (45/48) van de patiënten in de bipolaire groep was tevreden met 
het resultaat van de behandeling versus 80% (36/45) in de ballon groep (RR 1.2, 
95% CI 1.0 tot 1.4). Het aantal re-interventies was 5/52 (10%) in de bipolaire groep 
en 6/52 (12%) in de ballon groep (RR 1.02, 95% CI 0.9 tot 1.2). De kwaliteit van leven 
werd berekend met behulp van de menorragie vragenlijst score (Shaw). Er werd 
een significant tijdseffect gevonden (P<.001). De Shaw score was significant hoger 
in de bipolaire groep 12 maanden na de behandeling. (P=.025). 
Beide tweede generatie endometrium ablatie technieken verricht in deze 
studie zijn veilig en makkelijk uit te voeren op de POK met een paracerviaal 
block. Maar, gebaseerd op de resultaten van deze gerandomiseerde studie, blijkt 
de bipolaire endometriumablatie een hoger percentage amenorroe, patient 
tevredenheid en een hogere score op kwaliteit van leven te geven. 
Welke endometriumablatie techniek(en) heeft/hebben de voorkeur in de 
behandeling van hevig menstrueel bloedverlies?
In Hoofdstuk 8 wordt een systematische review gerapporteerd waarin de 
werkzaamheid, veiligheid en aanvaardbaarheid van verschillende methoden 
om het endometrium te beschadigen worden vergeleken, in premenopauzale 
vrouwen met HMB. Voor deelname aan de review kwamen gerandomiseerde 
gecontroleerde studies in aanmerking waarin verschillende endometriumablatie 
technieken werden vergeleken bij vrouwen met HMB zonder intra-uteriene 
afwijkingen. De uitkomsten waren reductie van HMB, verbetering van kwaliteit van 




leven, tevredenheid met het resultaat, complicaties en re-interventies zoals verdere 
chirurgische behandeling (incl. uterusextirpatie). Vijfentwintig studies (4040 
vrouwen met een studiegrootte variërend van 20 tot 372) werden geïncludeerd 
in de review. 
Concluderend is het systematisch vergelijken van verschillende individuele 
endometriumablatie methoden met de ‘gouden standaard’ eerste generatie 
technieken moeilijk. Dit komt door de snelle ontwikkeling van nieuwe methoden 
van endometriumdestructie. De meeste nieuwe technieken zijn technisch 
makkelijker te verrichten dan de hysteroscopische methoden, maar technische 
problemen met de nieuwe apparatuur moeten nog opgelost worden. 
De bestaande studies laten wel zien dat het aantal geslaagde ablaties, de 
tevredenheid en complicaties van de nieuwe technieken vergelijkbaar zijn met de 
hysteroscopische technieken.
Hoofdstuk 9 tenslotte geeft een algemene beschrijving van de resultaten uit 
dit proefschrift, beschrijft de klinische implicaties en bevat aanbevelingen voor 
toekomstig onderzoek. 
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Wat een fantastisch gevoel, mijn proefschrift is klaar! Het laatste half jaar heb 
ik fulltime de tijd gehad om aan mijn proefschrift te werken en daardoor is het 
ineens snel gegaan. Een proefschrift schrijven doe je niet alleen, maar met de 
hulp en steun van velen. Daarom wil ik graag iedereen bedanken die een bijdrage 
heeft geleverd aan mijn proefschrift, maar een aantal personen wil ik afzonderlijk 
bedanken.   
Allereerst wil ik alle vrouwen bedanken die hebben deelgenomen aan de studies. 
Na de behandeling vertellen de meeste vrouwen dat zij zeer tevreden zijn over 
het resultaat van de behandeling en dat de behandeling hun leven positief heeft 
veranderd. Zij menstrueren niet meer of maar heel weinig. Dat is een fantastisch 
resultaat. 
Prof. R.F.P.M. Kruitwagen, beste Roy, aan het einde van mijn onderzoek werd ons 
contact intensiever. Je was toen betrokken bij de artikelen, met snelle reacties op 
mijn hoofdstukken. Mede daardoor konden we het proefschrift snel afronden. 
Dank hiervoor. Verder vind ik het een eer dat ik als eerste bij je mag promoveren! 
Prof. Dr. B.W. Mol, beste Ben Willem, in het begin zag ik er tegenop om naar de 
afspraken met jou te gaan, want we zaten niet altijd op één lijn qua prioriteiten ten 
aanzien van het onderzoek, maar zonder jouw stimulans was het niet gelukt. Dat 
je door mijn HTA studie een deadline voor ZonMw hebt gemist en dit uiteindelijk 
tot positieve veranderingen heeft geleid vond ik bijzonder om te horen. Ik wil je 
bedanken voor je kritische visie en alle snelle reacties op mijn artikelen. Jij hebt 
mij geleerd niet zomaar wat aan te nemen, maar altijd te denken: ’Show me the 
evidence’. Veel succes en plezier Down Under!
Dr. M.Y. Bongers, lieve Marlies, door jou ben ik in het endometriumablatie 
onderzoek gerold. Ik kon de HTA trial voortzetten en hierdoor werd mijn promotie 
onderzoek opgestart. Je bent een voorbeeld voor mij, wereldwijd ben jij een van 
de endometriumablatie goeroes. Daarnaast ben je ook een fantastische opleider. 
Je staat altijd klaar voor de AIOS en op de OK ben je de rust zelve. Het is heerlijk 
om met jou te opereren. Jij hebt altijd nieuwe ideeën voor studies en staat altijd 
voor me klaar. Bedankt voor je fijne begeleiding! Het is helaas niet de 13e, maar ik 




vind het heel bijzonder dat ik nu precies 10 jaar na jouw promotie, op hetzelfde 
onderwerp promoveer! 
Prof. dr. J.L.H. Evers, Prof. dr. H.A.M. Brölmann, Dr. G.A.J. Dunselman, Dr. A. Timmermans 
en Prof. dr. G.D.E.M. Van der Weijden dank voor het lezen en beoordelen van mijn 
manuscript. 
Alle co-auteurs wil ik hartelijk danken voor hun kritische en waardevolle feedback 
op mijn manuscripten.
Maatschap gynaecologie en verloskunde van het Máxima Medisch Centrum, jullie 
zijn een inspirerend team. Jullie vullen elkaar aan en waarderen ieders kwaliteiten. 
Bedankt dat ik een half jaar aan mijn onderzoek kon werken. Ik heb zeer veel 
geleerd de afgelopen jaren en nu wordt het tijd om mijn opleiding voort te zetten 
in Maastricht.  
Lieve huidige en oud-collega arts-assistenten gynaecologie. Bedankt voor de 
gezellige tijd in het MMC. Fijn dat we af en toe lekker bij elkaar kunnen spuien. Lot, 
je bent een lieve collega. Je bent heerlijk enthousiast en een vrolijke noot. Je staat 
altijd klaar met je ‘Duck Face’. Malou, jij doet alles super snel, in opleiding komen en 
komend jaar nog promoveren. Knap hoor! Bedankt voor al je hulp (ook als semi-
arts)! Jos, die prognostische factoren heb jij mooi uitgezocht. Judith, bedankt voor 
je promotietips. Je bent een topper! En natuurlijk alle andere collega’s bedankt en 
degene die een promotietraject hebben lopen, jullie gaat het ook lukken! 
Lieve verloskundigen, verpleegkundigen, kraamverzorgenden, polikliniek 
medewerksters en secretaresses, bedankt voor jullie altijd aanwezige 
belangstelling en aandacht en natuurlijk glaasjes water. 
Wilma, bedankt voor het invoeren van alle vragenlijsten van de HTA trial.
 
Dames van de POK, jullie verbale anesthesie heeft heel wat vrouwen door de 
behandeling heen gesleept. 
Anne Lethaby, thank you for letting me participate in the Cochrane Review. 
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Gynaecologen van het Twee Steden Ziekenhuis en Zuidoost Kliniek, bedankt voor 
de inclusies voor de NOTE trial. 
Shirley Coenen-Murk, dank voor het maken van de mooie foto’s van het schilderij 
voor de kaft. 
Mijn lieve paranimfen, Femke Wilms en Janine Doodkorte. Lieve Femke, in het 
MMC hebben wij elkaar als collega’s ontmoet. Al snel gingen we last-minute naar 
Barcelona, dat was een super reis en sindsdien zijn we maatjes. Het voelde heel 
fijn en vertrouwd toen jij bij de geboorte van Joep en Roos aanwezig was. Dit 
jaar mocht ik bij de geboorte van jullie dochter zijn, dat vond ik heel bijzonder! 
Bedankt voor het maken van het schilderij voor de kaft van mijn boekje!
Lieve Janine, op de fiets naar de tennisbaan in Maastricht hebben wij elkaar 
gevonden. Verrassend, een vriendin die over auto’s kon kletsen. Ik vind het heerlijk 
om met de kindjes bij jou, Michiel en Emma op bezoek te zijn en dan eten we nog 
steeds chocolademousse als toetje. Begin juni wordt jullie tweede telg geboren. 
Ik vind het heel bijzonder dat jullie naast me staan op deze dag als paranimfen! 
Jullie zijn heel belangrijk voor me!
Lieve familie van Ballegooijen, Anton en Anneke, Hanne en Mark, Freek en Opa 
en Oma van Ballegooijen. Al bijna 15 jaar kom ik bij jullie over de vloer en sinds de 
eerste dag voelt het als een warm welkom. Bedankt voor alle gezellige etentjes en 
vakanties. Joep en Roos vinden het fantastisch op de ‘boerderij’ in Gameren. 
Lieve Joost, groot broertje, ik vind het heerlijk te zien hoe goed het met jou en 
Anouk gaat en samen met jullie dochter Catoo. Ik zie je genieten als trotse papa, 
wie had dat een paar jaar geleden gedacht! Jij woont in Rotterdam, door de afstand 
zien we elkaar minder, maar ik ben trots op je lieve broer! 
Lieve papa en mama, jullie verdienen een ereplaats in dit dankwoord. Bedankt 
voor jullie onvoorwaardelijke liefde en steun! Jullie staan altijd voor mij klaar. Jullie 
steun is heel belangrijk voor mij! Daarnaast zijn jullie een fantastische opa en oma 
voor Joep en Roos. Ik vind het prachtig om te zien hoe jullie genieten van hen en 
zij van jullie! 
Lieve Joep en Roos, ik geniet elke dag van jullie!




Lieve Mathijs, de laatste bijzondere woorden van dit dankwoord zijn voor jou. 
Vijftien jaar geleden in juni hebben wij elkaar ontmoet. Onze relatie heeft onze 
studententijd en een verbouwing doorstaan en nu hebben we samen twee 
prachtige kinderen. Ik wil jou bedanken voor jouw onvoorwaardelijke steun, je 
luisterend oor, jouw humor, jouw nieuwsgierigheid en soms ook fratsen en voor je 
liefde en de zorg voor de kinderen (als ik weer eens aan het werk ben). Ik hou van 
je! Ik kijk uit naar ons verdere leven samen! 
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